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Abstract 
Hematopoiesis is the tightly controlled and complex process in which the entire 
blood system is formed and maintained by a rare pool of hematopoietic stem 
cells (HSCs), and its dysregulation results in the formation of leukaemia. TRIB2, 
a member of the Tribbles family of serine/threonine pseudokinases, has been 
implicated in a variety of cancers and is a potent murine oncogene that induces 
acute myeloid leukaemia (AML) in vivo via modulation of the essential myeloid 
transcription factor CCAAT-enhancer binding protein α (C/EBPα). C/EBPα, which 
is crucial for myeloid cell differentiation, is commonly dysregulated in a variety 
of cancers, including AML.  
Two isoforms of C/EBPα exist - the full-length p42 isoform, and the truncated 
oncogenic p30 isoform. TRIB2 has been shown to selectively degrade the p42 
isoform of C/EBPα and induce p30 expression in AML. In this study, 
overexpression of the p30 isoform in a bone marrow transplant (BMT) leads to 
perturbation of myelopoiesis, and in the presence of physiological levels of p42, 
this oncogene exhibited weak transformative ability. It was also shown by BMT 
that despite their degradative relationship, expression of C/EBPα was essential 
for TRIB2 mediated leukaemia. A conditional mouse model was used to 
demonstrate that oncogenic p30 cooperates with TRIB2 to reduce disease 
latency, only in the presence of p42. At the molecular level, a ubiquitination 
assay was used to show that TRIB2 degrades p42 by K48-mediated proteasomal 
ubiquitination and was unable to ubiquitinate p30. Mutation of a critical lysine 
residue in the C-terminus of C/EBPα abrogated TRIB2 mediated C/EBPα 
ubiquitination suggesting that this site, which is frequently mutated in AML, is 
the site at which TRIB2 mediates its degradative effects. The TRIB2-C/EBPα axis 
was effectively targeted by proteasome inhibition.  
AML is a very difficult disease to target therapeutically due to the extensive 
array of chromosomal translocations and genetic aberrations that contribute to 
the disease. The cell from which a specific leukaemia arises, or leukaemia 
initiating cell (LIC), can affect the phenotype and chemotherapeutic response of 
the resultant disease. The LIC has been elucidated for some common oncogenes 
but it is unknown for TRIB2. The data presented in this thesis investigate the 
ability of the oncogene TRIB2 to transform hematopoietic stem and progenitor 
3 
 
cells in vitro and in vivo. TRIB2 overexpression conferred in vitro serially 
replating ability to all stem and progenitor cells studied. Upon transplantation, 
only TRIB2 overexpressing HSCs and granulocyte/macrophage progenitors (GMPs) 
resulted in the generation of leukaemia in vivo. TRIB2 induced a mature myeloid 
leukaemia from the GMP, and a mixed lineage leukaemia from the HSC. As such 
the role of TRIB2 in steady state hematopoiesis was also explored using a Trib2-/- 
mouse and it was determined that loss of Trib2 had no effect on lineage 
distribution in the hematopoietic compartment under steady-state conditions. 
The process of hematopoiesis is controlled by a host of lineage restricted 
transcription factors. Recently members of the Nuclear Factor 1 family of 
transcription factors (NFIA, NFIB, NFIC and NFIX) have been implicated in 
hematopoiesis. Little is known about the role of NFIX in lineage determination. 
Here we describe a novel role for NFIX in lineage fate determination. In human 
and murine datasets the expression of Nfix was shown to decrease as cells 
differentiated along the lymphoid pathway. NFIX overexpression resulted in 
enhanced myelopoiesis in vivo and in vitro and a block in B cell development at 
the pre-pro-B cell stage. Loss of NFIX resulted in disruption of myeloid and 
lymphoid differentiation in vivo. These effects on stem and progenitor cell fate 
correlated with changes in the expression levels of key transcription factors 
involved in hematopoietic differentiation including a 15-fold increase in Cebpa 
expression in Nfix overexpressing cells. The data presented support a role for 
NFIX as an important transcription factor influencing hematopoietic lineage 
specification.   
The identification of NFIX as a novel transcription factor influencing lineage 
determination will lead to further study of its role in hematopoiesis, and 
contribute to a better understanding of the process of differentiation. 
Elucidating the relationship between TRIB2 and C/EBPα not only impacts on our 
understanding of the pathophysiology of AML but is also relevant in other cancer 
types including lung and liver cancer. Thus in summary, the data presented in 
this thesis provide important insights into key areas which will facilitate the 
development of future therapeutic approaches in cancer treatment. 
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1 Introduction 
1.1 Hematopoiesis 
The term hematopoiesis describes the formation of all of the components of our 
blood system from a small pool of hematopoietic stem cells (HSCs). Prior to the 
1960’s it was known that our blood cells had a short lifespan, but the source of 
their constant turnover was not discovered until a seminal paper by Till & 
McCulloch (Till and McCulloch, 1961). Murine bone marrow (BM) cells were 
injected into irradiated mice and the formation of large hematopoietic colonies 
was observed in the recipient spleens. These colonies were formed from a single 
initiating cell, and the daughter cells could produce different hematopoietic 
lineages. This discovery provided the first evidence for HSCs with the defining 
characteristics of self-renewal and multi-potency. Since then, HSCs and 
hematopoiesis have been extensively studied.  
Fetal hematopoiesis occurs in sequential steps arising from several sites, 
beginning with primitive erythropoiesis in the yolk sac at embryonic day (E) 7.5, 
followed by the aorta-gonad-mesonephros (AGM) where the first HSCs can be 
detected at E11 (Dzierzak and Speck, 2008). These areas are succeeded by the 
fetal liver (FL) and spleen, with hematopoiesis moving to the thymus and finally 
the BM where definitive post-natal hematopoiesis is established. Fetal HSCs 
rapidly divide and expand while adult HSCs rarely divide with most remaining in 
a quiescent phase. In the adult, HSCs reside in the hypoxic niche of BM cavities 
and are capable of long-term self-renewal, as well as terminal differentiation 
into cells of the myeloid, lymphoid and erythroid lineages. Because 
differentiated cells are relatively short lived, HSCs are responsible for the 
generation of millions of new blood cells every day in order to satisfy the life-
long demands of the blood system. Various secreted growth factors and 
cytokines maintain a healthy growing environment for these self-renewing stem 
cells. They also turn on signal transduction pathways which alter a host of 
lineage specific transcription factors that are ultimately responsible for the cell 
fate decisions that drive differentiation.  
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1.1.1 Hematopoietic hierarchy 
The hematopoietic system is hierarchically arranged with a small population of 
multipotent hematopoietic stem and progenitor cells (HSPCs) lying at the apex 
of this hierarchy. During cell division the daughter cells of a HSC may either, 
remain a HSC (self-renewal), commit along a path of differentiation, or go 
through apoptosis. The HSC compartment contains cells termed long-term HSCs 
(LT-HSCs) which provide life-long renewal and short-term HSCs (ST-HSC) with 
limited repopulating activity (~8 weeks). With each step towards maturation, 
the cells lose self-renewal capacity and become more restricted within a given 
lineage branch. Multipotent HSPCs give rise to more restricted oligopotent 
progenitor cells which subsequently produce lineage restricted progenitor cells 
that will terminally differentiate into mature effector cells. HSCs which enter 
differentiation, first give rise to multipotent progenitor cells (MPPs) that lack 
self-renewal capacity but retain multi-lineage potential. Multi-colour flow 
cytometry has been used in combination with murine transplant studies to 
identify and characterise functional stem and progenitor cell populations in the 
mouse and human. HSC and MPP activities have been shown to reside in a small 
population of BM cells which lack lineage markers found on mature blood cells, 
and also express a receptor for the cytokine stem cell factor (SCF) called cKit, as 
well as stem cell antigen-1 (Sca-1). This population of cells are termed Lin-Sca-
1+cKit+ or LSKs (Weissman et al., 2001). A description of the identification of 
stem and progenitor populations based on cell surface markers is provided in 
1.1.2.  
Our understanding of the hierarchical arrangement of the hematopoietic system 
is constantly being challenged by new approaches, technologies and hypotheses. 
It had been thought that following the emergence of the MPP from the HSC, a 
myeloid/lymphoid branching occurs with the emergence of either the 
oligopotent common lymphoid progenitor (CLP) or common myeloid progenitor 
(CMP). The CLP will generate cells of lymphoid origin – B, T and NK cells. The 
CMP produces further and more restricted oligopotent precursors in the 
granulocyte macrophage progenitor (GMP) which gives rise to granulocytes and 
macrophages, or the megakaryocyte/erythrocyte progenitor (MEP) which gives 
rise to erythrocytes and platelets. The origin of dendritic cells, which is not fully 
understood, was suggested to be both from the CMP and the CLP. However, in 
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recent years this pyramidal model has been challenged and persuasive evidence 
has emerged suggesting that the MPP first differentiates into a lymphoid primed 
multipotent progenitor (LMPP) which has lymphoid and granulocyte-macrophage 
(GM) potential but lacks megakaryocyte-erythroid (MkE) potential, and another 
progenitor with MkE potential (Adolfsson et al., 2005, Arinobu et al., 2007). 
Indeed the putative LMPP compartment has also been suggested to have strong 
dendritic cell potential (Naik et al., 2013). Contrasting studies indicate that MkE 
progenitors may diverge from the MPP before the CMP/CLP branch-point (Pronk 
et al., 2007) and it was subsequently demonstrated that MkE progenitors may be 
derived directly from the HSC (Yamamoto et al., 2013). More recently a “two-
tier” hierarchy was proposed by John Dick and colleagues whereby in the adult 
hematopoietic system the top tier is composed of multipotent HSCs and MPPs 
and these cells give rise to a bottom tier of unipotent progenitors, with the 
megakaryocyte lineage progenitor (MkP) residing closer to the top tier (Notta et 
al., 2015). The pyramidal, LMPP and two-tier model are depicted in Figure 1. 1. 
 
Figure 1. 1 – Diagram of the hierarchical arrangement of the hematopoietic system. 
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1.1.2 Identification of stem and progenitor populations 
Using multicolour flow cytometry and murine BMT, functional stem and 
progenitor cells have been identified and characterised. In order for a cell to be 
classified as a bona fide HSC, it must be able to provide long-term reconstitution 
of the entire hematopoietic system when transplanted into lethally irradiated 
recipient mice. As outlined in 1.1.1, HSC and MPP populations reside in the LSK 
fraction of adult BM which comprises approximately 0.1% of total BM cells. The 
cKit receptor, also known as CD117, whose ligand is stem cell factor (SCF), is 
highly expressed on early hematopoietic stem and progenitor cells and its 
expression decreases as cells differentiate. Sca-1 is almost exclusively expressed 
on HSCs and MPPs and so can be used in conjunction with lineage markers and 
cKit to distinguish them (LSK compartment) from myeloid progenitor populations 
(CMP, GMP and MEP) which reside in the Lin-Sca-1-cKit+ (LK) fraction. There are 2 
main systems for sub-classifying the LSK population into functional groups - use 
of Thy-1.1 (also known as CD90) and Flk-2 (also known as FMS-like tyrosine 
kinase 3 or Flt3), and use of the SLAM family of molecules. Thy-1.1 (also known 
as CD90) is a cell surface glycoprotein expressed on HSCs but absent from more 
committed cells (Christensen and Weissman, 2001). Flt3, a cytokine receptor for 
the Flt3 ligand, is expressed on progenitor populations (MPP, CLP) but not HSCs. 
Using this system the loss of Thy-1.1 and gain of Flt3 expression signifies HSC 
maturation and loss of self-renewal. Therefore functional LT-HSCs reside in the 
Lin-Sca-1+cKit+ThyloFlt3- population while ST-HSCs are contained within the Lin-
Sca-1+cKit+ThyloFlt3+ population, with MPP cells shown to be Lin-Sca-1+cKit+Thy-
Flt3+. 
The SLAM family of molecules, including CD150 (Slamf1) and CD48 (Slamf2), are 
used to segregate the LSK compartment into HSCs, MPPs and more restricted 
hematopoietic progenitors (HPC-1 and HPC-2) (Oguro et al., 2013). As CD150 
expression decreases cells lose self-renewal ability i.e. functional HSCs express 
CD150 while MPPs are CD150-. CD48 expression increases as cells lose self-
renewal activity thus HSCs and MPPs are CD48- while HPC-1 and HPC-2 cells 
express CD48. The HPC-1 population (CD150-), which comprise approximately 
67% of LSKs, were shown to contain Flt3+ LSKs with myeloid and lymphoid 
potential, akin to an LMPP. HPC-2 cells, the smallest fraction at just 2% of LSKs, 
possessed a more myeloerythroid/megakaryocyte potential. It is worth noting 
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that HPC-2 cells express CD150, suggesting that they are more immature than 
the MPP fraction, supporting the “two-tier” hematopoietic model. CD150 and 
CD48 are used in this thesis to sub-classify the LSK compartment and an outline 
of the gating strategy is provided in Figure 1. 2. Human HSCs are typically 
purified using CD34 and CD38 and these markers will be discussed in detail in 
section 4.1.2. The Weismann laboratory at the University of California, 
pioneered the phenotypic identification of murine CLPs (Kondo et al., 1997) and 
CMPs, GMPs and MEPs (Akashi et al., 2000). The restricted lymphoid precursor 
cell, the CLP, was demonstrated to be an immature cell expressing low levels of 
cKit and Sca-1 and expressing IL7Rα i.e. Lin-Sca-1locKitloIL7Rα+ (Figure 1. 2). The 
group then used CD34, a stem and progenitor cell marker, in conjunction with 
Fcγ receptor-II/III (FcγR also known as CD16/32) to identify functional CMPs as 
Lin-cKit+CD34+CD16/32+, GMPs as Lin-cKit+CD34+CD16/32hi and MEPs as Lin-
cKit+CD34-CD16/32- (Figure 1. 2) 
 
Figure 1. 2 – Flow cytometric gating strategy used to identify murine HSPCs. 
1.1.3 Myelopoiesis 
Myelopoiesis describes the hematopoietic differentiation of myeloid cells, which 
encompass granulocytes, monocytes, erythrocytes and platelets (Figure 1. 3). 
Granulocyte is a blanket term for neutrophils which phagocytose pathogens, 
eosinophils which assist in destroying parasites and basophils which secrete 
histamines, all of which play an important role in the inflammatory response. 
Monocytes will mature into macrophages and enter tissue to phagocytose 
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damaged cells and invading pathogens. Myeloid cells can be detected by flow 
cytometry in the murine system where neutrophils express high levels of the 
GPI-anchored protein Gr1 as well as the integrin CD11b (also known as Mac-1), 
while eosinophils express intermediate levels of Gr1. Cells of the monocyte and 
macrophage lineage express CD11b and the adhesion G protein-coupled receptor 
F4/80, while erythroid cells are routinely detected with antibodies against 
TER119. Myeloid differentiation occurs initially in the BM with terminal 
differentiation occurring in the blood or peripheral tissues. 
1.1.3.1 Cytokines in myeloid differentiation 
An extensive family of cytokines regulate myelopoiesis and influence lineage 
choices of stem and progenitor cells including colony-stimulating factors (CSFs), 
IL-6, erythropoietin (EPO) and thrombopoietin (TPO) (Figure 1. 3). The CSF 
family consists of macrophage-CSF (M-CSF), granulocyte-CSF (G-CSF), 
granulocyte/macrophage-CSF (GM-CSF) and multi-CSF (Interleukin-3 or IL-3). The 
effects of M-CSF, which is synthesised by many cell types including endothelial 
and BM stromal cells, are mediated via the M-CSF receptor (MCSFR) which is 
primarily expressed on macrophages (Barreda et al., 2004). It promotes the 
proliferation, differentiation and survival of progenitor cells as they 
differentiate into macrophages. G-CSF is essential for the differentiation and 
survival of neutrophils. It is primarily produced by monocytes and macrophages 
and the G-CSF receptor (GCSFR) is expressed in immature and mature 
neutrophils. GCSFR expression is regulated by the key myeloid transcription 
factors CCAAT-enhancer binding protein α (C/EBPα) and Purine box factor 1 
(PU.1) (Smith et al., 1996). Gcsf-/- mice exhibit neutropenia with defects in 
myeloid progenitor cells (Liongue et al., 2009) and administration of G-CSF is 
widely used to treat neutropenia in humans as it stimulates production and 
survival of neutrophils. GM-CSF mediates proliferation and differentiation of the 
macrophage and neutrophil lineages and functionally overlaps with M-CSF, G-CSF 
and IL-3. As with G-CSF, GM-CSF is regulated by C/EBPα and PU.1 (Hohaus et al., 
1995), and is also used to therapeutically treat neutropenia caused by 
chemotherapy. Similar to GM-CSF, IL-3 is an early acting cytokine. It works with 
GM-CSF, IL-6 and EPO to stimulate multipotent stem and progenitor cells to 
differentiate into all of the myeloid lineages. IL-6 has been shown to synergise 
with IL-3 to promote proliferation of murine HSPCs in vitro (Heike and Nakahata, 
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2002) and IL-3 is commonly used in conjunction with IL-6 and SCF in in vitro  
assays to stimulate proliferation and survival of HSPCs. EPO is essential for 
definitive erythropoiesis while TPO is the main stimulatory cytokine involved in 
megakaryocytic commitment (Metcalf, 2008). 
 
Figure 1. 3 – Schematic representation of myeloid differentiation from the HSC 
1.1.3.2 Transcription factors in myeloid differentiation 
The lineage decisions of stem and progenitor cells to differentiate in the myeloid 
lineage are directed by the action of a variety of lineage specific transcription 
factors including PU.1, and members of the GATA family and C/EBP family 
(Figure 1. 3). PU.1, the protein encoded by the SPI1 gene, is an ETS-domain 
transcription factor essential for hematopoiesis. Spi1-/- mice are embryonic 
lethal with a complete absence of macrophages and B cells (Scott et al., 1994), 
and loss of PU.1 in the HSC impairs its repopulating ability (Dakic et al., 2005). 
PU.1 mediates the formation of CMPs and CLPs from the HSC. HSCs lacking Pu1 
fail to generate early myeloid and lymphoid precursors (Iwasaki et al., 2005). 
Pu1 is highly expressed in mature myeloid cells and is also detectable in the 
HSC, MPP, CMP, CLP and B cells. While Pu1 expression is downregulated during T 
cell and erythroid differentiation, the amount of PU.1 present in the MPP 
determines whether the cell will differentiate into a macrophage or a B cell. B 
cell development is favoured where Pu1 is expressed at lower levels, while high 
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Pu1 expression promotes macrophage differentiation (DeKoter and Singh, 2000).  
PU.1 has also been shown to be required for terminal granulopoiesis as 
granulocytes from Spi-/- fetal liver fail to fully differentiate in vitro (Dahl et al., 
2003).  
The GATA family comprise 6 transcription factors that bind to the DNA consensus 
sequence (A/T)GATA(A/G), with GATA1, GATA2 and GATA3 expressed in the 
hematopoietic system. GATA1 is essential for normal erythropoiesis. Gata1-/- 
mice die from severe anaemia at E10.5-11.5 (Fujiwara et al., 1996). Embryonic 
stem cells lacking GATA1 are unable to form mature red blood cells, while all 
other lineages are unperturbed (Pevny et al., 1995). Pu1 and Gata1 expression 
are mutually exclusive and there is evidence to suggest that PU.1 and GATA1 
directly interact and antagonise one another (Zhang et al., 1999). GATA1 has 
also been linked with megakaryocyte development where absence of GATA1 
leads to uncontrolled proliferation and disrupted maturation of megakaryocyte 
progenitors (Vyas et al., 1999). Gata2 is primarily expressed in HSCs where it 
regulates quiescence and apoptosis, and myeloid progenitors (Rodrigues et al., 
2012). Recently, low-level overexpression of GATA2 in mice was shown to 
promote myeloid progenitor cell turnover and block lymphoid differentiation 
(Nandakumar et al., 2015). GATA3 is involved in T cell differentiation and is 
described in brief in section 1.1.5. 
1.1.3.3 C/EBPα 
C/EBPs are a family of 6 transcription factors (α, β, γ, δ, ε, ζ) that modulate 
gene expression through interaction with promoters that possess the CCAAT box 
motif. They contain a highly conserved 86 residue C- terminal basic-leucine 
zipper (bZIP) domain which is responsible for DNA binding and dimerization, 
where the C/EBP family can form homodimers or heterodimers with other 
C/EBPs or other transcription factors (Figure 1. 4). Dimerization is required for 
DNA binding. C/EBPs are differentially expressed throughout the body and 
regulate a host of different activities including proliferation, growth and 
differentiation. CEBPA, the first of the C/EBP family to be discovered, is an 
intronless gene located on chromosome 19q13.1. C/EBPα is expressed in a 
variety of tissues including lung, liver and the hematopoietic compartment. 
There are 2 translated isoforms of the CEBPA gene – a full-length 358 amino acid 
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42 kilodalton (kD) product (p42) and an N-terminal truncated 30kD product (p30) 
which is translated from an alternative ATG start site at amino acid 120. Full-
length C/EBPα (henceforth referred to as p42), contains two transactivation 
domains (TAD1 and TAD2) while the p30 isoform, lacks the first 117 amino acids 
of p42 where TAD1 is located. The p30 isoform of C/EBPα is a main focus in 
chapter 3 of this thesis and it is described in more detail in section 3.1. Amongst 
other functions, TAD1 has been shown to be essential for C/EBPα mediated E2F1 
repression (Porse et al., 2001). TAD2, present in both p42 and p30, interacts 
with p21. Overexpression of C/EBPα induces growth arrest in numerous human 
cell lines including Hep3B2, HeLa and human fibrosarcoma cells HT1080 
(Timchenko et al., 1997). Protein expression was analysed in an HT1080 cell line 
engineered with an isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible 
C/EBPα construct and cells were analysed 2, 4, 8 and 24 hours (hrs) post IPTG 
addition. Induced expression of C/EBPα led to a significant increase in the 
expression of P21, but no change in the expression of other key cell cycle 
regulators including CDK2 and CDK4. Subsequently it was demonstrated that 
C/EBPα directly inhibits CDK activity through TAD2 mediated P21 interaction 
(Harris et al., 2001). Switch/Sucrose Non-Fermentable (SWI/SNF) is a chromatin 
remodelling complex which is involved in the regulation of lineage specific 
genes. TAD2 of C/EBPα has been shown to regulate adipocyte differentiation 
(Pedersen et al., 2001) and proliferation (Muller et al., 2004) through SWI/SNF 
interaction, discussed further in section 3.1.1. 
 
Figure 1. 4 – Schematic diagram of the structure of C/EBPα 
1.1.3.3.1 C/EBPα in myelopoiesis 
C/EBPα is an essential transcription factor in hematopoiesis and lineage 
determination. It is differentially expressed in stem and progenitor cells. With 
low expression in the HSC, its expression increases as cells progress towards 
terminal myeloid differentiation. Its expression is highest in GMPs where it is 
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switched off and another family member, C/EBPε is switched on to drive 
terminal differentiation (Lekstrom-Himes, 2001). Mice lacking Cebpe display 
disrupted granulopoiesis and fail to generate neutrophils and eosinophils 
(Yamanaka et al., 1997). C/EBPα has been shown to be essential for 
granulopoiesis (Zhang et al., 1997). Cebpa-/- mice died within 8 hours of birth. At 
birth they were indistinguishable from wild-type and heterozygous littermates, 
however analysis of the blood revealed a complete absence of mature 
neutrophils in Cebpa-/- mice compared with wild-type (WT) and heterozygous 
controls where 87% of white blood cells (WBCs) comprise neutrophils. While 
Cebpa-/- mice had the same numbers of monocytes and lymphocytes, their WBCs 
had the appearance of immature myeloid cells and stained positive for a marker 
of myeloid progenitor cells (Sudan black). Northern blot analysis was used to 
show that there were no differences in Mcsfr and Gmcsfr mRNA levels in fetal 
liver cells (FLCs) of WT, heterozygous and Cebpa-/- mice. However Gcsfr mRNA 
expression was virtually absent in Cebpa-/- mice and they also exhibited a 4-fold 
increase in Epor mRNA.  Indeed G-CSF, which can cross the placental barrier, 
administered to pregnant heterozygous mice caused a marked increase in 
mature granulocytes in the livers of WT mice, whereas the Cebpa-/- mice did not 
respond to G-CSF administration. Considering the presence of immature myeloid 
cells in the blood of Cebpa-/- mice, these data show that C/EBPα is essential for 
granulopoiesis and mediates differentiation in part via stimulation of the G-CSF 
receptor. 
Progression through the cell cycle is strictly controlled by a variety of regulators 
which coordinate entry into and transition between the sequential stages. The 
E2F family play a major role in the G1 to S phase transition where they act as 
either activators with cyclical expression (E2F1, E2F2, E2F3a) or repressors with 
constant expression (E2F4 and E2F5). Several studies have described E2F 
repression by C/EBPα and this function, which is unique to TAD1, present only in 
the p42 isoform of C/EBPα, is central to terminal granulocytic differentiation. 
Electrophoretic mobility shift assay (EMSA) analysis of nuclear extracts from 
mouse hepatocytes and 3T3 cells revealed, that C/EBPα associates in a complex 
with E2F although does not bind directly to it (Slomiany et al., 2000). The 
authors use an E2f responsive promoter in a reporter assay to show that C/EBPα 
directly represses transcriptional activation of the promoter by E2F. 
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Furthermore in cell lines C/EBPα could repress cell cycle activation of the E2f1 
promoter.  Down-regulation of c-Myc is required for myeloid differentiation and 
it has been identified as a target gene of C/EBPα by oligonucleotide array 
screening and representational difference analysis (Johansen et al., 2001). The 
authors mapped an E2F binding site on the c-Myc promotor which is critical for 
C/EBPα mediated negative regulation of c-Myc. Enforced expression of WT 
C/EBPα in 3T3 cells induced their differentiation, while an N-terminal mutant 
(D1-70) which lacks TAD1 was unable to induce differentiation (Porse et al., 
2001). D1-70 showed a 10-fold decrease in the ability to repress E2F1 mediated 
transcription compared to WT C/EBPα. The authors also created basic region 
(between TAD2 and ZIP) mutants – BRM1, 2, 3 and 5. In BRM1 (V287A, E290A), 
BRM2 (I294A, R297A) and BRM3 (D301A, K304A) point mutations were introduced 
in the non-DNA binding face of the basic region while the BRM5 (Y285A) mutation 
was introduced in the bZIP domain. They showed that BRM2 and BRM5 had 
impaired ability to repress E2F1 dependent transcription. BRM2 and BRM5 
transgenic mice, also lacked mature granulocytes in the BM and peripheral blood 
(PB) with no effect on other lineages apart from an increase in Ter119+ erythroid 
cells, paralleling observations made in the Cebpa-/- mice. It was subsequently 
shown that unlike WT C/EBPα, the mutant BRM2 could not induce granulocytic 
differentiation in 32D myeloblast cell line (Keeshan et al., 2003). While BRM2 
was able to bind E2F1, it was unable to induce expression of a C/EBPα target 
gene promoter. These data demonstrate that C/EBPα mediated inhibition of 
E2F1 is necessary for granulopoiesis and this activity is restricted to the p42 
isoform as p30 lacks the transactivation domain necessary for E2F1 repression.  
1.1.3.3.2 Fetal to adult switch 
C/EBPα has been shown to mediate the murine fetal to adult switch which 
occurs in HSCs 3-4 weeks after birth (Ye et al., 2013). Using a conditional 
deletion model the authors showed that loss of Cebpa, despite causing a 
significant reduction in BM cellularity, resulted in a 70 fold increase in LSK 
frequency. Analysis of the LSKs using SLAM markers showed an enriched LT-HSC 
population in the Cebpa knock out (KO) BM. It was shown that loss of Cebpa 
resulted in increased expression of cell-cycle related genes such as Ccna2, Ccnb2 
and Cdk4, and cell cycle analysis confirmed that loss of Cebpa induced 
proliferation of LT-HSCs. Gene expression analysis revealed that adult KO HSCs 
clustered with E15.5 FL HSCs from WT mice with over 1000 overlapping gene 
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changes, and differed significantly from control adult HSCs. Analysis of Cebpa 
expression showed a dramatic increase in HSCs from 4 week old mice compared 
to 2 week old mice. Indeed overexpression of C/EBPα in fetal HSCs was able to 
switch them from a proliferative to a quiescent state. The authors identify N-
Myc as a direct target of C/EBPα and suggest that inhibition of N-Myc by C/EBPα 
blocks proliferation in new-born HSCs and promotes HSC quiescence in the adult 
system. 
In addition to playing critical roles in steady state hematopoiesis, C/EBPα is also 
one of the most commonly mutated genes in acute myeloid leukaemia (AML) and 
these mutations are described in detail in 1.2.2.2.1.  
1.1.4 B cell lymphopoiesis 
Lymphopoiesis is the differentiation of lymphoid cells, which encompass B, T and 
NK cells. B cells are a key component of the adaptive immune system where 
they secrete antibodies to fight invading pathogens. B cells express B cell 
receptors (BCR) composed of immunoglobulin (Ig) M or D on their cell surface, 
which permit binding to specific antigens to initiate an immune response. B cells 
are formed and mature in the BM before migration to peripheral lymphoid 
tissues such as the spleen and lymph nodes. In the BM, B cell differentiation 
occurs in a number of well-defined phases governed by the sequential action of 
increasingly lineage-restricted transcription factors (Figure 1. 5). Early B cell 
development is characterised by the rearrangement of the Ig H and L chain loci 
in a process known as V(D)J rearrangement. Pre-pro-B cells are the earliest B 
cell precursor generated by the CLP and there is evidence to suggest that these 
cells may still maintain multi-lineage potential. They give rise to the fully 
committed pro-B cell which in turn gives rise to the pre-B cell. The pre-B cell 
does not express surface IgM but, unlike the pro-B cell, initiation of V(D)J 
rearrangement takes place, and it also expresses a surface IgM precursor called 
the pre-BCR. Pre-B cells give rise to immature B cells which express surface IgM 
(BCR) and V(D)J rearrangement is complete. These cells in turn produce mature 
B cells which express both IgM and IgD on the cells surface as well as other 
surface proteins including B220 and CD19. B220, a 220kD CD45 tyrosine 
phosphatase  (also known as CD45RA), is a pan B-cell marker expressed on all 
committed B cells and is essential in regulating antigen receptor mediated 
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signalling. Expression of B220 is not restricted to B cells however, and can also 
be found on subsets of T and dendritic cells. CD19 expression emerges at the 
pro-B stage and it is expressed on all B cells downstream of this point. CD19 is a 
phosphoglycoprotein that facilitates signal transduction via surface Ig and is 
expressed on all B cells from the pro-B cell stage of differentiation onwards. 
Anti-B220 and anti-CD19 fluorochrome conjugated antibodies are used 
throughout this thesis to identify mature B cells in the BM, spleen and PB by flow 
cytometry. 
 
Figure 1. 5 – Schematic representation of the stages of B cell development 
Each step of B cell development is regulated by the action of key transcription 
factors. Lineage priming of the HSC by Ikaros is an essential step in B cell lineage 
commitment and the generation of the pre-pro-B cell. Ikaros deficient mice 
display a developmental arrest at the LMPP stage of differentiation resulting in a 
complete lack of B cell production while myeloid differentiation is undisrupted 
(Georgopoulos et al., 1994). Ikaros was subsequently shown to repress genetic 
programs associated with self-renewal in the HSC and promote those associated 
with B lineage commitment (Ng et al., 2009). Indeed Ikaros is also necessary for 
the normal expression of key lymphoid signalling receptors Flt3, IL7Rα and 
Notch1 (Sitnicka et al., 2003). As described in 1.1.3, PU.1 is a master regulator 
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of the myeloid/lymphoid bifurcation step whereby low concentrations of PU.1 
promote B lineage commitment from the MPP/LMPP while higher levels drive 
myelopoiesis. E box binding protein 2A (E2A) is an essential transcription factor 
in early B cell lineage commitment. E2a-/- mice exhibit a B cell arrest at the pre-
pro-B cell stage with mice completely devoid of mature B cells (Bain et al., 
1994). E2A is required for initiating and maintaining expression of downstream 
effectors of B cell commitment from the pre-pro-B cell, including early B cell 
factor (EBF1) and Pax5 (Kwon et al., 2008). EBF1 expression is initiated via 
either E2A or IL-7 mediated promoter activation in the CLP. It has been shown to 
regulate the transcription factor network in CLPs responsible for downstream B 
lineage commitment. Ebf1-/- CLPs lack B-lineage associated genes including Pax5 
(Zandi et al., 2008), while enforced expression of EBF1 in MPPs drives B cell 
differentiation in vitro and suppresses myeloid differentiation through down-
regulation of PU.1 and C/EBPα (Pongubala et al., 2008). In the hematopoietic 
system, Pax5 is exclusively expressed in cells of the B lineage but absent from 
the earliest precursor the pre-pro-B cell. Pax5-/- mice display arrested B cell 
differentiation at the early pro-B cell stage (Nutt et al., 1999). Pax5-/- progenitor 
cells express E2a and Ebf1 but lack expression of target gene Cd19 indicating 
that Pax5 operates downstream of E2a and Ebf1. PAX5 controls B lineage 
commitment through down-regulation of key genes including Notch1 and Csfr1 
and maintains their repression during the later stages of lymphopoiesis (Delogu 
et al., 2006).  
1.1.5 T cell lymphopoiesis 
T cells originate in the BM before committed lymphoid progenitor cells migrate 
into the thymus via the cortico-medullary junction to form early thymocyte 
progenitors (ETPs) which subsequently differentiate into mature T and NK cells 
(Figure 1. 6). Within the thymic cortex the earliest developing thymocytes lack 
expression of the T cell glycoproteins CD4 and CD8 and thus are termed double 
negative (DN) cells. During the DN stage, T cells lose all other lineage potential 
and the T cell receptor (TCR) –α, -γ and –β gene loci undergo rearrangement. DN 
cells with successful rearrangement of TCR-β migrate through the cortex of the 
thymus towards the medulla where they proliferate extensively and differentiate 
into double positive (DP) T cells which express both CD4 and CD8. DP T cells 
migrate into the medulla proper where they mature into either CD4 single 
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positive (SP) or CD8 SP cells that will eventually leave the thymus via blood 
vessels and travel to peripheral lymphoid organs. One of the key transcriptional 
regulators of T cell development is Notch1. 
 
Figure 1. 6 – Diagram of T cell development in the BM and thymus 
Notch1 belongs to a family of 4 class 1 transmembrane glycoproteins (NOTCH 1-
4) that have a highly conserved canonical signalling pathway which is involved in 
a variety of developmental cell processes. Notch signalling plays an imperative 
role in hematopoiesis. In KO mouse studies the lymphoid progenitors of Notch1-/- 
mice migrate to the thymus where they become B cells, demonstrating the 
necessity for NOTCH1 in T cell commitment (Wilson et al., 2001). Conversely 
mice transplanted with BM transduced with NOTCH1 showed a block in B cell 
differentiation and increased T cells in the bone marrow (Pui et al., 1999). 
NOTCH1 signalling is essential for commitment to the T cell lineage and for early 
stages of differentiation but during β-selection (TCR rearrangement) NOTCH1 
signalling is switched off and very low levels of NOTCH1 are detected in later 
stages of T cell development. NOTCH1 mutations are present in approximately 
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50% of all T-ALLs and in some cases of AML. NOTCH1 has two domains that are 
frequently mutated in T-cell acute lymphoblastic leukaemia (T-ALL) - the 
heterodimerization domain (HD) and the C-terminal PEST (region rich in proline, 
glutamic acid, serine and threonine) degradation domain. Gain-of-function 
mutations in these regions result in upregulated NOTCH1 expression by either 
ligand activation or a decrease in protein degradation respectively. 
Thus the expression of cell-restricted transcription factors is essential to initiate 
or inhibit expression of lineage-instructive genes, as stem and progenitor cells 
progress through different stages of maturation.   
1.2 AML 
Leukaemia is broadly divided into two subtypes; acute and chronic leukaemia. 
Acute leukaemia is characterised by a block in differentiation in a blood cell, 
and uncontrolled proliferation of these immature blast cells. The most common 
forms of acute leukaemia are found in the myeloid and lymphoid blood lineages. 
Acute lymphoblastic leukaemia (ALL) accounts for 78% of all paediatric 
leukaemia cases (Grigoropoulos et al., 2013). AML, the most common adult form, 
accounts for less than 1% of new leukaemia diagnoses in the UK (4.5 new 
diagnoses per 100,000 people per year) but represents 33% of all leukaemia 
cases (Cancer Research UK, 2012). This is because AML is a particularly 
heterogeneous disease with a plethora of genetic lesions contributing to its 
pathology, making it very difficult to effectively target therapeutically. Studying 
normal hematopoiesis allows us to gain insight into the complex network of 
pathways involved in differentiation, and understanding how these pathways 
become dysregulated is central to better comprehension of the disease.  
1.2.1 AML classifications 
AML is a clinically and biologically heterogeneous disease and for many years the 
development of AML was thought to occur through a “two-hit” process i.e. two 
types of mutations are required to induce AML. Class I mutations (which include 
Flt3 and cKit) result in uncontrolled proliferation of cells, and class II mutations 
including C/EBPα, nucleophosmin1 (NPM1), homeodomain-containing 
transcription factor (HOX) and promyelocytic leukaemia-retinoic acid receptor α 
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(PML-RARα), that affect myeloid transcription factors causing a block in 
differentiation so that the cells fail to mature. However approximately 50% of 
AML patients do not carry a class I mutation and recent research has revealed 
several common mutations which cannot be identified as class I or II (Shih et al., 
2012). These mutations, broadly termed class III, incorporate mutations in 
epigenetic modifiers such as DNA (cytosine-5)-methyltransferase 3A (DNMT3A), 
and mutations in the hydoxylmethylation pathway such as tet methylcytosine 
dioxygenase 2 (TET2) and isocitrate dehydrogenase 1/2 (IDH1/2) mutations. 
Demonstrating the limitations of the “two-hit” model, the identification of these 
groups of mutations extends our understanding of the complex pathogenesis of 
AML.  
There are two established systems used to classify AML into subtypes, the 
French-American-British (FAB) and World Health Organization (WHO) systems.  
1.2.1.1 FAB classification 
The FAB classification system was first published in 1976 and is based primarily 
on morphologic observations from blood and BM films (Bennett et al., 1976). 8 
categories of AML were described with M0, M1 and M2 representing a 
myeloblastic phenotype with increasing maturation and M3 encompassing 
promyelocytic leukaemia. Myelomonocytic leukaemia is denoted M4 (without 
eosinophils) or M4eos (with eosinophils). Acute monocytic leukaemia is 
represented by M5, M6 describes leukaemia of early erythroid precursors (acute 
erythroid leukaemia) and M7 leukaemia of early platelet cells (acute 
megakaryoblastic leukaemia). Because the FAB system relies primarily on 
morphologic characteristics of patient samples, and does not take into account 
the diverse cytogenetic background of AML patients within a given group, it 
provides limited prognostic information.  
1.2.1.2 The WHO classification 
The WHO system is based on biological, clinical, genetic and immunophenotypic 
features, allowing a more integrated approach to the identification of a given 
AML (Swerdlow et al., 2008). It categorises samples broadly into 7 groups – AML 
with certain genetic abnormalities, AML with myelodysplasia-related changes, 
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AML related to previous chemotherapy or radiation, AML not otherwise specified, 
myeloid sarcoma, myeloid proliferation related to Down’s syndrome and 
undifferentiated and biphenotypic acute leukaemias. AMLs with certain genetic 
abnormalities are further characterised as those with favourable or unfavourable 
outcome. Favourable karyotypes include translocation (t)(8;21) which results in 
the formation of the runt-related transcription factor 1 (RUNX1)/ETO fusion 
gene (also known as AML1/ETO), inversion (inv)(16) which produces the core 
binding factor β/myosin heavy chain 11 (CBFB/MYH11) fusion gene, and t(15;17) 
which causes the fusion of the PML and RARα genes resulting in acute 
promyelocytic leukaemia (APL) (Chaudhury et al., 2015). AML with RUNX1-ETO or 
CBFB/MYH11 present are collectively known as core binding factor AML (CBF-
AML). Those within the ‘AML not otherwise specified’ category fall into similar 
categories as the FAB subtypes M0-M7 with the addition of 2 further groups – 
acute basophilic leukaemia and acute panmyelosis fibrosis. In the most recent 
update the WHO classification system added 2 additional categories – AML with 
mutated CEBPA, and AML with mutated NPM1, due to the prevalence of these 
mutations in AML (Vardiman et al., 2009). 
1.2.2 Common mutations and abnormalities 
In addition to the aforementioned chromosomal rearrangements, approximately 
half of AML patients have cytogenetically normal AML (CN-AML). Within the 
diverse pool of genetic aberrations found in AML, there are some which are 
found more frequently than others. 
1.2.2.1 Class I mutations 
Flt3 (also known as CD135) is a cytokine receptor expressed on hematopoietic 
progenitor cells in particular MPPs and CLPs. FLT3 is found mutated in up to 30% 
of AML patients and is broadly associated with a poor clinical outcome. There 
are 2 classes of FLT3 mutations which result in constitutive activation of FLT3 
signalling - internal tandem duplications (ITD) found in up to 25% of AML patients 
(Nakao et al., 1996), and point mutations in the tyrosine kinase domain (TKD) 
found in 5-10% of AML patients. Activating FLT3 mutations result in aberrant 
activation of downstream pathways including phosphatidylinositol 3-kinase 
(PI3K)/AKT and signal transducer and activator of transcription (STAT5), which 
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promote cellular proliferation. The cKit receptor is a tyrosine kinase structurally 
related to Flt3 that, as alluded to earlier, plays an important role in 
hematopoiesis and stem cell proliferation through its ligand SCF. Up to 80% of 
myeloblasts in AML express cKIT (Ikeda et al., 1991). Activating mutations in the 
cKIT gene are found in up to 25% of CBF-AMLs, and are also common in other 
cancers including testicular, melanoma and gastrointestinal. Similar to Flt3, they 
may be point mutations affecting the TKD or ITD mutations resulting in 
activation of the cKIT receptor (Wakita et al., 2011).  
1.2.2.2 Class II mutations 
1.2.2.2.1 CEBPA mutations 
One of the most commonly mutated genes in AML is CEBPA, with mutations 
reported in between 5% and 14% of AML cases (Pabst and Mueller, 2009). CEBPA 
mutations are primarily of two types either an N-terminal frame-shift, or C-
terminal in-frame mutation (Pabst et al., 2001). N-terminal CEBPA mutations 
cause a truncation of the full length 42kD isoform (p42) resulting in the 
expression of the 30kD isoform (p30) which, as outlined in 1.1.3.3.1, lacks a 
transactivation domain necessary for C/EBPα mediated E2F repression. C-
terminal mutations exhibit insertions or deletions in the bZIP domain which 
affect the DNA binding activity of C/EBPα. CEBPA mutations are associated with 
M1 or M2 (myeloblastic) CN-AML with a favourable outcome, and, unusually, with 
expression of the T-cell surface marker CD7 and increased expression of 
erythroid genes including GATA1 and EPOR. In over 70% of CEBPA mutated AMLs, 
both alleles exhibit a mutation but despite their prevalence, biallelic CEBPA 
mutations almost never result in a complete loss of C/EBPα. Over 90% of 
patients with biallelic mutations carry both the N- and C-terminal mutation 
(Pabst and Mueller, 2007). Indeed there is a growing body of evidence to suggest 
that C/EBPα expression is necessary for the induction of AML in some instances. 
MLL translocations (discussed in 1.2.2.2.3) are a very common lesion found in 
AML, present in around 10% of patients and resulting in the increased expression 
of genes including MEIS1 and HOXA9. A study has shown that expression of 
C/EBPα is required for the initiation but not maintenance of MLL-rearranged AML 
(Ohlsson et al., 2014). A conditional deletion mutant Cebpafl/fl;Mx1Cre was 
treated with polyinosinic-polycytidylic acid (poly I:C) and control (Cebpafl/fl) and 
Cebpa-deleted (CebpaΔ/Δ) HSPCs were isolated and transduced with control or 
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MLL-ENL overexpressing retrovirus. When transplanted into irradiated recipients 
control Cebpafl/fl mice developed lethal AML with a latency of just 10 weeks 
where as CebpaΔ/Δ transplanted mice remained healthy. The authors generated 
primary MLL-ENL AMLs from Cebpafl/fl;Mx1Cre and Cebpafl/fl before transplanting 
into secondary recipients. The recipients were then treated with poly I:C to 
delete Cebpa from the established leukaemia. Loss of Cebpa at this stage had no 
effect on the latency or phenotype of this disease. In another study loss of 
Cebpa from established Hoxa9/Meis1-induced leukaemia resulted in improved 
survival (Collins et al., 2014). As with the aforementioned study, overexpression 
of HOXA9/MEIS1 in a Cebpa null background was unable to drive 
leukaemogenesis, but in this case deletion of Cebpa from an established 
HOXA9/MEIS1 leukaemia resulted in a delay in disease latency from 40 to 60 
days. 
In addition to these commonly occurring mutations, C/EBPα is dysregulated in a 
variety of other ways e.g. hypermethylation of the CEBPA promoter leading to 
gene silencing (Chim et al., 2002). Common AML mutations resulting in fusion 
oncoproteins can inhibit CEBPA mRNA transcription including  AML1-ETO 
(1.2.2.2.6), PML-RARα (1.2.2.2.5) and CBFB/MYH11  (Paz-Priel and Friedman, 
2011). Several posttranslational modifications of the C/EBPα protein have also 
been documented. C/EBPα is phosphorylated at serine 21, resulting in a 
conformational change which inhibits its ability to induce granulocytic 
differentiation (Ross et al., 2004). The p42 isoform of C/EBPα has also been 
shown to be sumoylated (Hankey et al., 2011). It has been suggested that p42 
sumoylation may occur as a result of increased p30 expression (Geletu et al., 
2007) which itself cannot be sumoylated, highlighting a dominant negative role 
for p30 over p42, discussed in more detail in section 3.1.1.1. Proteasomal 
degradation of C/EBPα mediated by TRIB2 induces AML in vivo (Keeshan et al., 
2006) and is discussed in detail in 1.3.4.1.1, and elucidating the nature of this 
relationship is a major focus in chapter 3. 
1.2.2.2.2 NPM1 
NPM1 is a ubiquitously expressed phosphorylated protein which shuttles between 
the cytoplasm and nucleus where it mediates a range of activities including 
regulation of p53 and ribosome assembly and transport (Lindstrom, 2011). NPM1 
mutations, which occur in one third of all AMLs and up to 60% of CN-AML cases, 
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result primarily from a frameshift caused by an insertion into exon 12 of the 
gene. The resultant protein, termed NPM1c+, lacks at least one key tryptophan 
residue in the C terminal nuclear export signal (NES) region, resulting in NPM1 
transiting out of the nucleus and into the cytoplasm (Falini et al., 2006). It is not 
fully understood how cytoplasmic NPM1c+ contributes to leukaemogenesis nor 
the prognostic significance of NPM1 mutations, however a recent review of 13 
previously published studies suggested that NPM1 mutations correlate with a 
favourable outcome for AML patients (Liu et al., 2014). 
1.2.2.2.3 Mixed-lineage leukaemia fusion genes 
Mixed-lineage leukaemia (MLL) is a histone methyltransferase protein essential 
for regulating gene expression in hematopoiesis. MLL forms a large multi-subunit 
protein complex which negotiates chromatin modification through methylation, 
acetylation and nucleosome remodelling (Slany, 2009). It also associates with 
the WD repeat-containing protein 5 (WDR5), discussed further in section 3.1.1.4, 
which recognises a methylation mark introduced by MLL at histone 3 lysine 4 
(H3K4). While MLL mediated chromatin modification is a requirement for the 
transcription of many genes, HOX genes are among those most dependent on it 
and as discussed next are frequently dysregulated as a result of the formation of 
MLL fusion genes. Translocations affecting MLL (11q23) are found in both 
myeloid and lymphoid leukaemia. To date MLL has been associated with 79 
translocation partner genes (Meyer et al., 2013) but the most common are ENL, 
AF9, AF4, ELL and AF10. MLL-ENL overexpression in BM cells in a B cell 
permissive serial replating assay resulted in immortalisation of a B220+CD19- cell 
capable of continuous replating and generating B220+CD19- leukaemia growth in 
vivo when transplanted into recipient mice (Zeisig et al., 2003). The MLL-ENL 
leukemic cells also expressed CD11b and cKit to a lesser extent.  MLL leukaemia 
is typically aggressive and common in paediatric patients. 
1.2.2.2.4 Dysregulation of HOX genes 
In vertebrates the genes that encode the highly conserved HOX proteins are 
found in 4 clusters - A, B, C, and D - on separate chromosomes. In the 
hematopoietic system HOX genes are differentially expressed on stem and 
progenitor cells. They are highly expressed in primitive cells and their expression 
is downregulated with differentiation. HOXA genes are expressed in the myeloid 
lineage, HOXB in erythroid and HOXC in the lymphoid lineage (Alharbi et al., 
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2013). HOXA9 is the most highly expressed HOX family member in human HSCs 
and progenitor populations. Its overexpression in vivo results in a long latency 
murine AML (Kroon et al., 1998). HOX proteins usually require the binding of a 
cofactor to mediate their effects the most common belonging to the pre-B-cell 
leukaemia (PBX), and myeloid ecotropic insertion site (MEIS) families which also 
have essential roles in hematopoiesis. HOX mutations are one of the most 
common Class II mutations found in AML and NUP98 is one of the most frequent 
HOX fusion partners. Fusion with NUP98 has been documented for HOXA9, A11, 
A13, D11, D13 and C13. Murine AML induced by HOXA9/NUP98 fusion protein 
overexpression is associated with long latency (~1 year) but with co-
overexpression of cofactors MEIS1 the latency is greatly decreased. In addition to 
dysregulation by mutation, HOX gene expression is frequently upregulated by 
other common chromosomal rearrangements in AML. Usually MLL regulates HOX 
gene transcription through direct binding, however MLL fusion proteins hyper-
activate HOX transcription resulting in a block in myeloid differentiation (Slany, 
2009). HOX gene expression is used as a prognostic factor as it correlates with 
intermediate or unfavourable outcome. 
1.2.2.2.5 PML RARα 
Over 98% of APL (M3) patients, and 13% of all AML patients, are positive for the 
t(15;17) translocation which results in the fusion of RARA with PML producing 
the oncoprotein PML-RARα (Goddard et al., 1991). RARα is a transcription factor 
that is activated by all-trans retinoic acid (RA) and 9-cis retinoic acid. Its activity 
controls the transcription of genes involved in apoptosis, differentiation and 
granulopoiesis. RARα binds to regions of DNA and recruits corepressors to repress 
gene transcription but stimulation with its ligand results in recruitment of a 
coactivator protein which induces transcription. PML is a tumour suppressor 
protein involved in a wide range of processes including repression of cell growth 
and proliferation and induction of apoptosis. The PML-RARα oncoprotein results 
in a block in differentiation of granulocytes and uncontrolled growth resulting in 
an accumulation of leukemic promyelocytes. APL is one of the most treatable 
forms of leukaemia as it responds to RA therapy which reverses RARα repression 
of transcription and induces differentiation of leukemic blasts leading to 
apoptosis. As a single agent ATRA treatment has been reported to induce 
complete remission in 85% of patients, and in combination with standard 
chemotherapeutics up to 95% (Coombs et al., 2015). 
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1.2.2.2.6 RUNX1 
RUNX1, also called acute myeloid leukaemia 1 (AML1) protein, is a transcription 
factor involved in the regulation of HSC differentiation through interaction with 
an array of genes including PU1 and CEBPA. Several chromosomal translocations 
in AML pathophysiology involve the RUNX1 gene. t(8;21) is one of the most 
common AML rearrangements and results in the fusion of the RUNX1 gene with 
ETO. The RUNX1-ETO or AML1-ETO fusion protein is present in approximately 12% 
of AML patients (Lam and Zhang, 2012). 
1.2.2.3 Mutations of epigenetic modifiers 
DNMT3A is a highly conserved 130kD protein which catalyses DNA methylation, 
an epigenetic modification in which a methyl group is added to DNA that can 
stably alter gene expression by switching on or off gene transcription. Aberrant 
DNA methylation is a hallmark of cancer. Mutations in DNMT3A are present in 
approximately 20% of AML cases. Despite much research, the mechanism through 
which DNMT3A mutations contribute to leukaemogenesis remains elusive. There 
are some patterns emerging for co-occurring mutations. DNMT3A mutations do 
not exist in patients with t(15;17), inv(16) or t(8;21), nor in MLL-rearranged 
leukaemia (Yang et al., 2015). However 60% of patients carrying a DNMT3A 
mutation also carry an NPM1 mutation and they are also positively correlated 
with FLT3-ITD and IDH1 mutations albeit to a lesser extent, but how these 
mutations interact in the pathology of AML is unknown.  
The commonly recurring chromosomal translocations and molecular 
abnormalities in AML are briefly discussed here but many other less frequently 
occurring genetic lesions have been described in AML. Most gene mutations 
identified in CN-AML, also occur in AML with abnormal and complex karyotypes, 
and frequently in the presence of additional mutations further increasing the 
complexity of this disease. It is this complexity and heterogeneity that makes 
AML such a difficult disease to target therapeutically.  
1.2.3 Chemotherapeutic treatment of AML 
The treatment of AML with chemotherapeutic drugs occurs in 2 phases – 
intensive induction therapy to destroy the bulk of leukaemia cells, and 
consolidation therapy to destroy long-lasting leukaemia cells. Induction 
  46 
 
treatment usually involves two drugs – namely cytarabine (also known as ara-C) 
and an anthracycline such as liposomal daunorubicin. Cytarabine is an anti-
metabolite which damages DNA in the S-phase of the cell cycle halting cancer 
cell division. Daunorubicin interacts with DNA by intercalation and inhibits the 
progression of topoisomerase II. The standard approach termed “7+3” involves 7 
days of cytarabine administration followed by 3 days of an anthracycline. 
Etoposide, which forms a complex with DNA and topoisomerse II to prevent the 
re-ligation of DNA strands, is also frequently administered with cytarabine and 
daunorubicin in patients below 60 years of age. Consolidation therapy usually 
involves several cycles of cytarabine (Kadia et al., 2014). As mentioned briefly, 
APL is induced by t(15;17) and is treatable with RA but the overall prognosis for 
AML in general is poor with only 40% of patients under 60 years of age surviving 
more than 5 years (Stein and Tallman, 2016).  
Many commonly recurring cytogenetic lesions confer poor prognosis and as such 
extensive work is being carried out to develop additional chemotherapeutic 
agents based on the molecular phenotype of a given AML. Patients with FLT3-ITD 
mutations have a high relapse rate and poor prognosis. Small molecule tyrosine 
kinase inhibitors (namely gilteritinib, quizartinib and midostaurin) are currently 
being investigated for their efficacy in AML treatment with limited success thus 
far. Patients with IDH1/2 mutations fall into the intermediate to poor outcome 
groups and inhibitors of mutant IDH1/2 are currently in clinical trials. In addition 
to molecularly targeted agents, several antibody-drug conjugates against unique 
cell surface receptors expressed on leukemic cells are also being developed. 
Despite the clear complexity of AML as eluded to above, the standard “7+3” 
treatment prevails even for patients with molecularly and cytogenetically 
complex AML. The development of new therapies such as those mentioned for 
FLT3 and IDH1/2 mutations are the result of extensive characterisation of a 
given lesion. Thus it is imperative to gain a better understanding of molecular 
perturbations that contribute to AML pathogenesis in order to expose new 
targets for more tailored treatment. There is a strong correlation between 
dysregulated TRIB2 expression and human acute leukaemia and this thesis aims 
to further examine the role of TRIB2 in hematopoiesis and AML pathogenesis. 
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1.3 Trib2 
Trib2 is a member of the Tribbles family of pseudokinases that comprise 3 
members; Trib1, Trib2 and Trib3. 
1.3.1 Discovery 
Tribbles (trbl) was first identified as a novel regulator of string - a CDC25 
homolog - in drosophila. Genetic screening for mutations resulting in improperly 
formed ventral furrows in drosophila embryos revealed trbl as a candidate gene 
(Seher and Leptin, 2000). Sequencing of trbl revealed that it encodes a protein 
similar to the SNF1 class of serine/threonine kinases but with an asparagine (N) 
to arginine (R) substitution in the catalytic loop domain. In the drosophila 
embryo, string controls entry into mitosis but during gastrulation a delay in 
mitosis of cells on the ventral side of the embryo is required for the formation of 
the ventral furrow. A parallel study subsequently showed that trbl inhibited 
string, permitting formation of the ventral furrow (Grosshans and Wieschaus, 
2000). Embryos lacking trbl did not exhibit the mitotic delay during gastrulation, 
and by injecting synthetic trbl mRNA into Drosophila embryos, the authors 
demonstrated that trbl overexpression inhibited mitosis. The authors also 
further characterised the kinase domain of trbl and found changes in 3 
additional residues; a lysine (K) to R swap in the adenosine triphosphate (ATP) 
binding site, an aspartic acid (D) to serine (S) exchange, and a highly conserved 
histidine (H) residue in the catalytic loop was substituted with a leucine (L). The 
authors hypothesised that such deviations would mean trbl may lack kinase 
function.  
In a gain-of-function screen for genes whose overexpression would affect cell 
division during oogenesis in the developing drosophila, authors identified 15 (out 
of 8500) lines with aberrant cell division (Mata et al., 2000). In one of the 15 
lines, overexpressed trbl was shown to result in extra cell divisions with very 
high frequency. Co-transfection of trbl and string resulted in a reduction of 
string protein levels and in the presence of a proteasome inhibitor, the 
degradation was reversed indicating that trbl controls string protein turnover in 
a proteasome–dependent manner. In drosophila oogenesis the C/EBP 
transcription factor slbo is required for the migration of border cells. Trbl was 
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shown to negatively regulate slbo in vivo by targeting it for ubiquitin mediated 
degradation (Rorth et al., 2000). These 4 studies identified trbl as a regulator of 
key developmental stages by mediating protein degradation.  
1.3.2 Structure of TRIB proteins 
The three mammalian homologs of trbl, TRIB1, TRIB2 and TRIB3, are highly 
conserved among vertebrates and share substantial sequence similarity, in 
particular TRIB1 and TRIB2 exhibit 71.3% overlap with one another (Yokoyama 
and Nakamura, 2011).  Structurally the TRIB family are composed of an N-
terminal region, a C-terminal region and a central pseudokinase domain (Figure 
1. 7). The N-terminal domain is rich in proline and serine residues, a common 
feature of proteins with a short half-life. The C-terminal domain contains a 
highly conserved constitutive photomorphogenic 1 (COP1) E3 ubiquitin ligase 
binding motif, and a mitogen-activated kinase/extracellular-signal-regulated 
kinase-1 (MEK1) binding motif (Qi et al., 2006, Yokoyama et al., 2010). As 
mentioned above the TRIB pseudokinase domain has characteristic features of a 
canonical kinase but lacks critical motifs and residues including a motif required 
for anchoring ATP (GXGX2GXV), and a sequence (DFG) required for catalysis 
(Hanks and Hunter, 1995). The conserved amino acids of canonical kinases, 
absent in the TRIB family, bind to divalent metal ions and align ATP before 
phosphoryl-transfer. Until recently no kinase activity had been reported for the 
TRIB family of proteins thus the persistent classification of the family as 
pseudokinases. However recently recombinant human TRIB2 protein was used in 
a fluorescence-based ligand interaction assay and demonstrated weak ATP 
binding activity in the absence of divalent metal cations, which can be targeted 
by small molecule inhibitors (Bailey et al., 2015).    
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Figure 1. 7 – Schematic diagram of the Trib family 
 
1.3.3 Functions of TRIB2  
The TRIB family have been shown to be dispensable for development in the 
vertebrate system (Yamamoto et al., 2007, Takasato et al., 2008, Okamoto et 
al., 2007) suggesting overlapping functions between the 3 mammalian isoforms. 
TRIBs are expressed in most human tissues with TRIB2 expression highest in PB 
leukocytes (Kiss-Toth et al., 2004). TRIB proteins localize in both the cytoplasm 
where they mediate proteasomal degradation of signalling proteins including 
mitogen-activated protein kinase kinase (MKK) and C/EBPα, and also in the 
nucleus where they associate with target promoters such as C/EBPζ (CHOP) and 
activating transcription factor 4 (ATF4)(Lohan and Keeshan, 2013).  
1.3.3.1 Protein degradation 
The proteolytic function of Trbl has been conserved in vertebrates where the 
TRIB family regulate cell cycle and differentiation in a cell-specific context. 
TRIB2 mediates protein degradation by binding directly to target proteins and 
recruiting the E3 ubiquitin ligase COP1 into a protein complex, marking the 
target protein for degradation. Members of the C/EBP family (α, β, γ) have been 
shown to regulate adipocyte differentiation, a process which is also modulated 
by sets of signal cascades including mitogen-activated protein kinases (MAPK), 
extracellular signal-regulated protein kinase (ERK) and jun kinase (JNK). 
Overexpression of TRIB2, and also TRIB3, inhibits the differentiation of 3T3-L1 
adipocytes in vitro (Naiki et al., 2007). Gene expression analysis in TRIB2 
overexpressing 3T3-L1 cells showed that Cebpb mRNA levels were unchanged in 
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the presence of TRIB2 or TRIB3 but Cebpa levels were significantly reduced. At 
the protein level TRIB2 (but not TRIB3) overexpression resulted in reduction of 
the LAP isoform of CEBPB which contains the DNA binding and trans-activation 
domains with no effect on the LIP isoform – an inhibitory isoform which lacks the 
trans-activating domain and is translated from an alternative start site. 
Treatment with MG132, a cell permeable proteasome inhibitor, rescued LAP 
protein levels and in a co-immunoprecipitation (CO-IP) experiment TRIB2 was 
shown to bind to LAP but not LIP suggesting that TRIB2 selectively degrades this 
CEBPB isoform in a proteasome dependent manner to inhibit adipogenesis.  
It is worth noting that while TRIB3 overexpression in adipocytes did not lead to 
C/EBPβ degradation it did inhibit adipocyte differentiation through suppression 
of AKT phosphorylation. TRIB2 mediated proteasomal dependent degradation of 
C/EBPα has also been demonstrated in the lung (Grandinetti et al., 2011) and 
hematopoietic system (Keeshan et al., 2006) and is discussed in detail in 
1.3.4.2.2 and 1.3.4.1.1 respectively. Indeed TRIB1 has also been shown to 
degrade C/EBPα in the hematopoietic system (Yokoyama et al., 2010). Acetyl-
coenzyme A carboxylase (ACC) is a multi-subunit enzyme that catalyses 
carboxylation of acetyl-CoA providing a substrate for the biosynthesis of fatty 
acids. TRIB3 was the first to be shown to degrade ACC in adipose tissue in a COP-
1 dependent manner (Qi et al., 2006), and this was subsequently demonstrated 
for TRIB1 and TRIB2 (Dedhia et al., 2010).  
1.3.3.2 MAPK/ERK Signalling 
MAPKs are a highly conserved serine/threonine kinase family integral to 
fundamental cellular processes like proliferation, differentiation and survival. 
MAPK activation involves a three step process whereby MAPK is activated upon 
phosphorylation by MAPK kinase (MAPKK) which is first phosphorylated by MAPKK 
kinase (MAPKKK) in response to stimuli such as mitogens, cytokines and growth 
factors. Six groups of MAPKs have been characterized including ERK which 
responds to growth factors and mitogens, and JNK and p38 which primarily 
respond to stress stimuli. Activation of MAPK is involved in the inflammatory 
activation of monocytes. In a study of regulators of monocyte activation, TRIB2 
was shown to be downregulated following treatment of a human monocytic 
leukaemia cell line, THP-1, with either acetylated low-density lipoprotein 
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(AcLDL) or lipopolysaccharide (LPS) (Eder et al., 2008). Alone AcLDL treatment 
of THP-1 cells does not induce production of the proinflammatory cytokine 
interleukin-8 (IL-8), but in combination with LPS treatment it further increases 
LPS-induced IL-8 production. When TRIB2 expression was targeted using an 
siRNA, IL-8 production in response to LPS treatment was significantly higher in 
cells with silenced TRIB2 than in cells expressing TRIB2. IL8 expression is 
regulated by MAPK pathways and pharmacologically blocking JNK or MEK1 (but 
not p38) inhibits LPS-induced IL-8 production. In TRIB2 silenced THP-1 cells MAPK 
activation was potentiated in response to LPS-dependent MAPK activation 
suggesting a negative regulatory role for TRIB2 in MAPK specific inflammatory 
activation. CO-IP studies showed that TRIB2 specifically interacts with MEK1 and 
MKK7 but not with MKK4 in monocytes and this binding is dependent on the 
TRIB2 kinase-like domain. Thus the authors hypothesise that monocytes 
downregulate TRIB2 in response to stimulation, shown here by AcLDL or LPS, 
resulting in loss of TRIB2 binding to MEK1 or MKK7 thus, increasing activation of 
ERK and JNK respectively, resulting in increased IL-8 production.      
1.3.3.3 AKT Signalling 
Activated AKT, a serine/threonine kinase, mediates a host of downstream 
responses including glucose homeostasis. The AKT signal transduction pathway is 
usually activated by PI3K which in turn is activated by a range of stimuli such as 
hormones and growth factors. A yeast two-hybrid assay, used to identify proteins 
upstream of AKT which could attenuate its activity, revealed TRIB3 as a putative 
regulator of AKT activity (Du et al., 2003). To validate this link the authors 
overexpressed AKT in the HepG2 cell line and performed a CO-IP experiment and 
found that both TRIB2 and TRIB3 interact with AKT. To address whether these 
interactions affect AKT activity, HEK293 cells were treated with Insulin-like 
growth factor (IGF1) to induce AKT phosphorylation at Thr308 and Ser473. 
Overexpression of TRIB2 and TRIB3 blocked IGF1 induced AKT phosphorylation in 
293T cells.   
1.3.3.4 Toll-like receptor signalling 
Toll-like receptors (TLRs) comprise a family of ten type 1 transmembrane 
proteins expressed on cells involved in the innate immune response such as 
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macrophages and dendritic cells where they detect a wide range of pathogens 
and molecules to initiate the innate and adaptive immune response. TLR5 
recognises flagellin, the principle component of bacterial flagella, and TRIB2 has 
been identified as a binding partner of TLR5. A study of colonic tissue biopsies in 
patients with inflammatory bowel disease showed TRIB2 expression was 
decreased when compared with normal control tissue samples, and those cells 
displaying decreased TRIB2 were mainly epithelial cells (Wei et al., 2012). 293T 
cells transfected with TLR2, TLR4, TLR5 and TLR9 were each stimulated with the 
appropriate ligand and it was shown that TRIB2 mRNA and protein expression 
was upregulated upon TLR5 stimulation by flagellin. In an NF-κB luciferase 
reporter assay, TRIB2 inhibited NF-κB activation by TLR-5 in a dose dependent 
manner. Conversely knockdown of TRIB2 resulted in an increase NF-κB activity 
when TLR5 expressing cells were stimulated with flagellin. The authors showed 
that knockdown of TRIB2 significantly reduced TLR5 mediated phosphorylation of 
the JNK and p38 pathway but no effect on the ERK pathway was observed. By 
CO-IP the authors showed that NF-κB2 (p100) interacts with Trib2. Thus the 
authors demonstrated a novel role for TRIB2 in regulation of TLR5 signalling 
through modulation of specific MAPK pathways to inhibit NF-κB activity. 
1.3.3.5 Hematopoiesis 
In the human hematopoietic system gene expression analysis has revealed that 
TRIB1 expression is highest in mature BM granulocytes, monocytes and B cells, 
while TRIB2 expression is significantly higher in the T cell compartment (Liang et 
al., 2013). TRIB3 expression is generally low in the hematopoietic compartment. 
Recently TRIB2 was implicated in the development of the megakaryocyte and 
erythroid lineages (Mancini et al., 2012). The authors used Cebpa, Gata1 and 
friends of GATA-1 (Fog1) conditional knockout mice to study the role of these 
transcription factors in megakaryocyte and erythroid differentiation and showed 
that GATA-1 is required for erythroid development, FOG-1 is required for the 
formation of megakaryocyte and erythroid precursor cells, and also that FOG-1 
could suppress myeloid progenitor specification. They suggest that TRIB2 
mediated degradation of C/EBPα may be the mechanism through which FOG-1 
can suppress myeloid potential. Microarray analysis showed Trib2 to be 
expressed in MkE precursor cells but down-regulated in pre-GMs and CLPs. They 
also found a binding site on the Trib2 promoter that binds both GATA-2 and FOG-
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1 and this was confirmed by chromatin immunoprecipitation (ChIP) assay. 
Furthermore they show that in the conditional Fog1 KO mice, there is a strong 
reduction in Trib2 expression. These findings point towards a role for Trib2 in 
erythroid development. However, Trib2 has also been shown to be 
downregulated by EPO (Flygare et al., 2011) a cytokine essential for erythroblast 
development and survival. Thus far it has not been determined whether or not 
loss of Trib2 from the hematopoietic compartment affects lineage distribution 
and stem and progenitor cell differentiation and this is a major focus of chapter 
4, section 4.3.4. 
1.3.4 The role of TRIB2 in cancer 
The Tribbles family have been implicated in many different types of cancer 
including acute leukaemia, melanoma, lung and liver cancer. 
1.3.4.1 TRIB2 in acute leukaemia 
1.3.4.1.1 AML 
Trib2 was first identified as a murine oncogene, when its overexpression in a 
BMT led to the development of a potent AML with a 6 month latency (Keeshan et 
al., 2006). In this model, TRIB2 preferentially degrades the p42 isoform of the 
myeloid transcription factor C/EBPα and causes an increase in the truncated p30 
isoform which has oncogenic functions. As discussed in detail in 1.1.3.3.1, in the 
hematopoietic system C/EBPα is essential for granulopoiesis (Zhang et al., 1997) 
and TRIB2 mediated degradation of p42 blocks granulopoiesis. This block in 
granulopoiesis is coupled with uncontrolled proliferation of the myeloblast cells 
and leads to a transplantable AML with 100% penetrance and a median latency of 
25.5 weeks. Degradation of C/EBPα by TRIB2 was shown to be via a proteasome 
dependent pathway as in a CO-IP experiment TRIB2 only associated with p42 in 
the presence of the proteasome inhibitor MG132. Structure-function analysis of 
TRIB2 revealed that deletion or mutation of the C-terminal COP1-binding site 
prevented TRIB2 mediated degradation of C/EBPα and thus failure to induce AML 
in vivo (Keeshan et al., 2010). Mutation of the TRIB2 pseudokinase domain 
prevented TRIB2 mediated C/EBPα degradation.  
The TRIB2 induced increase in the p30 isoform has not yet been explained. TRIB2 
might be proteolytically cleaving the p42 isoform or it could be switching on the 
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translation of the p30 isoform which has its own alternative translation initiation 
site (Lin et al., 1993). While it lacks the N-terminal, p30 still contains the 
transactivation domain TAD2 and, as will be discussed in detail in section 
3.1.1.1, p30 has been shown to be a dominant negative regulator of the p42 
isoform and also binds different target genes (Pabst et al., 2001). A recent 
publication described a regulatory loop involving E2F1 and TRIB2, whereby E2F1 
binds to the TRIB2 promoter to increase translation of the TRIB2 protein (Rishi et 
al., 2014). TRIB2 then degrades p42 so that E2F1 repression is decreased. TRIB2 
also causes an increase in p30, which lacks the ability to repress E2F1, and in 
this study p30 was shown to synergise with E2F1 to increase the level of TRIB2 
promoter activation thus creating a positive feedback loop that contributes to 
the oncogenecity of TRIB2 (Figure 1. 8). 
 
Figure 1. 8 – Diagram depicting Trib2 mediated degradation of p42, and p30 driven positive 
feedback loop of E2F1 regulation of Trib2 expression 
 
As discussed in 1.2.2.2.4, overexpression of the HOX or HOX-NUP98 induces AML 
in vivo and Meis1 overexpression is a co-operating event in their 
leukaemogenesis, although Meis1 alone has no transforming ability. MEIS1 was 
retrovirally overexpressed in preleukemic NUP98-HOXD13 (ND13) cells and ChIP 
analysis revealed occupation of TRIB2 by MEIS1 (Argiropoulos et al., 2008). The 
authors showed that overexpression of TRIB2 on ND13 BM cells resulted in 
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increased cell growth. The site of integration of recombinant viral vectors can 
lead to activation of proto-oncogenes or inactivation of tumour suppressor 
genes, thereby contributing to leukaemogenesis. Viral insertion mutagenesis 
screens have been used to identify many oncogenes in murine tumours. Analysis 
of insertion sites in TRIB2 tumours uncovered HoxA9 as a site of proviral 
insertion in 1 out of 4 tumours, which resulted in significantly increased HOXA9 
expression (Keeshan et al., 2008). Mice transplanted with BM cells 
overexpressing both TRIB2 and HOXA9 rapidly develop AML with a much shorter 
latency (79 days) than those transplanted with TRIB2 (169 days) or HOXA9 (152 
days) alone. In a study of HOXA9/MEIS1 tumours, Trib1 was identified as a viral 
insertion site with TRIB1 expression upregulated as a result of the insertion (Jin 
et al., 2007). Like TRIB2, transplantation of BM cells co-expressing TRIB1 and 
HOXA9 generated a much more aggressive AML in vivo than induced by TRIB1 or 
HOXA9 alone. 
Gene expression analysis of 13,000 genes in 285 human AML samples clustered 
patients into 16 groups based on their molecular signatures (Valk et al., 2004). 
Patients with CEBPA mutations were found in cluster 4 and 15. Elevated TRIB2 
expression was observed in a subset of samples in cluster 4 which did not 
harbour any mutations including CEBPA, indicating that CEBPA dysregulation was 
through a different mechanism in these patients (Keeshan et al., 2006). Further 
analysis of cluster 4 patient samples revealed that as expected CEBPA expression 
was very high in the samples which carried CEBPA mutations, but in those 
without mutations its expression was silenced, and this group also showed 
overexpression of T-lymphoid genes including NOTCH1 and CD7, as well as CD34 
indicating an immature disease phenotype (Wouters et al., 2007). The authors 
explored a link between TRIB2 expression and NOTCH1 activation by treating 
NOTCH1-dependent murine cell lines, T6E and Scid.adh, with γ-secretase 
inhibitors to block NOTCH signalling and this lead to down-regulation of Trib2 
expression suggesting that Trib2 is a downstream target of NOTCH1. Conversely 
overexpression of intracellular notch (ICN1) in U937 cells resulted in an increase 
in Trib2 expression. ICN1 binds the transcriptional repressor CSL to activate it 
and ChIP analysis of the ICN1/CSL complex revealed direct binding to two sites 
upstream of the Trib2 transcriptional start site. These data demonstrate that 
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Trib2 is a direct Notch1 transcriptional target and that AML cases with elevated 
TRIB2 expression may be due to dysregulated NOTCH1 signalling. 
Recently gene expression analysis has revealed that TRIB2 expression levels, 
while generally low in AML, are higher in PML-RARα positive leukaemia (cluster 
12) than PML-RARα negative leukaemia (Liang et al., 2013). As described in 
1.2.2.2.5 PML-RARα is frequently associated with FLT3 mutations. Within this 
cluster samples with increased TRIB2 expression were observed in the FLT3-TKD 
positive group of PML-RARα positive leukaemia but not FLT3-ITD positive group. 
It was been shown that FLT3-ITD overexpression induces a myeloproliferative 
disease, whereas FLT3-TKD induced lymphoid disease (Grundler et al., 2005).  
1.3.4.1.2 T-ALL 
Trib2 expression is highest in T cells and there are several studies which 
implicate TRIB2 in T-ALL pathogenesis. As outlined in 1.1.5 NOTCH1 activation is 
essential for driving early T cell differentiation, and activating NOTCH1 
mutations are found in over 50% of T-cell acute lymphoblastic leukaemia (T-ALL) 
(Weng et al, 2004). As discussed above in section 1.3.4.1.1, gene expression 
profiling of 285 AML patient samples identified a subset of patients with high 
TRIB2 expression that also displayed aberrant NOTCH1 activation coupled with a 
mixed myeloid-lymphoid phenotype, and Trib2 was shown to be a direct 
transcriptional target of NOTCH1 (Wouters et al., 2007).  
More recently TRIB2 has been identified as a target of PITX1 (Nagel et al., 2011) 
a gene which is regularly activated in T-ALL. PITX1 was overexpressed in Jurkat 
cells, an immortalized human T lymphocyte cell line, and gene analysis revealed 
activation of TRIB2 expression. Aberrant TAL-1 activation is present in up to 60% 
of T-ALLs (Ferrando et al., 2002) and TRIB2 has also been identified as a 
downstream target of the transcriptional complex controlled by TAL-1 (Sanda et 
al., 2012). An inducible RNA interference screen in 2 TAL1-positive T-ALL cell 
lines revealed TRIB2 as an essential gene for cell growth. T cell lines expressing 
shRNAs targeting TRIB2 were unable to survive in culture. Silencing TRIB2 
expression in TAL1-positive T-ALL cell lines induced apoptosis, demonstrating 
that it is essential for the survival of these cells. Bioinformatic analysis of over 
2000 patient samples spanning 16 different acute and chronic leukaemia 
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subtypes revealed that there were significantly higher levels of TRIB2 in T-ALL 
and pre-B-ALL than any other leukemic subtypes (Hannon et al., 2012). 
There is also data supporting a role for Trib1 and Trib3 in leukaemia. Gene 
expression analysis of TRIB1 reveals it is significantly increased in M4 and M5 
AMLs, and AML with inv(16) and t(16;16) (Liang et al., 2013). Trib1 was 
identified as a retroviral insertion site in HOXA9/MEIS1 tumours and TRIB1 was 
shown to cooperate with HOXA9/MEIS1 in vivo to reduce disease latency from 
133 days (HOXA9/MEIS1) to 63 days (TRIB1/HOXA9/MEIS1) (Jin et al., 2007). 
Alone TRIB1, but not TRIB3, overexpression induced murine AML by C/EBPα 
degradation (Dedhia et al., 2010). A study of Down syndrome related AML 
revealed a mutation in the TRIB1 gene in 1 patient at arginine 107 (R107), 
located in the pseudokinase domain (Yokoyama et al., 2012). Mice transplanted 
with TRIB1 or mutant R107 overexpressing BM, all developed AML, but with a 
significantly shorter latency in the R107 transplanted cohort. While TRIB3 
overexpression is unable to induce murine AML in vivo (Dedhia et al., 2010), 
bioinformatic analysis found significant upregulation of TRIB3 expression in AML 
FAB subtypes M2 and M3, as well as in AML with t(8;21) and t(15;17) (Liang et 
al., 2013). 
1.3.4.2 TRIB2 in solid tumour cancer 
1.3.4.2.1 Melanoma 
Forkhead box proteins (FOX) are a superfamily of transcriptional regulators with 
diverse functions, and their dysregulation is implicated in a host of human 
cancers including melanoma. The FOXO subfamily, comprising FOXO1, FOXO3a, 
and FOXO4, regulate cell proliferation, survival and stress response. They are 
bona fide tumour suppressors. To identify regulators of FOXO activity, a 293T 
cell line was generated which could measure FOXO transcriptional activity 
(293foxREP) and a loss-of-function screen using an RNAi library of 7914 genes 
was performed (Zanella et al., 2010). TRIB2 silencing in the 293foxREP cell line 
resulted in the induction of FOXO transcription. TRIB2 expression was analysed in 
154 patient samples of a variety of tumour types including breast, prostate and 
thyroid. 70% of skin cancer tumours analysed displayed elevated TRIB2 
expression. Gene expression analysis of 43 normal and melanoma tissues 
revealed that TRIB2 expression was significantly upregulated in stage III or IV 
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melanoma. The authors then silenced TRIB2 expression in a luciferase reporter 
assay using the G-361 human melanoma cell line and showed that there was an 
increase in FOXO transactivation. TRIB2 knockdown in the G-361 line impaired 
cell growth and this effect could be rescued by overexpressing TRIB2. TRIB2 has 
also been identified as a candidate biomarker in melanoma diagnosis and 
progression as it exhibits low expression in healthy skin samples, and this 
increases in benign melanoma, with highest expression seen in malignant 
melanoma samples (Hill et al., 2015). 
1.3.4.2.2 Lung Cancer 
Expression of C/EBPα is essential for the differentiation of lung cells and its 
overexpression causes cell death in lung tumour cells. Considering the 
established relationship between TRIB2 and C/EBPα in leukaemogenesis, the role 
of TRIB2 in lung cancer has been examined. Transcriptional analysis of 8 non-
small cell lung cancer (NSCLC) cell lines revealed significant upregulation of 
TRIB2 in all, and analysis of TRIB2 expression in 68 human primary lung tumour 
samples showed an increase in TRIB2 mRNA in almost 30% of samples tested 
(Grandinetti et al., 2011). Knockdown of TRIB2 in NSCLC lines reduced their 
proliferation and increased apoptosis, whereas TRIB2 depletion in normal lung 
fibroblasts had no effect. This also translated in vivo where NSCLC lines 
transduced with control virus lead to the rapid generation of tumours while 
those transduced with a short hairpin RNA (shRNA) targeting TRIB2 remained 
free of tumours for up to 240 days post-transplant. The authors then 
demonstrated a negative correlation between TRIB2 and CEBPA expression in the 
68 primary samples previously examined. In a luciferase reporter assay the 
authors showed that the presence of TRIB2 resulted in a 3-fold decrease in 
activation of the reporter by C/EBPα, although the level of C/EBPα protein 
remained unchanged. Knockdown of TRIB2 resulted in a 5 to 10 fold increase in 
the expression of C/EBPα target genes GCSFR and NE2. These data show that in 
this context TRIB2 is exerting its oncogenic effects by modulating CEBPA 
transactivation as opposed to C/EBPα protein degradation as observed in AML 
induction. However the authors then performed immunoprecipitation-mass 
spectrometry in a NSCLC line transduced with TRIB2 and identified the E3 
ubiquitin ligase TRIM21 as a binding partner, which they confirmed by CO-IP. 
When C/EBPα and TRIB2 were co-transfected into 293T cells in the absence of 
TRIM21, little to no C/EBPα degradation was observed, but in the presence of 
  59 
 
TRIM21 there was a significant decrease in C/EBPα protein levels indicating that 
both TRIB2 and TRIM21 are required for C/EBPα degradation. 
1.3.4.2.3 Liver Cancer  
The wingless-type MMTV integration site (WNT) family of 19 secreted 
glycoproteins comprise a diverse family that regulate a host of functions from 
cell proliferation and stem cell self-renewal to migration and polarity, via β-
catenin dependent and independent mechanisms. Both activating and inhibiting 
mutations in WNT pathways are found in many cancer types including liver 
cancer. Nuclear translocation of β-catenin results in transcriptional activation of 
downstream genes via T cell factor (TCF) and the Wnt/TCF pathway has been 
well established in hepatocarcinogenesis. Genome-wide ChIP-seq analysis and 
transcriptional profiling of TCF4 was performed in liver cancer cells and the data 
were intersected with transcriptional profiling of the HepG2 human liver cancer 
cell line which had WNT activation blocked using a dominant-negative TCF4 
(Wang et al., 2013). The authors identified 63 genes with unique TCF4 binding 
regions that required WNT/TCF for expression of which TRIB2 was among the 
most highly enriched. Silencing of TRIB2 expression in HepG2 cells resulted in 
decreased cell proliferation and increased apoptosis, but had no effect on 
hepatocytes. TRIB2 loss also impaired HepG2 cell colony forming ability and the 
ability of the cells to generate tumours in vivo suggesting that TRIB2 is essential 
for human liver cancer cell survival. The authors also demonstrated that TRIB2 
was exerting its effects via interaction with 2 known tumour suppressor 
pathways in liver cancer, the Hippo and C/EBP pathways. TRIB2 knockdown in 
HepG2 cells resulted in an increase of endogenous C/EBPα, and ectopic C/EBPα 
expression induced apoptosis in HepG2 cells.  
The same group subsequently published a study showing that TRIB2 negatively 
regulates WNT activity (Xu et al., 2014). Overexpression of TRIB2 on two liver 
cancer cell lines (Bel-7402 and SMMC-7721) decreased cell proliferation, colony 
formation and growth in vivo. The authors chose these two cell lines because 
they have WT β-catenin, unlike the HepG2 line used in their previous study 
which carries a dominant active β-catenin mutation. In these lines, the authors 
showed that TRIB2 overexpression reduced WNT-mediated transcriptional 
activity and decreased levels of β-catenin and TCF4 protein but not mRNA. CO-IP 
experiments demonstrated that the E3 ligases β-TrCP, COP1 and SMURF3 all 
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bound to TRIB2 and their knockdown resulted in upregulation of β-catenin and 
TCF4. Indeed deletion of the E3 ligase binding region of TRIB2 impaired its 
ability to reduce β-catenin and TCF4 protein expression. This study highlights a 
dual role for TRIB2 in liver cancer acting as both a tumour suppressor and an 
oncogene highlighting the complex regulatory networks through which TRIB2 
exerts its function. 
Studies have also linked Trib1 and Trib3 to various forms of cancer. TRIB1 
expression has been shown to be essential for the survival of prostate cancer 
cells and is linked with an aggressive disease phenotype and poor prognosis (Lin 
et al., 2014). TRIB1 is also involved in the etiology of glioma (Tang et al., 2015), 
breast (Bhushan and Kandpal, 2011), ovarian (Puiffe et al., 2007) and follicular 
thyroid cancer (Puskas et al., 2005). In a study of over 200 colorectal cancer 
(CRC) patients TRIB3 expression was elevated and its expression correlated with 
poor overall survival (Miyoshi et al., 2009). The authors showed that knockdown 
of TRIB3 expression in 7 different CRC cell lines resulted in decreased cell 
growth. TRIB3 expression has also been shown to correlate with poor prognosis in 
breast cancer patients (Wennemers et al., 2011). Elevated TRIB3 expression was 
reported in 56 of 60 human lung cancer samples studied and correlated with 
poor prognosis in NSCLC (Zhou et al., 2013). 
Together these studies highlight the importance of TRIB2, and other family 
members, in the biology of cancer development across multiple cancer types. 
This thesis aims to provide further insight into the role of TRIB2 in hematopoiesis 
and AML pathogenesis in order to facilitate the future development of 
therapeutic strategies in a targeted approach to AML treatment. 
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2 Materials & Methods 
2.1 Plasmids and cell lines 
2.1.1 Plasmids 
All plasmids were purified from transformed chemically competent DH5α E.coli 
cells using the PureYield™ Plasmid Midiprep System (Promega) according to the 
manufacturers’ protocol. Concentration and purity were determined using a 
NanoDrop spectrophotometer ND-1000 (Labtech International).  
For the production of retroviral particles the MigR1 expression vector was used 
(Figure 2. 1). MigR1 is an MSCV based retroviral construct carrying an internal 
ribosome entry site (IRES) and expressing enhanced green fluorescent protein 
(GFP) (Pear et al., 1998). MigR1 based expression vectors were packaged by 
293T cells (2.2.1.1) using the packaging plasmid pCGP which encodes for the 
viral polyprotein gag and reverse transcriptase pol, and the envelope plasmid 
pCMV-VSV-G (VSVG). 
 
Figure 2. 1 – Plasmid map of retroviral expression vector MigR1 
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Rat C/EBPα (NM_012524) with a C-terminus fused HA tag was cloned into either 
MigR1 to produce MigR1-C/EBPα, or pcDNA3.1-myc-HIS (PHMA) to produce HA 
tagged PHMA-C/EBPα. Rat C/EBPα cDNA with a C-terminus fused HA tag lacking 
the upstream open reading frame (ORF) was subcloned into the PHMA backbone 
to produce the HA tagged PHMA-p42 plasmid. C/EBPα-p30 expressing plasmids, 
which encode the p30 isoform of C/EBPα, were made by PCR amplification 
starting at the nucleotides corresponding to amino acid 118 of C/EBPα followed 
by a stop codon. The PCR product was subcloned into either the MigR1 vector to 
produce MigR1-p30 or the PHMA vector to produce PHMA-p30. The C/EBPα 
mutant K313R was created by Genescript in a PHMA expression vector (PHMA-
K313R), and subcloned into the MigR1 backbone to produce MigR1-K313R. A 1032 
base pair (bp) fragment encoding murine Trib2 cDNA (+/- N terminus FLAG tag) 
was subcloned into either MigR1 to produce MigR1-TRIB2, or a pcDNA3.1-myc-HIS 
to produce TRIB2-pcDNA3.1. For the dual-luciferase reporter assay (2.2.4) the 
reporter plasmid pTK-WT-G-CSFR-luciferase (firefly) contained 4 consensus 
C/EBPα binding sites from the G-CSFR promoter and the mutant pTK-MUT-G-
CSFR-luciferase reporter construct contained 4 mutated C/EBPα binding sites. 
The pRL-TK (renilla) plasmid was used as a control. A 1203 bp fragment encoding 
the entire murine Nfix cDNA was subcloned (+/- N or C terminus MYC tag) into 
MigR1 to produce MigR1-NFIX. To date 4 murine transcriptional isoforms of NFIX 
have been found. The overexpression experiments outlined in chapter 5 were 
performed with NFIX transcript variant 2 (NM_010906). All plasmids were 
available in-house.   
Ubiquitin-HA, Ubiquitin/K48R-HA and Ubiquitin/K63R-HA used in ubiquitination 
assays (2.2.1.2) were kind gifts from Dr. R.J.Carmody, University of Glasgow. 
2.1.2 Cell Lines 
All cell lines were available in-house and were routinely tested for mycoplasma 
with the MycoAlert Mycoplasma Detection Kit (Lonza) in accordance with the 
manufacturers’ protocol. 
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2.1.2.1 HEK293T Cells 
HEK293T cells (also referred to as 293tsA1609neo) are a human embryonic 
kidney cell line used for high efficiency transfections. They were derived from 
the HEK293 cell line which was engineered to stably express the SV40 large T 
antigen (DuBridge et al., 1987). This permits episomal replication of plasmids 
that contain the SV40 origin of replication. These cells also have high expression 
of reverse transcriptase and envelope protein. As such they are used to produce 
high titre retroviruses and lentiviruses (Pear et al., 1993). HEK293T cells were 
cultured in Dulbecco’s modified Eagles medium (DMEM) (Invitrogen) 
supplemented with 10% fetal bovine serum (FBS) (Invitrogen) and 1% 
Penicillin/Streptomycin (PS) (Invitrogen) and 1%L-Glutamine (L-Glut) 
(Invitrogen). 
2.1.2.2 NIH/3T3 Cells 
NIH/3T3 cells are a mouse embryonic fibroblast cell line originally isolated from 
Swiss albino mouse embryo tissue (Todaro and Green, 1963). They are the gold 
standard in determining the efficiency of MSCV-based viruses, described in 
section 2.2.1.1.1.  They were cultured in DMEM supplemented with 10% FBS, 1% 
PS and 1%L-Glut. 
2.1.2.3 OP9 cells 
OP9 cells are a murine stromal cell line established from the calvaria of the 
toothless op/op mouse. These mice have a mutation which inhibits them from 
secreting M-CSF. The immunophenotype of OP9 cells has been reported to be 
identical to that of canonical mouse mesenchymal stem cells (Gao et al., 2010). 
OP9 cells are routinely used in different systems to study differentiation of stem 
and progenitor cells into myeloid, lymphoid and erythroid cells. In the presence 
of Flt3 and interleukin 7 (IL-7), OP9 cells support the differentiation of stem 
cells into B cells. OP9 cells were cultured in αMEM media (Invitrogen) 
supplemented with 20% FBS, 1% PS, 1% L-Glut, 1% 100 mM sodium pyruvate 
(Invitrogen), 1% 1M HEPES (Invitrogen), 0.1% 2-mercaptoethanol (BME) (Sigma-
Aldrich).  
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2.1.2.4 WEHI-3B cells 
WEHI-3B cells are a murine myelomonocytic leukaemia cell line derived from the 
BALB/c mouse which underwent paraffin injections to induce tumour 
development in plasma cells (Warner et al., 1969). These cells produce very high 
levels of IL-3 due to retroviral integration close to the IL-3 gene locus. 
Conditioned media from these cells are frequently used as a source of IL-3. 
WEHI-3B cells were maintained in RPMI1640 (Invitrogen), 10% FBS, 1%PS and 1%L-
Glut.  
2.1.2.4.1 WEHI conditioned media production 
WEHI-3B cells were seeded in T175 flasks at a concentration of 105 cells/ml to a 
final volume of 150 mls. After 3-4 days of incubation at 37oC, cell expansion 
results in the pH indicator causing a colour change. The conditioned media, now 
yellowish in colour, was removed and centrifuged at 300g for 10 mins. 
Supernatant was filtered through a 0.45 μm minisart® syringe filter (Dutscher 
Scientific), and then stored in 10 or 50 ml aliquots at -20oC. 
2.1.2.5 BHK/MKL cells 
The BHK/MKL cell line was originally established by transfecting baby hamster 
kidney (BHK) cells with an expression vector encoding for SCF. BHK/MKL cells 
secrete SCF and conditioned media from these cells is used as a source of SCF. 
BHK/MKL cells were maintained in DMEM, 10% FBS, 1% PS and 1%L-Glut. BHK/MKL 
conditioned media was produced by the method outlined in section 2.1.2.4.1. 
2.1.2.6 Ba/F3 cells 
Ba/F3 cells are an IL-3 dependent immortalized pro B cell line derived from a 
C3H mouse (Palacios et al., 1987). Withdrawal of IL-3 induces apoptosis in Ba/F3 
cells. They were cultured in RPMI1640, 10% FBS, 10% WEHI conditioned media 
(2.1.2.4.1), 1% PS and 1% L-Glut. 
2.1.2.7 32D cells 
32D cells are a murine myeloblastic cell line established from long-term murine 
BM cultures (Greenberger et al., 1983). Grown in the presence of IL-3 they 
remain undifferentiated, but removal of IL-3 induces apoptosis. 32D cells can be 
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induced to terminal granulocytic differentiation by replacing IL-3 with G-CSF. 
Thus they are useful for assessing the ability of a gene to induce or inhibit 
myeloid differentiation (described in section 2.2.3.1). 32D cells were maintained 
in RPMI1640, 10% FBS, 10% WEHI conditioned media (2.1.2.4.1), 1% PS and 1% L-
Glut. 
2.1.2.8 C/EBPα-/- cells 
The C/EBPα-/- (α-/-) cell line were originally derived from the fetal liver of Cebpa 
deficient mice (Zhang et al., 2002) and were maintained in Iscove’s modified 
Dulbecco’s medium (IMDM) (Invitrogen) supplemented with 15% FBS, 2% WEHI 
and 2% BHK/MKL conditioned media. 
2.1.2.9 Human leukaemia cell lines 
U937 cells are a human leukemic monocyte lymphoma suspension cell line 
isolated from a 37 year old male patient (Sundstrom and Nilsson, 1976). NB4 
cells were isolated from leukaemia blast cells taken from an APL patient with 
t(15;17) that were cultured on bone-marrow stromal fibroblasts for 3 months 
before establishment of an immortalised line (Lanotte et al., 1991). The K562 
suspension cell line was derived from a 53 year old female blast crisis phase 
BCR/ABL+ chronic myeloid leukaemia (CML) patient. They do not express C/EBPα 
at the protein (Scott et al., 1992) or the mRNA (Radomska et al., 1998) level. 
Kasumi1 cells are a leukemic cell line established from an AML patient with 
t(8;21) resulting in the formation of the AML1-ETO fusion oncogene (Asou et al., 
1991). As outlined in section 1.2.2.2.1, AML1-ETO downregulates CEBPA mRNA 
thus Kasumi1 cells do not express C/EBPα protein (Pabst et al., 2001). U937, 
NB4, K562 and Kasumi1 cells were all cultured in RPMI1640, 10% FBS, 1% PS and 
1% L-Glut. 
2.2 Tissue culture 
All tissue culture was performed in laminar air flow hoods (Biosafety Class II). 
Aseptic technique was adhered to throughout to ensure sterile work practices.  
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2.2.1 Transfection 
HEK293T cells were used for efficient transfection of DNA to produce retrovirus, 
and for transient protein expression. 
2.2.1.1 Production of retrovirus by calcium phosphate transfection 
5 x 106 HEK293T cells were seeded in a 10 cm dish at least 6 hrs in advance of 
transfection (Figure 2. 2). 2x transfection buffer (Table 2. 2) was freshly 
prepared in a 15 ml falcon tube. A DNA cocktail was prepared by combining 15 
μg of expression plasmid (MigR1), 10 μg of pCGP and 6 μg of VSVG with 50 μl of 
10x NTE (Table 2. 2) and 62.5 μl of 2M CaCl2, made up to 500 μl with double 
distilled water (ddH20). Media was removed from the plates and 3mls of fresh 
culture media was added gently to the plates without disrupting the adhered 
cells. 500 μl of 2x transfection buffer was added dropwise to the DNA cocktail. A 
1 ml pipette was used to blow bubbles slowly through the solution for 30 seconds 
(secs). The solution was then added drop by drop to the HEK293T cells evenly 
dispersing the drops across the plate. The plate was gently swirled before 
returning to incubator to ensure even distribution of the transfection solution. 
Cells were incubated at 37oC for 6-16 hrs before the media was removed and 
replaced with 4.5 mls of fresh culture media. Viral supernatants were harvested 
at 24, 36 and 48 hrs post-transfection. Supernatants were spun at 300 g for 5 
minutes (mins) at room temperature (RT) before being aliquoted into 1 ml 
aliquots and snap frozen on dry ice then stored at -80oC.  
  67 
 
 
Figure 2. 2- Overview of retroviral production and titration process 
2.2.1.1.1 Titration of viruses using 3T3 cells 
2 x 105 NIH/3T3 cells were seeded in a 6 cm dish in 3mls of culture media and 
incubated at 37oC overnight (Figure 2. 2). For each virus to be titred 2 dishes 
were prepared. 24 hrs later the culture media was removed and replaced with 
1ml of media supplemented with 4 μg/ml of polybrene (Sigma-Aldrich). 
Polybrene, also known as hexadimethrine bromide, is a positively charged 
cationic polymer which increases the efficiency of viral infection. It works by 
neutralising the charge repulsion between the viral particle and the cell surface. 
10 μl of freshly thawed virus was added to one plate, and 100 μl to another 
allowing a linear range of transfection efficiency to be determined. The plates 
were gently swirled before overnight incubation. 24 hrs later 2 mls of fresh 
media were added to each plate. 24 hrs after this the media was removed, 
plates washed and cells were tryspinsed and analysed for GFP expression by flow 
cytometry to determine the viral titre. The amount of virus needed was 
calculated as follows:  
(X / % titre) x (Tested volume in μl / 100) = Volume of virus (mls) needed in final 
volume of 4mls where X is the desired % titre 
For BMT experiments a 40% efficiency of transduction is optimal to avoid high 
titre virus resulting in multiple viral integrations in vivo. Thus to achieve equal 
transduction efficiencies using the above calculation:  
If 60% of 3T3 cells expressed GFP with 100 μl of virus (and thus ~6% with 10 μl) 
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then:  
(40/60) x (100/100) = 0.667 mls or 667 μl in a final volume of 4 mls 
If 25% of 3T3 cells expressed GFP with 10 μl of virus (and thus ~100% with 100 μl) 
then:  
(40/25) x (10/100) = 0.16 mls or 160 μl in a final volume of 4 mls 
2.2.1.2 TurboFect transfection for ubiquitination assays 
Transfections for ubiquitination assays (2.5.2) were performed using TurboFect 
Transfection Reagent (Fisher Scientific) as follows. 1.5 x 106 HEK293T cells were 
seeded in a 6 cm dish 24 hrs before transfection. 0.5 μg of Ub-HA (or K48-HA or 
K63-HA), 0.1 μg of HA tagged PHMA-C/EBPα (or PHMA-p42, PHMA-p30 or PHMA-
K313R) and 0.5 μg of Trib2-pcDNA3.1 were diluted to a final volume of 400 μl in 
serum free media (SFM). 8 μl of TurboFect reagent were added to the tube, 
mixed gently by pipetting and incubated for 20 mins at RT. The transfection mix 
was added to the cells in a dropwise manner and plates swirled to ensure even 
distribution before being returned to the incubator. Cells were harvested for 
downstream processing 24 hrs later. 
2.2.2 Retroviral transduction 
2.2.2.1 Suspension cell transduction 
Cells were passaged the day before transduction to ensure they would be in the 
log phase of growth when transduced. 3-4.5 x 106 cells were centrifuged at 300 g 
and resuspended in 3 mls of culture media supplemented with 4 μg/ml 
polybrene. Retrovirus was thawed rapidly and the appropriate volume, based on 
predetermined titre (2.2.1.1.1) was added to the cells. Cells were plated in a 6 
well dish and centrifuged at 1000 g for 90 mins at RT. Cells were incubated at 
37oC for 3-6 hrs. Cells were then transferred to a T75 flask with the addition of 
20 mls of warmed media. 
2.2.2.2 Primary cell transduction 
BM or FLCs were pre-stimulated overnight in DMEM supplemented with 15% FBS, 
1% PS, 1% L-Glut, 10 ng/ml recombinant murine (rm) IL-3 (Peprotech), 10 ng/ml 
rmIL-6 (Peprotech) and 100 ng/ml rmSCF (Peprotech) at a final concentration of 
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2-5 x 106 cells/ml. The following morning cells were washed from plates and 
centrifuged at 300 g for 10 mins at 4oC. Cells were resuspended in DMEM and 
counted. 40-60% loss of cells was expected. Cells were resuspended in pre-
stimulation cocktail without virus (3 mls per well with 4 ml volume of cytokines 
and polybrene). Cell concentration was 5-12 x 106 cells per well in 6 well plate. 
3 mls of cell suspension were transferred to the well at which point the virus was 
thawed rapidly and added to the appropriate well. Where the volume of virus 
required was less than 1 ml, the remaining volume was made up with SFM. Plates 
were centrifuged at 1000 g for 90 mins at RT. Cells were incubated at 37oC 
overnight before a second spinoculation was performed the following morning. 
1ml of cells from each well was transferred to a 1.5 ml Eppendorf tube and 
centrifuged at 300 g for 10 mins at 4oC. The supernatant was removed, pellet 
loosened by flicking, and resuspended in the appropriate volume of virus made 
up to 1 ml, and cytokines and polybrene (enough for 4 mls). The cell suspension 
was added back to the corresponding well and the plates were centrifuged at 
1000 g for 90 mins at RT. Cells were incubated at 37oC until required. 
2.2.3 Differentiation Assays 
2.2.3.1 32D Differentiation Assay 
32D cells were transduced with retrovirus expressing the gene of interest as per 
2.2.2.1. 24 hrs post-transduction, cells were washed twice with WEHI free 32D 
culture media. Cells were then plated at 0.1 x 106 cells per well in either 10% 
WEHI (or 5 ng/ml rmIL-3) or 25 ng/ml recombinant human (rh) G-CSF 
(Peprotech). Cells were analysed for up to 7 days. Flow cytometry was 
performed to determine percentage GFP expression, and expression of the 
mature myeloid markers CD11b, Gr1 and F4/80.  Control 32D cells stimulated 
with G-CSF will differentiate and display increased expression of mature myeloid 
markers when compared to control 32D cells maintained in IL-3. 
2.2.3.2 Colony forming unit assay 
Colony-forming unit (CFU) assays are used to study HSPC activity in vitro. Single 
stem and progenitor cells can proliferate and differentiate into colonies in a 
semi-solid methylcellulose media supplemented with cytokines (Figure 2. 3). The 
number of colonies produced, indicates the proliferative capacity of a given cell. 
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The morphology of the colonies and surface marker expression of the cells 
indicates the differentiation state of the cells. The ability of the cells to self-
renew can be assessed by serially replating cells i.e. WT HSPCs will exhaust by 
the 2nd replating (P) producing few or no colonies by P3. Cells that have been 
transformed by an oncogene will continuously replate in the CFU assay. 
Methocult GF M3434 (Stem Cell Technologies) methylcellulose media is 
optimised for use with murine BM and FL derived HSPCs. It is supplemented with 
rmSCF, rmIL-3, rhIL-6 and rhEPO. Aliquots of M3434 were thawed approximately 
30 mins before use at RT. During this time the primary murine cells were 
prepared. The number of cells required for triplicate 35 mm dishes was 
calculated (5-20 x 104), and transferred to a sterile tube. Cells were centrifuged 
at 300 g for 5 mins. Cells were resuspended in 400 μl of culture media, added to 
the thawed methylcellulose and mixed by pipetting up and down using a 16 
gauge blunt end needle (Stem Cell Technologies) fitted with a 3 ml luer slip 
syringe (Terumo). Methylcellulose was allowed to rest for approximately 10 mins 
to allow air bubbles to dissipate. Using the blunt end needle and syringe, 1.1 ml 
of the final cell mixture was transferred to 3 x 35 mm culture dishes. Up to 6 
dishes were placed in a 150 mm dish with 2 uncovered 35 mm dishes containing 
ddH20 to maintain humidity for optimal colony development. Cells were 
incubated for 7-14 days before colonies were counted, scored and cells analysed 
by flow cytometry. To assess transformation of stem and progenitor populations, 
cells were continuously replated to P5. 
 
Figure 2. 3 – Schematic depiction of CFU assay 
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M3434 permits the growth of multipotential granulocyte, erythroid, macrophage, 
megakaryocyte colonies (CFU-GEMM) and granulocyte-macrophage colonies (CFU-
GM), as well as the more restricted macrophage (CFU-M), granulocyte (CFU-G) 
and erythroid (BFU-E) colony types. These 5 colony types can be identified and 
counted based on their morphology using an inverted microscope and gridded 
scoring dish. GEMM colonies are typically very large with a dense core and a 
“cauliflower” shape. Granulocytic cells are round and bright and much smaller 
than cells of the monocytic lineage which are large and appear to have a grey 
centre permitting discrimination between CFU-GM which will contain both cell 
types, and CFU-G and CFU-M. BFU-E colonies contain erythroid cells which are 
hemoglobinised and thus appear red/brown in colour. 
2.2.3.3 OP9 B cell differentiation assay 
OP9 cells were seeded at 3 x 104 per well of a 6 well dish. 24 hrs later E14.5 
FLCs or BM cells were co-cultured on OP9 cells in the presence of 1 ng/ml of 
rmIL-7 (Peprotech) and 5 ng/ml of rmFlt3 (Peprotech) (Figure 2. 4). Every 2 days 
the media was removed from the dish, centrifuged and the pellet was 
resuspended in fresh culture media supplemented with fresh cytokines (after day 
8, Flt3 was no longer added) and returned to the plates. Every 4 days the cells 
were passed to a fresh sub-confluent feeder layer of OP9 cells which had been 
seeded the previous day. The spent OP9 cells were also maintained and fresh 
supplemented media was added to these plates to maximise cell recovery as 
stem cells tended to burrow beneath the stromal layer. Cells were assessed by 
flow cytometry at different time points for up to 16 days of co-culture. 
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Figure 2. 4 – Diagram depicting OP9 co-culture system used to differentiate B cells 
2.2.4 Dual-luciferase reporter assay  
This assay uses 2 types of luciferase to study gene expression at the 
transcriptional level. Firefly luciferase (61kD) and renilla luciferase (36kD) emit 
light in a chemical reaction whereby the luciferase enzyme catalyses the 
conversion of luciferin to oxyluciferin. Firefly produces yellow/green light in the 
550-570 nm range, while renilla produces blue light of 480 nm in length. The 
regulatory element (e.g. gene promoter) of interest is cloned into a vector 
upstream of the firefly luciferase gene. Cells are co-transfected with the firefly 
reporter vector and a control renilla reporter vector. A luciferase detection 
reagent is added to measure the amount of firefly luminescence – which is 
dependent on the response of the regulatory element to experimental 
conditions. Subsequently a renilla detection reagent is added to measure renilla 
luciferase activity which is independent of experimental modulation.  
5 x 104 293T cells per well were seeded in a 24 well dish. 24 hrs later they were 
co-transfected with 100 ng of G-CSFR promoter firefly luciferase constructs, 
containing either C/EBPα WT (pTK-WT-G-CSFR-luciferase) or mutant (pTK-Mut-G-
CSFR-luciferase) binding sites, and 400 ng of either an empty PHMA vector or 
PHMA-C/EBPα or PHMA-K313R, along with 10 ng of pRL-TK Renilla luciferase 
internal control plasmid. Luciferase activity was measured 24 hrs post-
transfection using the Dual-Luciferase Reporter Assay System (Promega). Cells 
were lysed using the passive lysis buffer in accordance with the manufacturers’ 
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protocol. Growth medium was removed and the cells washed carefully once with 
phosphate buffered saline (PBS) (Table 2. 2) and lysed in 100 μl of 1x lysis 
buffer. Luciferase detection was carried out in accordance with the 
manufacturers’ protocol using a GloMax 20/20 luminometer (Promega). 10 μl of 
cell lysate was added to 50 μl of firefly luciferase assay buffer and mixed 
thoroughly by pipetting before luciferase reading was taken. 50 μl of renilla 
luciferase assay buffer was then added and mixed by pipetting before luciferase 
reading was taken. Firefly luminescence readings were normalised to renilla 
values. 
2.2.5 Magnetic-activated cell sorting 
Magnetic-activated cell sorting (MACS) is a method for isolating cell populations 
based on their cell surface antigen expression. Positive selection (described in 
section 2.2.5.1) involves magnetic nanoparticles coated with antibodies against 
the antigen of interest being incubated with the cell population (Figure 2. 5), 
whereas negative selection (described in section 2.2.5.2) sees the cells of 
interest incubated with antibody coated magnetic particles directed against 
antigens that are not present on the cell of interest. Following incubation of the 
cells with the magnetic beads, cells are applied to a column held within a 
magnetic field and either the unbound cells that run through are collected 
(negative selection), or following the suspension passing through the column, the 
column is removed from the magnetic field and the cells that were bound to the 
beads are collected (positive selection). MS columns (Miltenyi Biotec) which can 
bind a maximum of 107 magnetically labelled cells were used where the 
maximum cell number did not exceed 2 x 108. LS columns (Miltenyi Biotec) which 
can bind a maximum of 108 magnetically labelled cells were used where the 
maximum cell number did not exceed 2 x 109. 
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Figure 2. 5 - Schematic diagram depicting MACS cell sorting 
2.2.5.1 cKit Purification 
Murine BM cells were isolated and red blood cells (RBCs) lysed as per 2.3.2. Cells 
were enumerated and centrifuged at 300 g for 10 mins at 4oC. Supernatant was 
aspirated completely and the pellet was resuspended in 80μl of MACS buffer 
(Table 2. 2) per 107 cells. To this, 20 μl of cKit (CD117) microbeads (Miltenyi 
Biotec) were added per 107 cells. Cells were mixed well and incubated for 15 
mins on ice. Cells were washed with 1 ml of buffer per 107 cells and centrifuged 
at 300 g for 10 mins. Pellet was resuspended up to 108 cells in 500 μl of buffer 
before proceeding with magnetic separation (2.2.5.3).  
2.2.5.2 Lineage Depletion 
Murine BM cells were isolated and RBCs lysed as per 2.3.2. Cells were 
enumerated and centrifuged at 300 g for 10 mins at 4oC. Supernatant was 
aspirated completely and the pellet was resuspended in a biotin-labelled lineage 
cocktail comprising CD3, CD4, CD8, B220, Ter119, CD11b (omitted for FLCs) and 
Gr1 (affymetrix eBioscience) (Table 2. 4). The cocktail was made with .07 
mg/ml of each antibody per 107 cells at a final dilution of 1:50. Cells were 
incubated on ice for 15 mins then washed with 1 ml of MACS buffer per 107 cells 
and centrifuged for 10 mins at 300 g. The pellet was resuspended in 80 μl of 
MACS buffer per 107 cells and 30 μl of anti-biotin microbeads (Miltenyi Biotec) 
per 108 cells. Cells were mixed well and incubated for 15 mins on ice. Cells were 
washed with 1 ml of MACS buffer per 107 cells and centrifuged for 10 mins. The 
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pellet was resuspended up to 108 cells in 500 μl of MACS buffer before 
proceeding with magnetic separation (2.2.5.3). 
2.2.5.3 Magnetic separation 
An MS or LS MACS column was placed in the magnetic field of the MACs Separator 
(Miltenyi Biotec). The column was equilibrated for 5 mins by adding 500 μl (MS 
Column) or 3 mls (LS Column) of MACS buffer to the column. The cell suspension 
was then applied to the column and the flow-through was collected.  The 
column was washed 3 times with the appropriate volumes of buffer –500 μl for 
MS column or 3 ml for LS column- and washes were collected with the flow-
through. This fraction contained cells unbound to the beads (i.e. for 2.2.5.1 cKit- 
cells, and for 2.2.5.2 for lineage– cells). To collect the bound fraction (i.e. for 
2.2.5.1 cKit+ cells, and for 2.2.5.2 lineage+ cells), the column was removed from 
the separator and immediately placed on a 15ml collection tube. Either 1 ml (MS 
column) or 5 mls (LS column) of MACS buffer were added to the column and the 
cells were flushed out by inserting the plunger into the column.  
2.3 Animal Work 
Animal work was carried out in accordance with the guidelines outlined in the 
Animals Scientific Procedures Act 1986. WT C57BL/6 mice were purchased from 
Harlan UK or Charles River UK. WT B6.SJL-Ptprca/BoyAiTac mice were kindly 
donated by Dr. Kamil Kranc and subsequently bred in house. All animals were 
maintained at the University of Glasgow, University College Cork and the 
University of Copenhagen, housed in accordance with their respective 
institutional guidelines. All work was carried out under the approval of the Home 
Office of the United Kingdom, Department of Health and Children Ireland, and 
Danish Ethical Committee. 
2.3.1 BMT 
The murine BMT is a powerful model for the study of hematopoietic stem and 
progenitor cell function, and when combined with retroviral transduction 
permits the study of the effects of a gene of interest on hematopoiesis and 
differentiation. The BMT model was used to transplant BM cells isolated from 
normal or fluorouracil (5-FU) treated donor mice transduced with a retrovirus of 
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interest (see 2.2.2.2) into donor mice whose hematopoietic compartment had 
been fully ablated through exposure to γ-irradiation (Figure 2. 6). 5-FU is a 
commonly used chemotherapeutic agent and when administered enriches for 
stem and progenitor cells in the BM. Where specified, in experiments where 
donor mice were treated with 5-FU, mice received intraperitoneal (IP) injections 
of injectable 5-FU 50 mg/ml solution (Accord Healthcare Limited) diluted in PBS 
to a final dose of 150-250 mg/kg. Following retroviral transduction 0.2-1.5 x 106 
cells were transplanted. When donor mice were not treated with 5-FU a total of 
3 x 106 cells were transplanted following retroviral transduction. The BMT model 
was also used to transplant leukemic cells or cells expanded in a CFU assay into 
mice whose hematopoietic compartment had been partially ablated by γ-
irradiation. In this case 1-6 x 106 donor cells were transplanted into recipient 
mice. Where specified, congenic transplants were performed (i.e cells from a 
CD45.2+ mouse strain were transplanted into a CD45.1+ recipient strain) allowing 
CD45.2 to be used to identify donor cells. Where syngeneic transplants were 
performed, GFP expression was used to monitor donor cells and disease 
progression. 
 
Figure 2. 6 – Experimental outline of a primary and secondary BMT. 
 
Recipient mice were subjected to either lethal (either 1 x 9 Grays (Gy) or 2 x 4.5 
Gys administered 4 hrs apart) or sublethal (1 x 6 Gys) whole body γ-irradiation. 4 
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hrs later mice received an intravenous (IV) injection of the appropriate number 
of donor cells in a final volume of 200ul of PBS supplemented with 2% FBS. Tail 
vein injections were performed using a 1ml insulin syringe with a 25g x 5/8” 
needle (VWR) after vasodilation stimulation under a heat lamp. Mice were 
maintained on 80 mg/L enrofloxacin (Baytril® injectable solution) supplied in 
the drinking water for 10-14 days post-transplant. Mice were monitored closely 
for signs of disease and blood samples taken every 2-4 weeks. For blood 
collection mice were first placed underneath a heat lamp to encourage 
vasodilation. The lateral tail vein was nicked with a lancet or the tip of a 25g 
needle and blood (15-50 μl) was collected in a Microvette ® capillary blood 
collection tube (Sarstedt). Mice were euthanized according to approved 
Schedule 1 killing methods.  
2.3.2 Harvesting tissues 
Immediately following confirmation of death, a cardiac puncture was performed 
using a 25G x 5/8” needle to remove blood for analysis. The femur, tibia and 
pelvic girdle were dissected out and cleaned carefully ensuring bones remained 
intact to maintain sterility of BM cells. Cleaned bones were dipped in 70% 
ethanol (EtOH) and rinsed in sterile PBS before crushing in PBS/2%FBS with a 
mortar and pestle to isolate BM cells. Cells were passed through a 40 μm cell 
strainer (Fisher Scientific). The spleen, thymus and lymph nodes were excised, 
and a single cell suspension was made by homogenising tissues through a 40 μm 
cell strainer in PBS/2%FBS using the plunger from a sterile 3 ml syringe 
(Terumo). For all tissues, cells were spun at 300 g for 10 mins at 4oC and RBCs 
were lysed by resuspending the pellet in RBC lysis buffer (Table 2. 2) and 
incubating on ice for 5 mins, before quenching the reaction with PBS.  
2.3.3 Transgenic mouse models 
2.3.3.1  Trib2-/- mice 
Trib2-/-mice (B6; 129s5-Trib2tm1Lex) were generated by Lexicon Genetics Ltd by 
targeting the coding and noncoding regions of exon 1. Mice were backcrossed to 
a C57BL/6 background for more than 10 generations.  
2.3.3.1.1 Genotyping and evaluation of Trib2 excision 
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Genomic DNA was isolated from tail or ear tissue of mice. Genotyping of Trib2 
WT and deleted alleles was performed using the following sets of primers: 5’- 
CACAATAGCGAGATATGGGAG-3’, 5’- GCAATGCGACAAGTTCGGAG -3’ and 5’- 
GCAGCGCATCGCCTTCTATC -3’ which amplified a 145bp WT allele and a 245bp 
deleted allele. PCR reactions were performed on a thermal cycler as follows: 5 
mins at 94oC, followed by 40 cycles of 30 secs at 94oC, 30 secs at 40oC and 1 min 
at 72oC, followed by 5 mins at 72oC before cooling to 4oC. 
2.3.3.2 Cebpa conditional model 
Cebpafl/fl;Mx1cre mice were crossed to Cebpa+/p30 (Kirstetter et al., 2008) (p30, 
also known as ‘L’ allele) to yield 4 genotypes - Cebpafl/+; Mx1Cre, 
Cebpafl/p30;Mx1cre, Cebpafl/+ and Cebpafl/p30. 8-14 week old Cebpafl/fl, 
Cebpafl/fl;Mx1Cre, Cebpafl/+, Cebpafl/p30 and Cebpafl/p30; Mx1Cre mice were poly 
I:C treated to excise the Cebpa allele (Figure 2. 7). Animals received 3 injections 
every second day with 300 μg poly I:C. Resultant genotypes were Cebpafl/fl 
(expressing solely p42 alleles which can give rise to p30), Cebpa∆/∆ (null for p42 
and p30), Cebpafl/+ (expressing solely p42 alleles which can give rise to p30), 
Cebpafl/p30 (expressing one p42 and one solely p30 allele), and Cebpafl/p30; 
Mx1Cre referred to as Cebpa∆/p30 - solely expressing one p30 allele (Figure 2. 7).  
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Figure 2. 7 - Schematic depiction of the generation of Cebpafl/f, CebpaΔ/Δ,,Cebpafl/+, Cebpafl/p30and 
Cebpa∆/p30 mice 
2.3.3.2.1 Genotyping and evaluation of C/EBPα excision 
Genomic DNA was isolated from tail or ear tissue of mice. Genotyping of floxed 
Cebpa allele was performed using the following sets of primers: 5’- 
CCACTCACCGCCTTGGAAAGTCACA-3’, 5’- CCGCGGCTCCACCTCGTAGAAGTCG-3’ 
and 5’- GTCCTGCAGCCAGGCAGTGTCC-3’ amplifying the 355 bp floxed allele and 
560 bp deleted allele. Genotyping of the Cebpap30 allele was performed using the 
following sets of primers: 5’-GAC TCC ATG GGG GAG TTA GAG-3’ and 5’- 
GCCTTGGAAAGTCACAGGAG-3’ amplifying a 270 bp WT allele and a 330 bp floxed 
allele. Confirmation of the presence or absence of Mx1Cre was performed using 
the following primers 5’- GCCTGCATTACCGGTCGATGCAACGA-3’ and 5’- 
GTGGCAGATGGCGCGGCAACACCATT-3’ amplifying the 706 bp Cre allele. PCR 
reactions were performed on a thermal cycler as follows: 4 mins at 94oC, 
followed by 35 cycles of 30 secs at 94oC, 30 secs at 55oC and 30 secs at 72oC, 
followed by 10 mins at 72oC before cooling to 4oC. 
2.4 Flow Cytometry 
Flow cytometry was performed using either a FACSCANTO, FACSCalibur or LSRII 
cell analyser (all BD Biosciences). For flow cytometry antibody information see 
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Table 2. 4. Unless otherwise stated samples were stained and analysed in FC 
Buffer (Table 2. 2), kept on ice throughout and compensation was carried out 
using unstained cells and single stained UltraComp Beads (affymetrix 
eBioscience). All data analysis was performed with FlowJo V7.6.5 or V10 
(Treestar Inc). All analysis was performed on single cells gated through FSC-A 
versus FSC-H. Apart from the apoptosis assay, viable cells were analysed by 
gating through FSC and SSC, and with a DAPI dead cell exclusion dye used where 
the antibody panel permitted.  
2.4.1 Determining surface antigen expression 
Cells were harvested, washed with FC buffer and stained with fluorochrome-
conjugated antibodies (50 μl per 5 x 106 cells) at 4oC for 30 mins protected from 
light. Where biotinylated antibodies were used, cells were washed with FC 
buffer following incubation with primary antibody, and incubated with 
fluorochrome-conjugated streptavidin for 15 mins at 4oC protected from light. 
Cells were washed again with FC buffer and flow cytometric analysis was 
performed.  
2.4.2 Apoptosis staining 
The tightly regulated process of programmed cell death is known as apoptosis. 
When cells enter apoptosis a phospholipid membrane protein normally bound 
internally, called phosphatidylserine, flips to the external membrane acting as a 
signal to macrophages. The cells then break apart and the fragments are 
engulfed by macrophages. To examine apoptosis by flow cytometry annexinV, 
which binds to phosphatidylserine, was used in conjunction with DAPI (Figure 2. 
8). Neither annexinV nor DAPI will stain healthy intact cells (Q1). Cells 
undergoing early apoptosis will stain positively for annexinV and negatively for 
DAPI (Q2). Cells in late apoptosis, when the cell membrane has broken apart, 
will stain positively for both annexinV and DAPI (Q3) and dead cells will only 
stain positively for DAPI (Q4). 
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Figure 2. 8 – Gating strategy for detecting stages of apoptosis using flow cytometry 
Cells of interest were centrifuged for 5 mins at 300 g and washed once with PBS 
before centrifuging as before. The cell pellets were resuspended in 50 μl of 
annexinV at a 1:100 dilution in Hank’s balanced salt solution (HBSS) (Sigma-
Aldrich). The cells were incubated for 15 mins at RT protected from light. 400 μl 
of HBSS was added to each tube along with DAPI to a final concentration of 
1:1000. Samples were analysed by flow cytometry according to the gating in 
Figure 2. 8.   
2.4.3 Proliferation assay 
CellTraceTM Violet (CTV) (Invitrogen) is a fluorescent cell permeable dye that 
covalently binds to intracellular amine molecules allowing it to be retained 
inside the cell for long periods of time. Each time the cells divide the 
fluorescent CTV halves allowing cell division to be measured by flow cytometry. 
CTV was prepared to a 5 mM concentration by adding 20 μl of DMSO to one vial 
of CTV reagent. The solution was stored at 4oC. Up to 1 x 106 cells were pelleted 
at 300 g for 5 mins and washed once in PBS/2%FBS. Cells were resuspended in 1 
ml of PBS/2%FBS to which 1 μl of 5 mM CTV was added. Cells were incubated for 
20 mins at 37oC protected from light. 4 mls of PBS/2%FBS were added to the 
cells and incubated for 5 mins at RT protected from light. The cells were then 
pelleted by centrifugation and washed once with complete media. The cells 
were seeded in the desired tissue culture dish with a sample taken to analyse by 
flow cytometry to confirm successful staining and to provide a day 0 control. 
Cells were subsequently assessed by flow cytometry at 24 hr intervals. 
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2.4.4 Fluorescence activated cell sorting 
Fluorescence activated cell sorting or FACS uses the principles of flow cytometry 
to sort populations of cells on the basis of surface maker expression. When 
isolating primary stem and progenitor populations, total BM cells or FLCs were 
first MACS purified by cKit+ selection (2.2.5.1) or lineage depletion (2.2.5.2). 
Cells of interest were harvested and washed with FC buffer and incubated with 
the appropriate antibodies. Cells were washed and resuspended in 400 – 600 μl 
of FC buffer and passed through a 40 μm cell strainer prior to sorting. Sorting 
was performed using a BD FACSAriaII (BD Biosciences). Schematic diagram of 
gating strategies used for the isolation of HSCs, MPPs, CLPs, CMPs, GMPs and 
MEPs is provided in Figure 1. 2. 
2.5 Protein Assays 
2.5.1 Western Blotting 
Western blotting refers to the process of protein isolation, gel separation and 
subsequent transfer to a membrane to permit detection by blotting with a 
specific antibody. 
2.5.1.1 Preparation of cell lysates 
2.5.1.1.1 Tris or RIPA lysis 
Cells were pelleted in a 1.5 ml Eppendorf tube at 300 g for 5 mins at 4oC. The 
media was aspirated from the cell pellet and the pellet was washed once with 
ice-cold PBS, supplemented with protease inhibitors – 1 mM 
phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich), 2 μg/ml aprotonin (Sigma-
Aldrich), 2 μg/ml leupeptin (Sigma-Aldrich), 1 μg/ml pepstatin A (Sigma-
Aldrich), 1 mM sodium orthovanadate (Na3VO4) (Sigma-Aldrich) and 1 mM sodium 
fluoride (NaF) (Sigma-Aldrich). Cells were lysed by adding Tris or RIPA lysis 
buffer (Table 2. 2) to cells and incubating on ice for 30 mins with gentle 
vortexing every 5 mins. Cells were then centrifuged at 14,000 g for 10 mins at 
4oC. The supernatant was transferred to a fresh tube and stored at -80oC for 
future use, or protein concentration was determined using Bradford Reagent 
(Bio-Rad) according to manufacturers’ protocol. The appropriate volume of 
protein was then resuspended in 2x SDS loading buffer (Table 2. 2) 
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supplemented with 4% BME and boiled for 5 mins at 95oC. Tubes were placed on 
ice to cool and then centrifuged for 30 secs. Sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and membrane transfer were 
then carried out as described in 2.5.1.2. 
2.5.1.1.2 Direct lysis 
For detecting C/EBPα expression, the direct lysis method was used. Cells were 
counted in duplicate to ensure accurate cell number. 1.5 x 105 cells were 
centrifuged in a 1.5ml Eppendorf tube for 5 mins at 300 g at 4oC. All media was 
aspirated from pelleted cells, and cells were washed once with PBS. Cells were 
pelleted as before and all PBS was aspirated, with great care taken not to 
disrupt the pelleted cells. Cells were directly resuspended in 20 μl of 2x SDS 
supplemented with 4% BME. The tube was vortexed and boiled for 3 mins at 
95oC. Tubes were placed on ice and stored at -80oC or if loading directly they 
were snap frozen on dry ice or in liquid nitrogen, before thawing and carrying 
out SDS-PAGE gel electrophoresis and transfer as described in 2.5.1.2. 
2.5.1.2 SDS-PAGE and membrane transfer 
Proteins were separated using an 8-12% separating gel depending on the size of 
the proteins being visualised. Gels were hand cast using the Mini-PROTEAN Tetra 
Cell casting system (Bio-Rad). Glass plates were cleaned thoroughly before 
assembling with spacers in the casting frame and fixing in the casting stand. 
10mls of desired percentage separating gel were prepared by mixing the 
appropriate volume of 30% Acrylamide/Bis-acyrlamide (Sigma-Aldrich) (3.3 mls 
for 10% gel) with the corresponding volume of ddH20 (4.1 mls for 10% gel), 2.5 
mls of 1.5 M Tris-HCl (ph 8.8), 100 μl of 10% w/v SDS (Sigma-Aldrich), 100 μl of 
10% ammonium persulfate (APS) (Sigma-Aldrich) and 5 μl of 
tetramethylethylenediamine (TEMED) (Sigma-Aldrich). The acrylamide was 
allowed to polymerise before 5 mls of stacking gel was prepared by mixing 830 μl 
of 30% Acrylamide/Bis-acyrlamide, 3.4 mls of ddH20, 630 μl of 1 M Tris-HCl (ph 
6.8), 50 μl of 10% w/v SDS, 50 μl of 10% APS and 5 μl of TEMED. The stacking gel 
was applied on top of the polymerised separating gel and the appropriate comb 
(10 or 15-well) was inserted between the plates. Once the stacking gel had 
polymerised the plates were fixed into the electrode assembly of the mini-tank 
(Bio-Rad) filled to the appropriate volume with running buffer (Table 2. 2), 
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samples were loaded and run at 100 volts until the gel had sufficiently resolved. 
Samples were run alongside a Precision Plus Protein Dual Colour Standards 
protein ladder (Bio-Rad). Gels were transferred onto a Protran nitrocellulose 
membrane (Whatman) using a 1x solution of transfer buffer (Table 2. 2). The 
membrane was first immersed in 1x transfer buffer along with gel blotting paper 
and sponges, before the gel/membrane sandwiches were assembled (as outlined 
in Figure 2. 9) in a Mini Trans-Blot cassette (Bio-rad). Cassettes were run at 100 
volts for 1 hr in the Mini Trans-Blot cell (Bio-rad).  
 
Figure 2. 9 – Diagram of the gel/membrane transfer sandwich 
2.5.1.3 Antibody labelling and detection 
All antibody incubation and washing steps were performed on an orbital shaker. 
All washes were done with 0.1% PBS-Tween (PBS-t). Membrane was stained with 
Ponceau S (Table 2. 2) to evaluate the efficiency of transfer. Stain was removed 
by washing 3 times in 0.1% PBS-t for 3 mins. Membrane was blocked in 0.1% PBS-t 
containing 5% non-fat milk for 30 mins at RT. Membrane was washed 3 times for 
5 mins in 0.1% PBS-t. Blot was then incubated with the appropriate 
concentration of primary antibody for either 2 hrs at RT, or overnight at 4oC. 
Membrane was washed 3 times for 5 mins. The blot was then incubated with the 
appropriate secondary horse radish peroxidase (HRP) antibody for 1 hr at RT.  
The blot was washed 3 times for 10 mins at RT. The membrane was then 
visualised on CL Exposure Film (Life Technologies) using Signal West Pico or 
Femto (Life Technologies) ECL reagent. Details of antibodies used for western 
blotting are provided in Table 2. 5. 
2.5.1.4 Stripping for re-probing 
When necessary the nitrocellulose membranes were stripped to remove primary 
and secondary antibodies to permit re-probing with another antibody. 
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Membranes were incubated at RT on an orbital shaker in 10 mls of 1x Restore 
Western Blot Stripping Buffer (Sigma-Aldrich) for 10-15 mins. Membranes were 
washed three times with 0.1% PBS-t before blocking in 5% non-fat milk for 1 hr. 
Membranes were then re-probed with the appropriate primary and secondary 
antibodies as described in 2.5.1.3.  
2.5.2 Ubiquitination assay 
Ubiquitination (also known as ubiquitylation) is a post-translational modification 
which attaches ubiquitin (Ub) to a lysine (K) residue of a protein (Figure 2. 10). 
Briefly, Ub is activated in an ATP-dependent reaction by the E1 Ub-activating 
enzyme, the E2 Ub-conjugating enzyme transfers the Ub molecule from E1 to an 
active site on E2, and finally the Ub molecule is ligated with the target substrate 
via the E3 protein ligase.  If subsequent Ub molecules are added in the same 
fashion then the substrate is described as polyubiquitinated. Ub molecules have 
7 lysine residues (K6, 11, 27, 29, 33, 48 and 63) and so several different types of 
Ub chains can be formed depending on which lysine residue of the bound Ub the 
additional molecules bind to. K48-Ub chains signal the protein for proteasomal 
degradation. Whereas K63-Ub chains protect the protein from degradation, 
instead its function is linked with DNA repair and receptor endocytosis. 
 
Figure 2. 10 – Diagram of the process of ubiquitination 
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2.5.2.1 Setting up the Ubiquitination IP 
Cells were transfected as described in 2.2.1.2. 24 hrs post transfection cells 
were harvested. Plates were first incubated with 10 mM N-Ethylmaleimide (NEM) 
(Sigma-Aldrich), which inhibits deubiquitinases, for 30 secs before supernatant 
was aspirated and each plate was washed with 1 ml of ice-cold PBS 
supplemented with 10 mM NEM. Cells were removed from the plate with 1 ml of 
ice-cold PBS supplemented with 10 mM NEM using a cell scraper, and transferred 
to a 1.5 ml Eppendorf tube. Cells were centrifuged at 300 g at 4oC for 3 mins to 
pellet the cells. The supernatant was aspirated and cells were lysed with the 
addition of 100 μl of 1% SDS. Cells were then boiled at 95oC for 5 mins. Following 
boiling the cells were placed on ice and sonicated at 30% amplitude for 10-20 
secs (at 1 sec intervals) using an EpiShear™ probe sonicator (Active Motif). 
Lysates were centrifuged at 14,000 g at 4oC for 10 mins. The cleared lysate was 
transferred to a clean Eppendorf tube. For the input sample, 10 μl of the lysate 
was taken and boiled with 10 μl of 2x SDS loading buffer, supplemented with 4% 
BME, for 5 mins at 95oC. These were either stored at -20oC until ready to use or 
run on a gel as described in 2.5.1.2. 900 μl of RIPA buffer (Table 2. 2) 
supplemented with 20 mM NEM and protease inhibitors (see 2.5.1.1.1) were 
added to the remaining 90 μl of protein lysate, along with 20 μl of Protein G Fast 
Flow Sepharose Beads (GE Lifesciences). Samples were incubated on a tube 
rotator (Stuart) at 4oC for 30 mins. Tubes were centrifuged for 1 min at 14,000g 
at 4oC. The supernatant was then transferred to a new 1.5 ml Eppendorf with 20 
μl of fresh beads and 2 μl of concentrated (2 mg/ ml) C/EBPα antibody (Santa 
Cruz Biotechnology). Samples were incubated overnight at 4oC on a tube rotator.  
2.5.2.2 Elution 
Tubes were centrifuged for 30 secs at 14,000 g at 4oC. Pelleted beads were 
washed three times with supplemented RIPA (see above) by inverting the tube 
10 times, and centrifuged for 30 secs at 14,000 g at 4oC. After the final wash, all 
supernatant was removed using a 26 gauge needle until beads were dry. 25 μl of 
2x SDS loading buffer (with 4% BME) was added to each tube, tubes were 
vortexed, briefly centrifuged and then boiled at 95oC for 5 mins. Tubes were 
then vortexed, centrifuged and the sample was transferred to a fresh tube using 
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an insulin syringe with a 25g x 5/8” needle (VWR) taking care not to transfer any 
beads. Samples were then run on a gel as described in 2.5.1.2. 
2.6 Gene Expression Analysis 
2.6.1 RNA extraction 
Total RNA was extracted using either the RNeasy Mini kit (Qiagen) for >50,000 
cells, or for smaller cell numbers the Arcutus PicoPure kit (Fisher Scientific) was 
used, in accordance with the respective manufacturers protocol. Eluted samples 
were quantified on a Nanodrop ND1000 spectrophotometer (Labtech 
International). RNA was stored at -80oC until required. 
2.6.2 cDNA synthesis 
RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription 
kit (Applied Biosystems). RNA samples were prepared with ddH20 to a 
concentration of 500 ng to 1 μg of RNA per 20 μl reaction and mixed with 2 μl of 
10x RT buffer, 0.8 μl of 100 mM dNTP mix, 2 μl of 10x RT random primers, 1 μl of 
RNase Inhibitor and 1 μl of MultiScribe Reverse Transcriptase (all Applied 
Biosystems). Samples were run in a Mastercycler thermal cycler (Eppendorf UK) 
with the following cycle – 10 mins at 25oC, 120 mins at 37oC, and 5 secs at 85oC. 
Synthesised cDNA was kept at 4oC in the short-term until ready for use or stored 
at -20oC for longer term storage. 
2.6.3 qRT-PCR 
qRT-PCR was performed on the ABI Prism 7900 sequence detection system 
(Applied Biosystems). 2 μl of cDNA were used per 20 μl PCR reaction containing 
10 μl of SYBR Green-PCR Master Mix (Applied Biosystems), 0.5 μl each of 10 uM 
forward and reverse primer and 7 μl of ddH20. Samples were amplified on the 
thermal cycler for 40 cycles as follows: 2 mins at 50oC, followed by cycle of 10 
mins at 95oC, 15 sec at 95oC and 1 min at 60oC, before cooling to 4oC. All 
reactions were performed in technical triplicates and the 2-ΔΔCT method was used 
to calculate the relative level of gene expression in each sample. A list of primer 
sequences is provided in Table 2. 3. 
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2.6.4 FluidigmTM high-throughput qPCR 
FluidigmTM is a high-throughput qPCR system to analyse large numbers of genes 
in a chip format (48.48 or 96.96). Samples are first pre-amplified and the 
resultant cDNA is used to examine 48 (or 96) genes across 48 (or 96) samples. 
The chip contains an integrated fluidic circuit (IFC) which combines the samples 
and primer-probe sets (also known as assays) in individual PCR reactions.  
2.6.4.1 Preamplification and exonuclease treatment 
Before use on the array, cDNA samples were first pre-amplified to enrich for loci 
of interest, and then treated with Exonuclease I (ExoI) to digest unincorporated 
primers. Forward and reverse primers were combined to a final concentration of 
20 mM each. Then 5 μl of each primer pair were combined to a total of 500μl 
with 1x DNA suspension buffer (Fluidigm™). Pre-amplification samples were 
prepared in a 96 well plate by combining 1.25 μl of the pooled primer mix with 
1.25 μl of cDNA and 2.5 μl of TaqMan PreAmp Master Mix (Applied Biosystems). 
Plates were sealed and amplified as follows: 10 mins at 95oC, 15 cycles of 15 
secs at 95oC followed by 4 mins at 60oC, then cooled to 4oC. To perform ExoI 
treatment, ExoI (New England Biolabs) was diluted to 4 U/μl in water with ExoI 
Reaction Buffer (New England Biolabs). 2 μl of diluted ExoI was added to each 
5μl preamplified sample, vortexed, centrifuged and placed in a thermal cycler 
for 30 mins at 37oC followed by 15 mins at 80oC before cooling to 4oC. Pre-
amplified samples were diluted 5-fold in TE buffer and used immediately or 
stored at -20oC until ready to use. 
2.6.4.2 Loading the chip 
The 48.48 dynamic array was used with scope for up to 43 assays (with 5 
housekeeping genes) and up to 16 triplicate samples. 96 well plates were used to 
prepare the assays and samples before loading the chip. To prepare the assays, 
first, primer pairs were prepared by combining forward and reverse primers to a 
final concentration of 20 mM each. Next 3 μl of 2x Assay Loading Reagent 
(Fluidigm™) was combined with 0.3 μl of 1x DNA suspension buffer and 2.7 μl of 
the pre-mixed primer pair in a well of a 96 well plate. Samples were prepared by 
mixing together 3 μl of 2x TaqMan Gene Expression Master Mix (Applied 
Biosystems) with 0.3 μl of 20X DNA Binding Dye Sample Loading Reagent 
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(Fluidigm™), 0.25 μl of 20X EvaGreen DNA binding dye (Biotium) and 2 μl of the 
pre-amplified ExoI treated cDNA sample (2.6.4.1) in a well of a separate 96 well 
plate. Plates were vortexed for 30 secs and centrifuged for 30 secs. Before use, 
the chip was primed as per the manufacturers’ protocol to prevent premature 
mixing of the samples and assays. 5μl from each well on the assay plate were 
loaded into the appropriate assay inlets on the left of the chip, and 5μl from 
each well on the sample plate were loaded into the appropriate sample inlets on 
the right of the chip (Figure 2. 11). The chip was placed in the IFC Controller MX 
system (Fluidigm™) where the integrated software initiated on-chip mixing of 
the components. The chip was then transferred to the BioMark HD system 
(Fluidigm™) to carry out qRT-PCR reactions, scanning and data collection. 
Fluidigm Real-Time PCR Analysis software (Fluidigm™) was used to perform data 
analysis and raw data were exported to Microsoft Excel where gene expression 
was calculated using the 2-ΔΔCT method. A list of primer sequences is provided in 
Table 2. 3. 
 
Figure 2. 11 – FluidigmTM 48.48 Dynamic Array 
 
2.7 Statistical analysis 
Unless otherwise stated data represents mean value +/- standard deviation (SD). 
For statistical analysis comparing 2 groups an unpaired, two-tailed, Students t-
test was used. For analysis of multiple groups a two-way ANOVA was applied. For 
comparison of survival curves a Log-rank test was used. Analysis was performed 
using GraphPad Prism 5 software (GraphPad Software Inc.). Significance was 
attained when the p-value ≤0.05 (*), <0.005 (**), <0.001 (***). 
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Table 2. 1 –Suppliers 
Name of Company Address 
Accord Healthcare Limited Durham, NC 27703, USA 
Active Motif Carlsbad, CA 92008, USA 
affymetrix eBioscience Hatfield AL10 9NA, UK 
Applied Biosystems Warrington, WA3 7QH, UK 
BD Biosciences, Oxford UK Oxford, OX4 4DQ, UK 
BioRad West Sussex, HP2 7DX, UK 
Biotium Hayward, CA 94545, USA 
Charles River UK Tranet, EH33 2NE, UK 
Drew Scientific Dallas, TX 75237, USA 
Dutscher Scientific Essex, CM13 3FR, UK 
Eppendorf UK Stevenage, SG1 2FP, UK 
Fisher Scientific Leicestershire, LE 1 5RG, UK 
Fluidigm™  San Francisco, CA 94080, USA 
GE Life Sciences Buckinghamshire, HP7 9NA, UK 
Genescript Piscataway, NJ 08854, USA 
GraphPad Software Inc. La Jolla, CA 92037, USA 
Harlan UK Ltd. Blackthorn, UK 
Integrated DNA technologies B-3001 Leuven, Belgium 
Invitrogen Paisley, UK 
Labtech International Ltd. Milton Keynes, MK5 8LB, UK 
Lexicon Genetics Ltd Basking Ridge, NJ 07920, USA 
Life Technologies Gent 9050, Belgium 
Lonza Basel, Switzerland 
Millipore West Lothian, EH54 7BN, UK 
Miltenyi Biotec Surrey, GU24 9DR, UK 
New England BioLabs Ipswich, MA 01938, USA 
PeproTech Ltd  London, W6 8LL, UK 
Promega Madison, WI 53711, USA 
Qiagen West Sussex, RH10 9NQ, UK 
Santa Cruz Biotechnology 69115 Heidelberg, Germany 
Sarstedt 51588 Numbrecht, Germany 
Sigma-Aldrich  Dorset, SP8 4XT, UK 
Stemcell Technologies  38000 Grenoble, France 
Stuart Staffordshire, ST15 0SA, UK 
Terumo Lakewood, CO 80215, USA 
Tree Star, Inc. Ashland, OR 97520, USA 
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VWR Wayne, PA 19087, USA 
Whatman plc  Kent, ME14 2LE, UK 
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Table 2. 2 –Recipes 
Solution Ingredient Concentration 
PBS NaCl 137 mM 
Diluent : ddH20 KCl 2.7 mM 
  Na2HPO4 10 mM 
  KH2PO4 1.8 mM 
2 x Transfection 
Buffer 
HEPES 42 mM 
Diluent : ddH20 NaCl 274 mM 
  Na2HPO4 1.4 mM 
10xNTE EDTA (ph8) 10 mM 
Diluent : ddH20 Tris-HCl (ph7.5) 100 mM 
  NaCl 5 M 
RBC Lysis Buffer NH4AC 150 mM 
Diluent : ddH20 KHCO3 10 mM 
  EDTA 0.1 mM 
MACS Buffer EDTA 2 mM 
1xPBS FBS 2% 
FC buffer HEPES 10 mM  
Diluent : 1x PBS NaN3 0.02% 
  BSA 0.20% 
Tris lysis buffer Tris pH7.4,  50 mM 
Diluent : ddH20 NaCl,  150 mM 
  EDTA  1 mM 
  NP-40 0.50% 
  Glycerol 5% 
RIPA lysis buffer Tris-HCl ph7.4 50 mM 
Diluent : ddH20 NaCl 150 mM 
  Triton x-100 1% 
  Sodium deoxycholate 1% 
  SDS 0.10% 
  EDTA 1 mM 
2XSDS Tris-HCl (ph6.8) 125 mM 
Diluent : ddH20 SDS 4% 
  Bromophenol blue 0.01% 
  Glycerol 20% 
Running buffer Trizma base 25 mM 
 Diluent : ddH20 Glycine 190 mM 
  SDS 0.10% 
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Transfer buffer Trizma base 25 mM 
 Diluent : ddH20 Glycine 190 mM 
  Methanol 20% 
Ponceau S Ponceau S 0.20% 
 Diluent : ddH20 Glacial acetic acid 5% 
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Table 2. 3 –DNA primer sequences 
Gene 
Symbol 
Oligonucleotide sequence (5'-3') 
Abl 
 
forward TGGAGATAACACTCTAAGCATAACTAAAGGT 
reverse GATGTAGTTGCTTGGGACCCA 
Gusb 
 
forward GGGACAAAAATCACCCTGCG 
reverse GCGTTGCTCACAAAGGTCAC 
B2M  
 
forward TGCTATCCAGAAAACCCCTCA 
reverse TTTCAATGTGAGGCGGGTGG 
Tbp 
 
forward GCAGTGCCCAGCATCACTAT 
reverse GCCCTGAGCATAAGGTGGAA 
Hprt1 
 
forward GAGAGCGTTGGGCTTACCTC 
reverse ATCGCTAATCACGACGCTGG 
Rnf20 forward ACCATCAATGCCCGGAAGTT 
  reverse GCAGCGATACTCTGGGGTTT 
Enox2 
 
forward CGGCTGTTTAAGGAGTAGCG 
reverse AGCTGGTTCAATCCTGGAACAT 
Nfix 
 
forward  AAACCAGCAAGGAGATGCGG 
reverse  TGATGCAGTCGCAACTGGAG 
Blink 
 
forward GGTAAGCCCTGGTATGCTGG 
reverse CTAGGGTGTACGGCTGCTTG 
E2a 
 
forward GCCTGGATACTCAGCCGAAG 
reverse TAGAAGGGGGAGGGGTAAGC 
Pax5 
 
forward GAC ATC TTC ACC ACC ACG GAA  
reverse AGGACTGTGGGCCTGGAAC  
Ikaros 
 
forward AGGGTCAAGACATGTCCCAAG 
reverse GCTGTGCTCCAGAGGTAGTG 
CD19 
 
forward AAACCTGACCATCGAGAGGC 
reverse GGGTCAGTCATTCGCTTCCTT 
Flt3 
 
forward TTGGCCTTTGTGTCTTCCGT 
reverse TTGCGAGCTGGTAGCGTTTA 
Ebf1 
 
forward CCATGTCCTGGCAGTCTCTGA  
reverse TCCATCCTTCACTCGGGCT  
Id1 
 
forward GAACCGCAAAGTGAGCAAGG 
reverse AACACATGCCGCCTCGG 
Id2 
 
forward CCTGGACTCGCATCCCACTA 
reverse AGGGAATTCAGATGCCTGCAA 
Id3 
 
forward CCTCTTAGCCTCTTGGACGAC 
reverse CAGCTGTCTGGATCGGGAGAT 
Pu1 
 
forward  CGCACGAGTATTACCCCTAT 
reverse GAGCTCCGTGAAGTTGTTCT 
Mpo forward CCCAGGCATAAAAACCCGT 
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 reverse TGAATTCTCCACTTCCCCCAG 
Mmp9 
 
forward ACGACATAGACGGCATCCAG 
reverse TGGGACACATAGTGGGAGGT 
C/ebpe 
 
forward GAGGCAGCTACAATCCCCTG 
reverse CACAGGGGCCTTGAGGACA 
Notch1 
 
forward ATCAAGCGCTCTACAGTGGG 
reverse AAACCTGACCATCGAGAGGC 
Gata3 
 
forward GGGTCAGTCATTCGCTTCCTT 
reverse GTTCACACACTCCCTGCCTT 
CD3delta 
 
forward GGAACACAGCGGGATTCTGG 
reverse ACCATCCTTCCACCGTTCCA 
CD3gamma 
 
forward TCTCATTGCGGGACAGGATG 
reverse TATTCCCGGTCCTTGAGGGG 
CD7 
 
forward CACCTGGATTTGGGCGTCAT 
reverse ACTGGTGTACGTCTTGGGC 
Rictor 
 
forward GAGGTGGAGAGGACACAAGC 
reverse CCGGACCATTCTGTCTCGTT 
Gata1 
 
forward CTCCCCAGTCTTTCAGGTGT 
reverse CAGGGTAGAGTGCCGTCTTG 
Gata2 
 
forward TCACCCCTAAGCAGAGAAGC 
reverse CATTGCACAGGTAGTGGCCC 
Fog1 
 
forward CAAACTTCCTCCAGACAGCC 
reverse CTCTGGTCTCTCCGTTGGTG 
Klf1 
 
forward CTAAGAGGCAGGCGGCACAT 
reverse CTGAGCGAGCGAACCTCC 
Fli1 
 
forward ATCTGAAGGGGCTACGAGGT 
reverse ACCACAGACAGAGCCTCCTTA 
Mpl 
 
forward AACAAGACCGCACTAGCTCC 
reverse GCGGTTCCTCCTCTTCACAT 
Trfr1 
 
forward   TCCGCTCGTGGAGACTACTT 
reverse  ACATAGGGCGACAGGAAGTG 
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Table 2. 4 –Flow cytometry antibodies 
Name of antibody Reactive species Clone Source 
AA4.1 (CD93) Mouse AA4.1 affymetrix eBioscience 
B220 (CD45R) Mouse RA3-6B2 affymetrix eBioscience 
CD3 Mouse CD3e affymetrix eBioscience 
CD4  Mouse RM4.5 affymetrix eBioscience 
CD8 Mouse 53-6.7 affymetrix eBioscience 
CD11b (Mac1) Mouse M1/70 affymetrix eBioscience 
CD11c Mouse N418 affymetrix eBioscience 
CD16/32 Mouse 2.4G2 affymetrix eBioscience 
CD19 Mouse eBIO1D3 affymetrix eBioscience 
CD34 Mouse ram34 affymetrix eBioscience 
CD41 Mouse MWReg30 affymetrix eBioscience 
CD43 Mouse eBioR2/60 affymetrix eBioscience 
CD45 Mouse 30-F11 affymetrix eBioscience 
CD45.1 Mouse A10 affymetrix eBioscience 
CD45.2 Mouse 104 affymetrix eBioscience 
CD48 Mouse HM48-1 affymetrix eBioscience 
CD71 Mouse R17217 affymetrix eBioscience 
CD105 Mouse Mj7/18 affymetrix eBioscience 
CD150 Mouse TC15-12F12.2 affymetrix eBioscience 
cKit (CD117) Mouse 2B8 affymetrix eBioscience 
F4/80 Mouse BM8 affymetrix eBioscience 
Flt3 (CD135) Mouse A2F10 affymetrix eBioscience 
Gr1 (Ly-6G) Mouse RB6-8CS affymetrix eBioscience 
IL7Ra (CD127) Mouse A7R34 affymetrix eBioscience 
MHCII Mouse AF6-120.1 affymetrix eBioscience 
NK1.1 Mouse PK136 affymetrix eBioscience 
Sca1 Mouse D7 affymetrix eBioscience 
sIgM Mouse III41 affymetrix eBioscience 
TCRβ Mouse H57-597 affymetrix eBioscience 
Ter119 Mouse Ter119 affymetrix eBioscience 
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Table 2. 5 –Western blot antibodies 
Name of antibody Reactive species Dilution Source 
Actin Mouse 1/1000 Sigma 
C/EBPα Rabbit 1/1000 Santa Cruz 
HA Mouse 1/1000 Sigma 
K48 Rabbit 1/1000 Millipore 
K63 Rabbit 1/1000 Millipore 
Trib2 (b-06) Mouse 1/1000 Santa Cruz 
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3 Results: C/EBPα in TRIB2 mediated 
AML induction 
Part of this chapter has been published in O’Connor et al, Oncogene, 2016, 
details provided in section 0. 
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3.1 Introduction 
The p30 isoform of C/EBPα was first identified by western blot in 3T3 cells when 
a C-terminal specific C/EBPα antibody detected 42kD and 30kD proteins 
(Birkenmeier et al., 1989). Further 3T3 cell protein analysis at different stages 
of adipocyte differentiation revealed a change in the p42/p30 ratio as cells 
differentiated with no change in Cebpa mRNA levels (Lin et al., 1993). In healthy 
individuals, translation from the alternate ATG start site of CEBPA sees p30 co-
expressed with p42 in some tissues, albeit at much lower levels than p42 
expression. As discussed in section 1.2.2.2.1, frequently occurring N-terminal 
mutations in CEBPA result in increased levels of the p30 isoform and this shift in 
the p30/p42 ratio in favour of p30 is also observed with TRIB2 overexpression as 
outlined in section 1.3.4.1.1.  
3.1.1 C/EBPαp30 targets 
While p30 retains DNA binding and dimerization activity as the bZIP domain is 
still present, it lacks TAD1 as described previously and thus is unable to repress 
E2F activity. The TAD2 domain is common to both p42 and p30 and shared 
transcriptional targets have been identified. As discussed in section 1.1.3.3, 
C/EBPα can induce adipocyte differentiation from precursor cells, and both the 
p42 and p30 isoforms of C/EBPα have been shown to interact with the SWI/SNF 
complex in adipocyte maturation (Pedersen et al., 2001). The remodelling of 
chromatin to permit access of highly condensed DNA (wound around histones) to 
transcriptional machinery in order to control gene expression is performed by 
large multiprotein complexes. SWI/SNF describes a group of proteins derived 
from the SWI and SNK genes which can destabilise histone-DNA interactions and 
facilitate nucleosome (chromatin subunit) remodelling in an ATP-dependent 
manner. SWI/SNF complexes contain either the BRG1 or BRM ATPases. SWI/SNF 
is a bona fide tumour suppressor and has been shown to be mutated in over 20% 
of all human cancers (Kadoch and Crabtree, 2015). To investigate the ability of 
the C/EBPα isoforms to interact with SWI/SNF, a CO-IP was performed in C33A 
cells which lack BRM - one of the ATPase subunits of SWI/SNF. C33A cells were 
transfected with either p42, p30 or a p30 mutant lacking TAD2 (D1-215), along 
with BRM, and a CO-IP revealed that p42 and p30 but not D1-215 associated with 
BRM confirming that TAD2 was the site of SWI/SNF interaction. Through this 
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TAD2 mediated interaction p42 and p30 were both shown to act as lineage-
instructive transcription factors directing differentiation in adipocytes. 
Other studies reveal that p42 and p30 bind the same transcriptional targets but 
confer different effects. Chemokine receptors are a family of receptors which 
can induce cell migration towards a gradient of chemotactic cytokines. C-X-C 
chemokine receptor type 4 (CXCR4) is upregulated in many types of cancer and 
is the receptor for stromal cell-derived factor-1 (CXCL12), a ligand important for 
HSC homing and quiescence (Burger and Burkle, 2007). In AML, CXCR4 induces 
leukemic cells to migrate beneath the stromal layer of the BM, allowing them to 
evade chemotherapy. Unsurprisingly, CXCR4 expression in AML is correlated with 
poor prognostic outcome.  A study of 220 de novo AML patient samples revealed 
that high CXCR4 expression was inversely correlated with CEBPA mutations, and 
positively correlated with WT CEBPA expression (Kuo et al., 2014). 293T cells 
were transfected with expression vectors carrying WT C/EBPα, or p30 or a C-
terminal mutated (CTM) C/EBPα. WT C/EBPα increased CXCR4 expression at the 
mRNA and protein level, whereas p30 decreased CXCR4 transcription. Thus the 
N-terminal CEBPA mutation resulting in increased p30 would cause repression of 
CXCR4 activity and this might contribute to the favourable outcome of patients 
with biallelic CEBPA mutations, by increasing sensitivity to chemotherapy. In 
another study of C/EBPα target gene promoters it was observed that p30 had a 
5-7 fold higher affinity than p42 for some promoters, namely Pu1 and Gcsfr and 
equal affinity for neutrophil elastase (Cleaves et al., 2004) . The authors 
subsequently show that, unlike p42 which positively regulates Gcsfr, p30 
represses its expression, and so increased p30 expression in AML with N-terminal 
CEBPA mutations may result in competition with p42 for specific target gene 
promoters to exert opposing effects.  
It is unclear how many target genes are shared between p42 and p30 but these 
studies outline both a complementary and competitive role for p30 on shared 
p42 target gene promoters. Several studies have also identified unique p30 
target genes. 
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3.1.1.1 C/EBPαp42 
Constructs of 5 different CEBPA N-terminal mutations were designed based on 
mutations identified in human AML samples. When WT and any of the 5 mutants, 
or WT and p30 vectors were in vitro translated at a 1:1 ratio, the resultant 
proteins reduced DNA binding activity compared to WT alone by over 80% (Pabst 
et al., 2001). Nuclear extracts were next isolated from 4 patients with N-
terminal mutations and 2 patients without CEBPA mutations and it was shown 
that there was a reduction in binding to the gene which encodes for G-CSFR 
(CSF3R) in all 4 mutants compared with the patients without CEBPA mutations. 
Considering the heterozygous nature of the vast majority of bi-allelic CEBPA 
mutations, the authors investigated whether the presence of p30 would affect 
the transactivation ability of the WT protein. Increasing amounts of each of the 
5 N-terminal mutant plasmids were transfected into CV1 cells, alongside a 
constant amount of WT plasmid in a luciferase reporter assay. The authors 
showed that the presence of any of the 5 mutants decreased the promoter 
activity, with a 2:1 ratio of mutant to WT sufficient to reduce the promoter 
activity to that seen with just the mutant plasmid. Interestingly when p30 was 
co-transfected with WT, a 1:1 ratio was sufficient to abrogate promoter 
transactivation from WT. These data suggest that p30 acts as a dominant 
negative regulator of p42, and that this function may contribute to 
leukaemogenesis in AML with N-terminal CEBPA mutations. 
3.1.1.2 Ubiquitin conjugating enzyme 9 
In order to elucidate the mechanism by which increased p30 can abrogate the 
DNA binding and transactivation potential of WT C/EBPα, the inducible 
K562C/EBPαp30-ER cell line was used to induce p30 expression through estradiol 
(ER) treatment, and samples were prepared for mass spectrometry to identify 
p30 target proteins (Geletu et al., 2007). The authors cross-referenced their 
results with proteins that were more than 2-fold upregulated in AML patients 
with an N-terminal mutation and identified 16 proteins common in both. 
Ubiquitin conjugating enzyme (Ubc9), which is upregulated in many cancers, was 
one of the novel p30 targets identified. Sumoylation is a post-translational 
protein modification in which 12kD small ubiquitin-like modifier (SUMO) proteins 
are added to or removed from proteins. Similar to ubiquitination, this process 
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occurs in 3 enzyme dependent steps with Ubc9 being the only E2 conjugating 
enzyme required for sumoylation. In a CO-IP, co-expression of WT C/EBPα and 
p30 in the presence of SUMO-1 enhanced sumoylation whereas no sumoylation 
was observed when p30 was co-expressed with the SUMO-deficient C/EBPα 
mutant K161R. Co-expression of p30 and SUMO with WT C/EBPα significantly 
reduced its ability to transactivate the Cebpa promoter in a luciferase reporter 
assay, while there was no change to the transactivation activity of K161R. The 
authors then showed using a Ubc9 siRNA that knockdown of Ubc9 could overcome 
the p30 mediated increase in sumoylation and transactivation block of WT 
C/EBPα. These data provide a novel mechanism for the observed dominant 
negative regulation of p42 by p30, with p30 negatively regulating p42 expression 
by inducing its sumoylation. 
3.1.1.3 Peptidyl-prolyl cis/trans isomerase  
Peptidyl-prolyl cis/trans isomerase (PIN1) was also one of the 16 p30 target 
proteins identified by Geletu et al. PIN1 activity regulates cell proliferation and 
survival through interaction with kinase signalling pathways (e.g. MAPK). PIN1 
was shown to be overexpressed in many human cancers including brain, cervical, 
lung, ovary and prostate. Analysis of PIN1 in human leukaemia samples showed 
higher levels of PIN1 expression in AML samples compared with controls, and 
higher PIN1 mRNA levels in CEBPA mutated AML compared with AML without 
CEBPA mutations (Pulikkan et al., 2010). PIN1 is an E2F1 target gene and carries 
3 E2F1 binding sites (Ryo et al., 2002), so the authors assessed PIN1 promoter 
activity by E2F1 in the presence and absence of p30. Co-transfection of p30 with 
E2F1 significantly increased the activation of the PIN1 promoter. Silencing of 
PIN1 using an inhibitor (PiB) in the myeloid leukaemia cell line Kasumi-6, which 
endogenously express both p42 and p30, induced myeloid differentiation. Thus 
the authors hypothesise that p30, which lacks the E2F repression domain of p42, 
synergises with E2F1 to enhance the transcription of PIN1. As outlined in the 
introduction, a similar feedback loop was described for TRIB2 whereby E2F1 
binds the TRIB2 promoter increasing TRIB2 translation, which in turn degrades 
p42 and increases p30 which synergises with E2F1 to activate the TRIB2 promoter 
(Rishi et al., 2014). 
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3.1.1.4 WD repeat-containing protein 5 
MLL is a histone methyltransferase which mediates H3K4 methyltransferase 
activity via its SET protein domain. WDR5 is a core subunit of MLL/SET1 H3K4 
methyltransferase complexes which are global regulators of gene transcription. 
It has been recently identified as a binding partner of p30 but not p42. Protein 
complexes were purified from cell lines overexpressing p42 and p30 and then 
mass spectrometry has identified 64 proteins that associated with p42, and 52 
with p30, with only 14 in common to both (Grebien et al., 2015). Of the 52 
identified p30 associated proteins, only 3 were related with transcription, and 2 
of those 3 involved in histone modification/chromatin remodelling. One was 
SMARCD2 which is a component of the SWI/SNF complex discussed in 3.1.1, the 
other was WDR5. CO-IP confirmed that p30 but not p42, associated with WDR5 in 
32D cells. Because WDR5 is required for H3K4 methylation by SET/MLL, and this 
methylation mark is associated with actively transcribed promoters, the authors 
performed H3K4me3 ChIP on p42 or p30 expressing cells. The results revealed a 
strong correlation between p30 binding and H3K4me3 marks on chromatin with 
53% of p30 binding regions positive for the methylation marks, compared with 
just 18% of p42 binding regions. 2606 p30 target genes were shown to be actively 
transcribed with more than 10% of these genes showing significant changes in 
mRNA expression. Those upregulated were related with cell cycle control and 
mitosis, where as those downregulated were related with endoplasmic reticulum 
stress and suppression of transcription. Knockdown of Wdr5 in p30 but not p42 
expressing 32D cells resulted in upregulation of genes associated with myeloid 
differentiation as well an increase in Gr1 and CD11b expression in response to G-
CSF stimulation.  
These studies show that while p30 lacks a pivotal C/EBPα transactivation domain 
(TAD1), it not only retains some overlapping function with p42 through TAD2, 
but also has unique binding partners which mediate an array of functions.  
3.1.2 Experimental mouse models of p30 in AML 
As described in 1.2.2.2.1, up to 15% of AML patients have mutations in the 
CEBPA gene. The mutations are primarily found in patients with a normal 
karyotype and classified as M1 or M2 under the FAB classification system 
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(1.2.1.1). CEBPA mutations can be categorised as either N-terminal frame-shift 
mutations which result in a truncation of the p42 isoform with p30 remaining 
intact or C-terminal in-frame insertions or deletions which impede the DNA 
binding ability by disrupting the basic zipper domain. The N-terminal frame-shift 
mutation resulting in increased levels of p30 protein occurs most frequently. 
However it has been reported that most AML patients have more than one CEBPA 
mutation (>70%) and of those, the vast majority (>90%) have biallelic N-terminal 
and C-terminal mutations (Pabst and Mueller, 2007). As outlined earlier, 
perinatal lethality in the Cebpa-/- mouse results from hypoglycaemia (Wang et 
al., 1995). The first conditional Cebpa knockout (KO) mouse was developed by 
Dan Tenens’ laboratory. They generated the Cebpafl/fl strain, crossed them with 
Mx1-Cre transgenic mice and treated them with poly I:C thus producing the 
CebpaΔ/Δ  conditional KO. Analysis of the hematopoietic system of the C/EBPαΔ/Δ 
mouse revealed while the adult BM was filled with immature myeloblasts, the 
loss of Cebpa and resultant block in myeloid differentiation was not enough to 
induce AML in vivo (Zhang et al., 2004). Considering that the nature of CEBPA 
mutations indicates that CEBPA expression is rarely completely silenced, several 
murine models have been developed to facilitate the study of CEBPA mutations 
in AML. 
3.1.2.1 The BRM2 knock-in murine model 
C/EBPα is considered a tumour suppressor because it directly represses E2F 
activity (Slomiany et al., 2000) as outlined earlier. The p30 isoform of C/EBPα 
lacks the E2F repressor domain, thus in patients with N-terminal mutations, the 
excess p30 levels lead to dysregulation of E2F1 repression. To examine how 
C/EBPα-mediated E2F repression contributes to AML development, Claus 
Nerlovs’ group generated a mouse with a homozygous knock-in mutation called 
BRM2 which abrogates E2F repression (Porse et al., 2005). The BRM2 point 
mutation preserves the ability of C/EBPα to bind DNA and activate promoters 
but it prevents the complex between C/EBPα and E2F from forming thus 
preventing E2F repression. By 36 weeks, the BRM2 mice develop a 
myeloproliferative disease overtime exhibiting splenomegaly and an increase in 
CD11b+Gr1+ cells. However BRM2 mice did not succumb to full-blown AML. In 
addition to confirming the tumour suppressor function of E2F repression by 
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C/EBPα, this model demonstrates that disrupting this function alone is not 
sufficient to mimic the pathology of CEBPA mutated AML. 
3.1.2.2 The L/+ and L/L knock-in murine model 
In order to more accurately recapitulate the commonly occurring CEBPA 
mutations found in humans, Nerlov’s group then generated a knock-in mouse 
where translation of p42 is specifically ablated (Kirstetter et al., 2008). 
Translation of p42 was disrupted by placing a Lox-P flanked cassette between 
the p42 and p30 initiation codons so that cre-mediated deletion of this cassette 
resulted in termination of p42 translation from the AUG, while maintaining p30 
translation (termed the ‘L’ allele). Mice carrying the L allele were crossed with 
MxCre mice producing mice heterozygous for the allele (CebpaLp30/+ also known 
as L/+), which were subsequently crossed to form the homozygous L/L mice 
which only expressed the p30 isoform. After 18 months L/+ mice displayed no 
disruption in any hematopoietic tissues and no perturbations to granulocytic 
differentiation being virtually indistinguishable from +/+ controls. L/L mice 
uniformly succumbed to AML after 9-14 months exhibiting excessive Cd11b+Gr1lo 
blasts in the BM, massive splenomegaly and infiltration of blast cells into the 
liver. Mimicking the most prevalent CEBPA mutation in vivo the authors here 
showed that p30 alone drives efficient transformation of granulocytes in the 
absence of p42. 
3.1.2.3 The K/L and K/K knock-in murine model 
Nerlov’s group subsequently developed a mouse model to recapitulate the 
incidences of both the N-terminal and C-terminal mutations in CEBPA mutated 
AML. A knock-in allele was generated which mimicked one of the most commonly 
occurring C-terminal mutations i.e. the K313 duplication (K313dup) termed the K 
allele. The K313dup was first identified in CD7+ M1 AML and it was shown to have 
lower protein stability than WT C/EBPα (Carnicer et al., 2008). The mutation 
may represent up to 10% of all CEBPA mutations. By combining the K allele (C-
terminal mutation) with the aforementioned L allele (N-terminal mutation) to 
produce +/+, K/K, K/L and L/L mice (CD45.2+) the authors could recapitulate 
the spectrum of biallelic patient mutations (Bereshchenko et al., 2009). The 
authors transplanted FLCs from each genotype into CD45.1/2+ recipient mice 
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with CD45.1+ competitor BM cells. Analysis at 4.5 weeks post-transplant revealed 
expansion of the LSK compartment, primarily ST-HSCs and LMPPs, in K/L and K/K 
transplanted mice but not +/+ or L/L. K/L, K/K and L/L transplanted cells all 
induced lethal AML in recipient mice with the most aggressive disease arising 
from the K/L transplanted disease, and the longest latency from the K/K 
transplanted cells. The K/L and L/L leukaemia were granulocytic with myeloid 
blasts detected in the PB and infiltration into the spleen. However, only 25% of 
K/K leukaemias resembled this phenotype (myeloid with maturation). The 
remainder contained very few differentiated myeloid cells and instead were 
characterised by an increase in immature erythroid cells. The authors 
determined the reduced ability for K/K cells to induce myeloid AML with 
maturation was due to an inability to form committed myeloid progenitors. GMPs 
were detected at normal levels in L/L and +/+ mice, slightly lower in K/L mice 
and drastically reduced in K/K mice. This model demonstrates that the most 
aggressive AML was induced when the C-terminal and N-terminal mutations were 
combined and the ability of excess p30, arising from the N-terminal mutation, to 
induce myeloid differentiation was needed to form a myeloid leukaemia with 
maturation.  
3.1.2.4 The C/EBPα-Nm and C/EBPα-Cm overexpression murine model 
In another study 244 samples from patients with myelodysplastic syndrome (MDS) 
or AML were analysed and it was found that the biallelic heterozygous CEBPA 
mutations occur primarily in de novo AML whereas single N or C-terminal CEBPA 
mutations occur in therapy-related AML or MDS (Kato et al., 2011). The authors 
then generated an N-terminal mutant producing p30 only (C/EBPα-Nm) which 
carried a T60fsX159 mutation between the p42 and p30 translational start sites, 
and a C-terminal mutant (C/EBPα-Cm) carrying a 304_323 duplication in the bZIP 
region. BM cells transduced with either mock, C/EBPα-Nm or C/EBPα-Cm 
retrovirus were transplanted into lethally irradiated recipients and it was shown 
that all C/EBPα-Cm transplanted mice developed AML within 4-12 months 
characterised by CD11b+Gr1+cKitint/hi BM and splenic leukemic cells and 
splenomegaly. Less than half C/EBPα-Nm transplanted mice developed disease, 
and in those that did a B-cell acute lymphoblastic leukaemia (B-ALL) was 
generated in most, characterised by accumulation of B220+CD19+cKitint/hi 
leukemic cells which infiltrated the spleen and liver. The authors then co-
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transduced BM cells with C/EBPα-Nm and C/EBPα-Cm retrovirus, and transplanted 
cells expressing both into lethally irradiated recipient mice. These mice 
succumbed to disease with a shorter latency (3-5 months) than mice 
transplanted with one or the other mutant. They also exhibited an increased 
number of leukemic cells, and these cells were of a more immature 
CD11bintGr1loB220locKitlo myeloid blast phenotype when compared with the 
C/EBPα-Cm transplanted mice. Contrary to observations made by Bereshchenko 
et al, the authors here conclude that it is the C-terminal mutation of CEBPA 
which affects differentiation, while the N-terminal mutation (i.e. excess p30) is 
responsible for expansion of the preleukemic cells. 
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3.2 Aims and objectives 
The transcription factor C/EBPα is essential for granulocytic differentiation and 
while both isoforms p42 and p30 are commonly dysregulated in AML as well as 
other cancers, complete loss of C/EBPα expression rarely occurs. The oncogene 
TRIB2 drives AML in vivo by selectively degrading p42 but it remains to be shown 
whether or not C/EBPα expression is required for TRIB2 mediated AML. Indeed 
with TRIB2 mediated loss of p42, there is a marked increase in p30 expression in 
the resultant AML. TRIB2 has been shown to cooperate with other oncogenes 
(1.3.4.1.1) and it is unclear if p30 and TRIB2 cooperate in leukaemia induction. 
In fact the role of the p30 is not well understood in either normal hematopoiesis 
or AML. There is limited data available on the effect of p30 expression on steady 
state hematopoiesis and as outlined in 3.1.2 contradictory evidence exists 
implicating p30 in either a differentiation role in AML (Bereshchenko et al., 
2009) or promoting proliferation of leukemic blasts (Kato et al., 2011). As such 
the specific aims of this chapter were: 
i.  To determine the effect of enforced p30 expression on steady state 
hematopoiesis using an in vivo transplantation technique 
ii.  To examine the proteolytic relationship between TRIB2 and C/EBPα 
isoforms p42 and p30 
iii.  To address the role of p42 and p30 in TRIB2 mediated AML 
induction by utilising a conditional animal model to 
a. Determine if C/EBPα is required for TRIB2 leukaemia 
pathogenesis   
b. Examine if p30 cooperates with TRIB2 to drive AML 
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3.3 Results 
3.3.1 C/EBPα-p30 disrupts myelopoiesis in vivo 
To address the effect of excess p30 on hematopoiesis a BM transduction and 
transplantation experiment was performed. In this model, donor mice were 
treated with 5-FU to deplete differentiated cells and enrich stem and progenitor 
populations. 5-FU also stimulates HSPCs into cycling supporting better retroviral 
transduction efficiency. The donor derived BM cells were isolated and 
transduced with titre-matched control MigR1 or p30 overexpressing retrovirus 
and transplanted into lethally irradiated recipients (Figure 3. 1A). The mice 
were sacrificed at 8-14 weeks post-transplant. Upon examination there was no 
difference in the number of circulating WBCs (Figure 3. 1B) nor in the spleen 
weights (Figure 3. 1C) between control MigR1 and p30 transplanted mice. A 
previously published attempt at transplanting p30 overexpressing cells into 
recipient mice was unsuccessful (Schwieger et al., 2004). The authors used a 
C/EBPα mutant, mut10, which expressed p30 but not p42 and transplanted BM 
cells overexpressing control or mut10 into lethally irradiated recipients. After 12 
weeks the authors were unable to detect GFP in either the blood or BM of 93% of 
mice transplanted with p30 overexpressing cells, whereas all mice receiving 
control transduced cells expressed GFP (range 2%-79%). The authors deduced 
that high expression of p30 impaired stem and progenitor cell survival. It should 
also be noted that upon analysis of the small percentage of mice which 
successfully engrafted the donor p30 expressing cells (<10%), the authors 
reported no effect of p30 overexpression on lineage distribution.  
With this in mind GFP expression in the BM, spleen, PB and thymus of the MigR1 
and p30 chimeric mice was first analysed. While the GFP expression detected in 
p30 mice was lower overall than in MigR1 controls, there were moderate levels 
of chimerism achieved in most tissues for most mice (Figure 3. 2). Any tissues 
with lower than 5% GFP expression were omitted from further flow cytometric 
analysis. The BM, spleen, PB and thymus were next analysed for markers of 
mature myeloid (CD11b, Gr1), B (B220, CD19) and T (CD4, CD8) cells. Contrary 
to the findings of Schwieger et al, there was a significant increase in the 
percentage of CD11b+Gr1+ myeloid cells in the GFP+ compartment of the BM and 
spleen of p30 chimeric mice (Figure 3. 3) when compared with MigR1 controls. 
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This correlates well with previously published observations in the L/L model 
(discussed in section 3.1.2.2). Before leukemic transformation, the authors 
noted that the L/L mice exhibited a CD11b+Gr1+ phenotype (the L/L-2 
phenotype) between 2 and 6 months.  
This was coupled with a significant decrease in the percentages of B220+CD19+ B 
cells in the BM and spleen, and also in the PB (Figure 3. 4). There was a small 
but significant increase of CD4+ cells in the BM of the p30 mice (Figure 3. 5A), 
but no significant differences in CD4 and CD8 expression in the other tissues 
(Figure 3. 5). These data suggest overexpression of the p30 disrupts myelopoiesis 
in vivo.  
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Figure 3. 1 – BMT model to determine the effect of p30 overexpression on 
hematopoiesis 
BM isolated from 5-FU treated donor mice was transduced with control MigR1 or 
p30 overexpressing retrovirus and transplanted into 6-10 week old lethally 
irradiated recipient mice. Mice were sacrificed 8-14 weeks post-transplant and 
analysed. (A) Schematic overview of BMT. (B) Graph of the number of WBCs in 
PB of MigR1 (n=12) or p30 (n=11) transplanted mice. (C) Graph of the spleen 
weights of MigR1 (n=13) or p30 (n=11) transplanted mice. Scatter plots display 
mean +/- SD and data represents mice from 2 independent transplants. 
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Figure 3. 2 - Analysis of GFP expression in MigR1 and p30 transplanted mice 
Mice transplanted with MigR1 (n=10-12) or p30 (n=10-11) expressing BM were 
sacrificed 8-14 weeks post-transplant and percentage GFP expression was 
determined in the BM, spleen, PB and thymus by flow cytometry. Scatter plots 
display mean +/- SD and data represents mice from 2 independent transplants. 
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Figure 3. 3 – Overexpression of p30 enhances myelopoiesis in vivo. 
(A) Representative flow cytometric analysis of BM cells from mice reconstituted 
with BM cells transduced with MigR1 or p30 retrovirus, showing engraftment of 
GFP (left panel) and CD11b and Gr1 expression in the GFP- and GFP+ fractions. 
(B) Graph of percentage number of GFP+ myeloid cells (CD11b+Gr1+) in the BM, 
spleen and PB of MigR1 (n=6-13) and p30 (n=6-9) transplanted mice. Tissues with 
<5% GFP expression were omitted from analysis. Results are representative of 2 
independent virus transduction and transplantation experiments, +/-SD. *p≤0.05 
  114 
 
 
Figure 3. 4 – Overexpression of p30 results in a decrease in mature B cells in 
vivo. 
(A) Representative flow cytometric analysis of BM cells from mice reconstituted 
with BM cells transduced with MigR1 or p30 retrovirus, showing engraftment of 
GFP (left panel) and B220 and CD19 expression in the GFP- and GFP+ fractions. 
(B) Graph of percentage number of GFP+ myeloid cells (B220+CD19+) in the BM, 
spleen and PB of MigR1 (n=6-13) and p30 (n=6-9) transplanted mice. Tissues with 
<5% GFP expression were omitted from analysis. Results are representative of 2 
independent virus transduction and transplantation experiments, +/-SD. 
**p<0.005, ***p<0.001. 
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Figure 3. 5 – The effect of p30 overexpression on CD4 and CD8 expression in 
vivo.  
(A) Graph of percentage number of GFP+ CD4+ cells in the BM, spleen and PB of 
mice reconstituted with BM cells transduced with MigR1 (n=6-13) or p30 (n=6-9) 
retrovirus. (B) Graph of percentage number of GFP+ CD8+ cells in the BM, spleen 
and PB of MigR1 (n=6-13) and p30 (n=6-9) transplanted mice. (C) Graph of 
percentage number of GFP+ CD4+ CD8+ cells in the thymus of MigR1 (n=7) and p30 
(n=4) transplanted mice. Tissues with <5% GFP expression were omitted from 
analysis. Results are representative of 2 independent virus transduction and 
transplantation experiments, +/-SD. *p≤0.05 
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3.3.2 Overexpression of C/EBPα-p30 induces AML in vivo 
As described in section 3.1.2 the oncogenic effects of N-terminal mutations 
resulting in excess p30 are well established. Unlike those models, in the 
overexpression transplant model discussed in 3.3.1 excess p30 is present with 
physiological levels of p42. Under these conditions excess p30 was shown to 
disrupt myelopoiesis. However, it was unclear whether the observation of 
increased CD11b+Gr1+ cells in the p30 chimeric mice was the result of p30 
promoting myeloid differentiation or p30 causing aberrant proliferation of 
mature cells. To evaluate this it was decided to extend the time-line of the 
transplant model in a small number of animals. Of 5 mice transplanted with p30 
overexpressing BM cells, 2 succumbed to disease at 26 (M1) and 36 (M2) weeks 
respectively, while a third mouse (M3) did not develop disease (Figure 3. 6A). 
The remaining 2 mice from the experiment have been omitted from analysis as 
due to unexpected premature death it could not be determined if they had 
succumbed to disease. Upon examination, the mouse which did not develop 
disease did display engraftment of donor cells in the BM but no signs of 
disruption to myelopoiesis (Figure 3. 6B). Analysis of the leukemic mice, M1 and 
M2, revealed elevated WBC counts and splenomegaly (Figure 3. 7A and B) and 
distinct GFP clones in each disease (Figure 3. 7C). M1 carried 2 clones - the 
predominant GFPlo clone and very low expression of a GFPhi clone, with M2 
almost exclusively carrying a GFPhi clone. Upon flow cytometric analysis, the BM 
cells of the M1 GFPhi clone had a myeloproliferative phenotype with a very high 
percentage of CD11b+Gr1+ cells present and virtually no lymphocytes. However 
BM cells of the predominant M1 GFPlo clone were almost completely bereft of 
myeloid and B cell markers with virtually all cells aberrantly expressing CD8 with 
over 40% co-expressing CD4 (Figure 3. 8). On the other hand in the BM of M2, the 
predominant clone was GFPhi and this had virtually identical surface marker 
expression to the GFPhi clone in M1 with an elevated percentage of CD11b+Gr1+ 
cells and an almost complete absence of B and T cell markers (Figure 3. 9). In 
contrast in M2 the GFP- (25.6%) and GFPlo (1.44%) populations were virtually 
indistinguishable from one another, with normal myeloid and T cell marker 
expression, and lower than normal B cell marker expression.  
To determine if these diseases with 2 distinct phenotypes induced by p30 
overexpression represented overt transplantable leukaemia, secondary 
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transplants were performed with cells from the primary p30 diseases (Figure 3. 
10). In 2 independent experiments, 6 x 106 leukemic spleen cells or 4 x 106 
leukemic BM cells from M1 were transplanted into a total of 6 recipient mice. 
After 10 weeks there was no detectable GFP in the PB of all transplanted mice. 
Cells transplanted from M2 however were able to generate leukaemia in 
secondary hosts with all transplanted mice succumbing to disease with a mean 
latency of 27 weeks (Figure 3. 11A). They had very high WBC counts and 
splenomegaly (Figure 3. 11B and C). Flow cytometric analysis of the leukemic BM 
cells showed that the secondary disease resembled the GFPhi clone from the 
parent AML, but with aberrant B220 expression (Figure 3. 12) and a more 
immature myeloid phenotype. Thus in an overexpression BMT model in the 
presence of physiological levels of p42, p30 was able to induce a transplantable 
AML in vivo in 1 out of 3 cases. Thus it was hypothesised that the increased 
proliferation of myeloid cells observed in the short-term BMT in section 3.3.1 
could weakly (33%) transform to full blown leukaemia. 
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Figure 3. 6 – Overexpression of p30 induces leukaemia in vivo 
(A) Kaplan-Meier survival curve of mice reconstituted with BM cells transduced 
with p30 expressing retrovirus, with 2 of 3 mice succumbing to disease at 26 and 
36 weeks respectively. (B) Flow cytometric analysis of BM from the surviving 
mouse showing engraftment of GFP+ p30 expressing donor cells (left panel) and 
normal levels of CD11b and Gr1 expression in the GFP- and GFP+ compartments 
of the BM.  
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Figure 3. 7 – Analysis of p30 leukemic mice 
Graph of (A) WBC counts and (B) spleen weights of p30 leukemic mice. Grey 
dashed line represents normal range from a healthy mouse. (C) Scatter plots of 
GFP expression in BM of M1 (left panel) and M2 (right panel).  
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Figure 3. 8 – Flow cytometric analysis of GFP clones of M1 leukemic BM cells 
Flow cytometric analysis of the expression of markers of mature myeloid (CD11b, 
Gr1), B (B220, CD19), and T (CD4, CD8) cells on BM cells from M1 through GFP- 
(left panel), GFPlo (middle panel) and GFPhi (right panel).  
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Figure 3. 9 – Flow cytometric analysis of GFP clones of M2 leukemic BM cells 
Flow cytometric analysis of the expression of markers of mature myeloid (CD11b, 
Gr1), B (B220, CD19), and T (CD4, CD8) cells on BM cells from M2 through GFP- 
(left panel), GFPlo (middle panel) and GFPhi (right panel). 
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Figure 3. 10 – Schematic overview of secondary and tertiary p30 overexpression 
transplants 
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Figure 3. 11 – M2 but not M1 transplanted cells induce AML in secondary 
recipients 
(A) Kaplan-meier survival curve of sub-lethally irradiated mice transplanted with 
primary leukemic cells from M1 (n=6) or M2 (n=3). M1 transplanted cells failed to 
engraft in secondary hosts. M2 transplanted mice succumbed to disease with a 
median latency of 27 weeks. Graph of (B) WBC counts and (C) spleen weights of 
leukemic mice transplanted with M2 primary p30 leukemic cells. Grey dashed 
line represents normal range from a healthy mouse. 
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Figure 3. 12 – Flow cytometric analysis of BM of p30 (M2) secondary leukaemia. 
Representative flow cytometric analysis of BM from p30 (M2) secondary 
leukaemia. Percentage GFP expression in the BM (histogram) and analysis of B 
cells (B220, CD19), myeloid cells (CD11b, Gr1) and T cells (CD8, CD4) in the GFP- 
and GFP+ compartment of the BM are shown. 
  
  125 
 
3.3.3 Trib2 degrades p42, but not p30, via K48 mediated 
ubiquitination  
Given that above it was determined that p30 overexpression could induce a 
transplantable AML in vivo and considering the ability of TRIB2 to cooperate with 
other oncogenes as previously outlined, the question remains if TRIB2 and p30 
cooperate to induce AML. As outlined in 1.3.4.1.1, TRIB2 induces AML by causing 
proteasomal degradation of p42 and an increase in p30. As previously discussed 
it has been shown that the degradation of p42 by TRIB2 is proteasome 
dependent (Keeshan et al., 2006) and TRIB2 has a COP1-binding domain which is 
essential for C/EBPα degradation (Keeshan et al., 2010). COP1 is an E3 ubiquitin 
ligase which forms a complex with TRIB2 and C/EBPα that is necessary for p42 
degradation. Ubiquitination, as described in 2.5.2, is a process whereby proteins 
are modified by being tagged at a K residue with 8.5kD molecules of the Ub 
protein, which may act as a signal for their degradation via the proteasome. It 
occurs in three steps – activation, conjugation and ligation, with each step being 
catalysed by a separate class of enzyme - E1 ubiquitin-activating enzymes, E2 
ubiquitin-conjugating enzymes and E3 ubiquitin ligases.  In order to determine if 
TRIB2 was inducing Ub specific degradation of C/EBPα, an in vitro ubiquitination 
assay was performed. Briefly 293T cells were transfected with C/EBPα, TRIB2 
and UB, cells lysed 24 hrs later and ubiquitination was detected by CO-IP of the 
target protein followed by anti-UB blotting. It was shown that in the presence of 
TRIB2 there is a dramatic increase in C/EBPα ubiquitination (Figure 3. 13 - top 
panel)  
As outlined earlier, Ub molecules have 7 lysine residues themselves, K6, 11, 27, 
29, 33, 48 and 63, and successive addition of Ub molecules to a substrate is 
called polyubiquitination. Several different types of Ub chains can be formed 
depending on which lysine residue of the previous Ub molecule they attach to. 
K48-Ub chains signal the protein for proteasomal degradation while K63-Ub 
chains protect the protein from degradation. Using K48 and K63 specific 
antibodies it was shown that ubiquitination of C/EBPα by TRIB2 was not via the 
non-degradative K63 polychain pathway (Figure 3. 13 middle panel) but the K48 
polychain degradative pathway (Figure 3. 13 bottom panel). These data would 
suggest that inhibiting the proteasome could negate the function of TRIB2 by 
preventing the degradation of p42. To test this hypothesis, U937 cells which 
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endogenously express TRIB2 and C/EBPα, were transduced with control MigR1 or 
MigR1-TRIB2 retrovirus. GFP+ cells were sorted after 16-24 hrs and treated with 
10nM Bortezomib, a proteasome inhibitor developed for treating multiple 
myeloma. Cells expressing TRIB2 displayed increased sensitivity to Bortezomib 
treatment (Figure 3. 14A). Conversely U937 cells overexpressing C/EBPα showed 
decreased sensitivity to Bortezomib induced proteasome inhibition indicating 
that enforced C/EBPα expression was able to rescue Bortezomib induced cell 
death (Figure 3. 14B). Two CEBPA null leukemic cell lines, K562 (Radomska et 
al., 1998) and Kasumi1 (Pabst et al., 2001), were also transduced with MigR1 or 
MigR1-TRIB2 and in the absence of C/EBPα expression, increased TRIB2 levels 
had no effect on Bortezomib induced toxicity (Figure 3. 14C and D). These data 
demonstrate that the TRIB2 mediated K48-specific ubiquitination of C/EBPα can 
be targeted by proteasome inhibition.      
Considering the selective way in which TRIB2 degrades p42 in vivo in AML 
induction it was determined whether or not TRIB2 would also induce p30 
ubiquitination. Either p42 or p30 were transfected, with Ub, into 293T cells with 
or without TRIB2. TRIB2 was unable to ubiquitinate p30 (lane2) despite a 
significant increase in p42 ubiquitination in the presence of TRIB2 (lane4) (Figure 
3. 15). As mentioned above, the site of ubiquitination on the substrate is a K 
residue. Previously outlined in 1.2.2.2.1, a common recurrent CEBPA mutation 
occurs at residue K313 that results in a duplication of the K residue, K313KK 
(K313dup). Thus it was hypothesised that this may be a potential site for TRIB2 
mediated C/EBPα ubiquitination. To explore this, a CEBPA mutant was made by 
site-directed mutagenesis in which the K residue at site 313 was mutated to an 
arginine (R). K313R or WT C/EBPα, were co-transfected with UB into 293T cells 
with or without TRIB2. The K313R mutation resulted in loss of TRIB2 induced 
C/EBPα ubiquitination (lane 2) when compared with WT C/EBPα (Lane 4) (Figure 
3. 16). Indeed background levels of K313R ubiquitination (lane 1) also appeared 
lower than WT C/EBPα (lane3) suggesting increased protein stability. To ensure 
that the results observed were not due to a mutation-related loss of function, a 
dual luciferase reporter assay was performed. Indeed K313R was still able to 
stimulate the luciferase reporter construct of Gcsfr, a C/EBPα target gene, at 
equivalent levels to WT C/EBPα (Figure 3. 17A). To confirm that the K313R 
mutant retained functional C/EBPα activity, a Cebpa null cell line (α-/-) which 
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differentiates upon enforced expression of C/EBPα was transduced with control 
MigR1, MigR1-C/EBPα or MigR1-K313R retrovirus and analysed for Gr1 expression 
by flow cytometry. After 2 days in culture both WT C/EBPα and K313R 
overexpression had resulted in a comparable increase in expression of the 
mature granulocyte marker (Figure 3. 17B and C). Thus mutating the K313 
residue did not abrogate the transcriptional or functional activity of C/EBPα.  
Together these data show that K313 represents a site of TRIB2 mediated 
ubiquitin conjugation on C/EBPα and mutation of this site abrogates ubiquitin-
dependent proteasomal degradation of C/EBPα by TRIB2.   
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Figure 3. 13 – Analysis of TRIB2 mediated ubiquitination of C/EBPα 
293T cells were transfected with ubiquitin-HA, TRIB2, C/EBPα and PHMA empty 
vector control, and a ubiquitination assay was performed. Immunoblotting for 
HA detects total ubiquitination (top IP panel), K63 species of polyubiquitination 
(second IP panel), K48 species of polyubiquitination (third IP panel), and C/EBPα 
detects IP protein (bottom IP panel). Immunoblotting for TRIB2 and C/EBPα 
detects input levels and actin serves as a loading control (input panels). 
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Figure 3. 14 – Degradation of p42 by TRIB2 can be targeted by Bortezomib 
induced proteasome inhibition in leukaemia cell lines.  
Sorted GFP+ cells transduced with MigR1 control, and MigR1-TRIB2 (A, C, D) or 
MigR1-C/EBP (B) retrovirus were treated +/- 10nM Bortezomib for 16-24hrs and 
analysed by flow cytometry for DAPI expression. Graph of fold change in cell 
death as determined by DAPI positive cells. Data displayed is average of 3 
technical replicates, and is representative of 2 independent experiments. ns 
denotes not significant, *P≤0.05,**P<0.005 by Student´s unpaired t test.
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Figure 3. 15 – Analysis of TRIB2 mediated ubiquitination of C/EBPα isoforms p42 
and p30 
293T cells were transfected with ubiquitin-HA, TRIB2, p30, p42 and PHMA empty 
vector control, and ubiquitination assay was performed. Immunoblotting for HA 
detects total ubiquitination (top IP panel), and C/EBPα detects IP protein 
(bottom IP panels). Immunoblotting for TRIB2 and C/EBPα detects input levels 
and actin serves as a loading control (input panels). 
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Figure 3. 16 – Analysis of TRIB2 mediated ubiquitination of K313R mutant 
293T cells were transfected with ubiquitin-HA, TRIB2, C/EBPα, K313R and PHMA 
empty vector control, and ubiquitination assay was performed. Immunoblotting 
for HA detects total ubiquitination (top IP panel), and C/EBPα detects IP protein 
(bottom IP panel). Immunoblotting for TRIB2 and C/EBPα detects input levels 
and actin serves as a loading control (input panels).  
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Figure 3. 17 – C/EBPα mutant K313R retains transcriptional and differentiation 
activity 
(A) 293T cells were co-transfected with the Gcsfr promoter firefly luciferase 
constructs containing either the WT C/EBPα (WT GCSFR) or mutant binding sites 
(Mut GCSFR), and either an empty PHMA vector or vector containing C/EBPα or 
K313R, along with a pRL-TK Renilla luciferase internal control plasmid. 
Luciferase activity was measured 24 hrs post-transfection. Bar chart represents 
reporter luciferase activity for each sample normalised for renilla values, and 
graphed relative to the control sample. Results analysed using two-tailed 
unpaired t-test and representative of 3 independent experiments. The Cebpa 
null cell line (a-/-) were transduced with control MigR1, MigR1-C/EBPα or MigR1-
K313R retrovirus and analysed for Gr1 expression after 48 hrs. (B) Graph of 
average percentage Gr1 expression +/- SD and (C) representative histograms of 
Gr1 expression. Data represents 1 experiment with 3 technical replicates.  
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3.3.4 Degradation of p42 is the key driver of TRIB2-induced AML  
The data thus presented has demonstrated that p30 overexpression can induce 
transplantable AML in vivo and that TRIB2 degrades p42 by ubiquitination but 
cannot degrade p30. As previously discussed, CEBPA mutations rarely result in 
complete loss of C/EBPα expression and there is evidence to suggest that some 
oncogenes require a threshold of C/EBPα expression for AML initiation (Ohlsson 
et al., 2014, Collins et al., 2014) as outlined in 1.2.2.2.1. In order to evaluate a 
cooperative relationship between p30 and TRIB2 in AML induction, it was first 
investigated whether or not the presence of C/EBPα was essential for the 
oncogenic effects of TRIB2. A BMT was performed using the previously described 
conditional Cebpafl/fl; Mx1Cre mouse model, where poly I:C treatment facilitates 
ablation of Cebpa in the hematopoietic compartment. Two weeks post deletion, 
cKit+ HSPCs isolated from the BM of poly I:C treated control Cebpafl/fl and 
Cebpa∆/∆ animals were transduced with MigR1-TRIB2 retrovirus. The transduced 
cells were then transplanted into lethally irradiated recipient mice, and 
monitored for disease progression. As expected, all mice reconstituted with 
Cebpafl/fl cells expressing TRIB2 developed lethal AML with a median latency of 
33 weeks, but in striking contrast, TRIB2 transduced Cebpa∆/∆ HSPCs failed to 
give rise to AML (Figure 3. 18A). The BM of Cebpa∆/∆ transplanted mice was 
examined 14 months after transplantation, and GFP+ cells were detected 
suggesting that the TRIB2 expressing Cebpa∆/∆ cells are able to properly home to 
the BM but were not able to initiate leukaemia (Figure 3. 18B). Thus, despite 
TRIB2 functioning to degrade C/EBPα to induce AML, the complete absence of 
C/EBPα abrogates TRIB2 oncogenicity, suggesting that a certain threshold of 
C/EBPα (p42 or p30) expression is necessary for TRIB2 to initiate AML.   
Considering the necessity of C/EBPα expression for TRIB2 to induce AML, it was 
next determined whether p42 degradation or p30 accumulation was the key 
driver of this pathway, and whether p30 could cooperate with TRIB2 to 
accelerate disease progression. In order to investigate this, a transplant model 
was designed which utilised donor cells from an established Cebpa conditional 
knockout model (described in 3.1.2.2) that either only expressed the p30 isoform 
(previously L/L, referred to here as Cebpa∆/p30), or were heterozygous for this 
allele still expressing p42 on one allele (previously L/+, referred to here as 
Cebpafl/p30 cells). CD45.2+ donor cells from poly I:C treated 8-14 week old 
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Cebpafl/+, Cebpafl/p30 and Cebpafl/p30; Mx1Cre (i.e. Cebpa∆/p30) mice were 
harvested two weeks post deletion, transduced with MigR1 or MigR1-TRIB2 
retrovirus and transplanted into CD45.1+ lethally irradiated recipients (Figure 3. 
19). Cebpafl/+ mice carried full-length Cebpa on both alleles and thus had WT 
levels of p42 and p30, therefore MigR1 transplanted mice were expected to 
remain disease free, while TRIB2 transplanted mice were expected to develop 
AML as previously published (Keeshan et al., 2006) (Figure 3. 20). Cebpafl/p30 
mice carry 1 allele with full-length Cebpa and one p30 only allele and as such 
had lower levels of p42 and excess p30, thus MigR1 transplanted mice were 
expected to remain disease free as previously reported (Kirstetter et al., 2008). 
However it was not known if the excess p30 would cooperate with TRIB2 and 
affect the disease latency as TRIB2 has been shown to cooperate with other 
oncogenes (Keeshan et al., 2008). Cebpa∆/p30 mice which carried p30 on one 
allele only expressed p30 and were null for p42. As outlined in 3.1.2.2, mice only 
expressing p30 (also known as L/L) have been shown to uniformly develop 
leukaemia therefore the MigR1 transplanted mice were expected to develop 
leukaemia within 9-14 months as previously published. Following transduction, a 
fraction of the donor cells were kept in in vitro culture for 3 days post 
transplantation and assessed for GFP expression to ensure comparable levels of 
transduction were achieved between samples (Figure 3. 21A). Following 
transplantation, CD45.2 and GFP expression were monitored at 7 weeks post-
transplant (Figure 3. 21B and C) in peripheral blood and every 2-3 weeks 
thereafter (Figure 3. 22) showing recipient reconstitution with donor cells.  
Control cohorts of mice transplanted with Cebpafl/+ and Cebpafl/p30 cells 
transduced with MigR1 did not develop any disease, as expected. Analysis of 
these mice showed completely normal hematopoiesis as evidenced by normal 
WBC counts (Figure 3. 23A), spleen weights (Figure 3. 23B) and distribution of 
peripheral blood cells (Figure 3. 23C-E). Indeed flow cytometric analysis also 
showed that mice from both of these groups displayed normal BM, peripheral 
and splenic hematopoiesis (Figure 3. 24). The mice transplanted with TRIB2 
transduced Cebpafl/+ cells developed AML, with a median latency of 49 weeks, 
also as expected. However, mice transplanted with TRIB2 transduced Cebpafl/p30 
cells developed a much more aggressive AML with an accelerated latency of 29 
weeks (Figure 3. 25A) as evidenced by elevated white blood cell counts and 
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splenomegaly (Figure 3. 25B and C). This supports our hypothesis that p30 could 
cooperate with TRIB2 to accelerate AML. Mice transplanted with MigR1 
transduced Cebpa∆/p30 cells developed AML with a median latency of 40 weeks, 
as previously published for CebpaL/L mice (“L” refers to p30). However no 
significant acceleration of the disease was seen in mice transplanted with TRIB2 
transduced Cebpa∆/p30 cells (median latency of 35 weeks) (Figure 3. 26A) 
indicating that the presence of p42 was important for the cooperativity of TRIB2 
and p30. Indeed, comparing TRIB2 induced AML in Cebpafl/p30 and Cebpa∆/p30 
background, the excess p30 accelerated AML only in the presence of p42 (Figure 
3. 26B). Flow cytometric analysis of leukemic cells from Cebpafl/+-TRIB2, 
Cebpafl/p30-TRIB2, Cebpa∆/p30-MigR1  and Cebpa∆/p30-TRIB2 AML cells confirmed a 
predominantly cKit+ disease (Figure 3. 27). Protein analysis of C/EBPα expression 
between the Cebpafl/+-TRIB2, Cebpafl/p30-TRIB2, Cebpa∆/p30-TRIB2 and Cebpa∆/p30-
MigR1 AML cells groups verified the expected p42 and p30 expression levels in 
leukaemic BM cells (Figure 3. 28). In the Cebpafl/+-TRIB2 cohort (lane 1) there 
was a shift in the leukemic ratio of p42:p30 with a decrease in p42 and increase 
in p30 when compared with control (lane 6). As expected, increased p30 
expression was also observed in the Cebpafl/p30-MigR1 (lane 2) and Cebpafl/p30-
TRIB2 (lane 3) samples, with a clear reduction in p42 expression with TRIB2 (lane 
3 versus lane 2). Comparable levels of p30 were present in the absence of p42 in 
Cebpa∆/p30-MigR1 (lane 4) and Cebpa∆/p30-TRIB2 (lane 5) samples. Taken together 
these data show that despite TRIB2 functioning to degrade p42, C/EBPα is 
essential for the initiation of TRIB2 mediated AML and only in the presence of 
p42 is there a cooperative effect seen with p30. 
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Figure 3. 18 – C/EBPα is required for TRIB2 mediated AML induction 
(A) Kaplan-Meier survival curve of mice reconstituted with either Cebpafl/fl or 
CebpaΔ/Δ bone marrow cells transduced with TRIB2 expressing retrovirus. The 
median survival of mice reconstituted with Cebpafl/fl -TRIB2 cells was 33 weeks 
(n=12), none of the mice reconstituted with CebpaΔ/Δ-TRIB2 cells developed 
leukaemia within 60 weeks (n=10). ***P<0.0001 by Log-rank test. (B) Fraction of 
cells expressing GFP in bone marrow of leukemic mice (Cebpafl/fl-TRIB2) or when 
the experiment was terminated 60 weeks post transplantation (Cebpa∆/∆-TRIB2). 
Data are represented as mean +/- SD, ***P<0.0001 by Student’s t-test. This 
experiment was performed by Dr. Ewa Ohlsson, in a collaboration with Professor 
Bo Porse, University of Copenhagen.  
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Figure 3. 19 – Schematic overview of BM transplantation experiment 
CD45.2+ donor cells from poly I:C treated 8-14 week old Cebpafl/+, Cebpafl/p30 
and Cebpa∆/p30 mice were harvested two weeks after deletion, transduced with 
MigR1 or MigR1-TRIB2 retrovirus and transplanted into lethally irradiated CD45.1+ 
recipient mice. 
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Figure 3. 20 – Schematic overview of predicted outcomes of bone marrow 
transplant experiment 
Mice transplanted with MigR1 transduced Cebpafl/+ cells (full-length C/EBPα 
translated from both alleles) were expected to remain disease free while those 
transplanted with TRIB2 expressing Cebpafl/+ should develop AML. Mice 
transplanted with MigR1 transduced Cebpafl/p30 cells (1 allele from which full-
length CEBPA is translated and 1 allele from which p30 is translated) were 
expected to remain disease free but it was not known if excess p30 would 
cooperate with TRIB2 in mice transplanted with TRIB2 expressing Cebpafl/p30 
cells. Mice transplanted with MigR1 expressing Cebpa∆/p30 cells (p30 translated 
from both alleles) were expected to uniformly develop leukaemia within 9-14 
but it was not known if TRIB2 and p30 would cooperate in the absence of its 
substrate p42. 
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Figure 3. 21 – Engraftment of donor cells in recipient mice. 
(A) Graph of percentage of GFP expression in donor BM cells, tracked in vitro for 
3 days post BMT. (B) Engraftment of transplanted cells is shown as average 
percentage of CD45.2+ cells in peripheral blood at 7 weeks post BMT +/- SD, and 
(C) average percentage of CD45.2+GFP+ cells in the peripheral blood at 7 weeks 
post BMT +/- SD. 
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Figure 3. 22 – Analysis of GFP expression in CD45.2+ cells in the PB over time 
Representation of disease progression as an increase in CD45.2+GFP+ cells 
detected over time in the PB of Cebpafl/+-MigR1 and Cebpafl/+-TRIB2 mice (top 
panel), Cebpafl/p30-MigR1 and Cebpafl/p30-TRIB2 mice (middle panel), and 
Cebpa∆/p30-MigR1 and Cebpa∆/p30-TRIB2 mice (bottom panel). 
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Figure 3. 23 – Analysis of PB cells and spleen weights in control groups 
Evidence of normal hematopoiesis in Cebpafl/+-MigR1 (n=9) and Cebpafl/p30-MigR1 
(n=6) control groups is shown as (A) average WBC count +/- SD, (B) average 
spleen weights +/- SD, (C) average number (K/ul) of neutrophils (NE), 
lymphocytes (LY), monocytes (MO) and eosinophils (EO) +/- SD, (D) average 
number of platelets (PLT) and mean platelet volume (MPV) +/- SD, and (E) 
average number of RBCs, amount of hemoglobin (Hb) and percentage hematocrit 
(HCT) in the PB +/- SD.   
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Figure 3. 24 – Flow cytometric analysis of tissues from control mice 
(A) Representative flow cytometric or CD11b and Gr1 expression in BM, PB and 
spleen cells isolated from Cebpafl/+-MigR1 (n=9) and Cebpafl/p30-MigR1 (n=6) 
control mice. (B) Representative flow cytometric analysis of cKit expression on 
BM cells isolated from Cebpafl/+-MigR1 and Cebpafl/p30-MigR1 control mice. (C) 
Graph of average percentage cKit expression on BM of control mice +/- SD 
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Figure 3. 25 – Survival curve of Cebpafl/+ and Cebpafl/p30 transplanted mice 
(A) Kaplan-Meier survival curve of mice reconstituted with either Cebpafl/+ or 
Cebpafl/p30 BM cells transduced with MigR1 or TRIB2 expressing retrovirus. None 
of the mice reconstituted with Cebpafl/+-MigR1 (n=9) or Cebpafl/p30-MigR1 (n=6) 
developed leukaemia within 60 weeks. The median survival of mice 
reconstituted with Cebpafl/+-TRIB2 cells was 49 weeks (n=4), while the median 
survival of mice reconstituted with Cebpafl/p30-TRIB2 was 29 weeks (n=8). 
***P<0.0001 by Log-rank test. (B) Average spleen weights +/-SD and (C) average 
WBC +/- SD of each cohort of transplanted mice depicting normal hematopoiesis 
in the Cebpafl/+-MigR1 (n=9) or Cebpafl/p30-MigR1(n=6) groups, and leukaemia in 
the Cebpafl/+-TRIB2 (n=4), Cebpafl/p30-TRIB2 (n=8), CebpaΔ/p30-MigR1 (n=6) and 
CebpaΔ/p30-TRIB2 (n=8) groups. 
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Figure 3. 26 – Survival curve of CebpaΔ/p30 transplanted mice 
(A) Kaplan-Meier survival curve of mice reconstituted with Cebpa∆/p30 BM cells 
transduced with MigR1 or TRIB2 expressing retrovirus. The median survival of 
mice reconstituted with Cebpa∆/p30-MigR1 cells was 40 weeks (n=6), while the 
median survival of mice reconstituted with Cebpa∆/p30-TRIB2 cells was 35 weeks 
(n=8). P=0.8111 by Log-Rank test. (B) Kaplan-Meier survival curve comparing 
mice reconstituted with Cebpafl/p30-TRIB2 or Cebpa∆/p30-TRIB2 BM cells. *P≤0.05 
by Log-rank test. 
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Figure 3. 27 – Expression of cKit in BM cells of transplanted mice 
Graph of average percentage cKit expression in CD45.2+ BM cells of mice 
transplanted with Cebpafl/+-MigR1 (n=9), Cebpafl/+-TRIB2 (n=4), Cebpafl/p30-MigR1 
(n=6), Cebpafl/p30-TRIB2 (n=8), CebpaΔ/p30-MigR1 (n=6) and CebpaΔ/p30-TRIB2 (n=8) 
expressing cells +/- SD. 
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Figure 3. 28 – Western blot analysis of C/EBPα expression in BM cells from 
transplant cohorts 
CD45.2+DAPI- leukemic BM cells were sorted for by FACS and directly lysed in SDS 
buffer as described in 2.5.1.1.2. Western blot analysis was performed. ns 
denotes non-specific band, and actin serves as a loading control.  
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3.4 Discussion  
The data show that overexpression of p30 induced myeloid differentiation in vivo 
which, in a small-scale study, resulted in a weakly penetrant transplantable 
AML. It was found that TRIB2 selectively degrades p42 by K48 mediated 
proteasome dependent ubiquitination but was not able to ubiquitinate the p30 
isoform. Degradation of p42 by TRIB2 could be targeted using the proteasome 
inhibitor Bortezomib. Mutation of residue K313 abrogated this function indicating 
that this site which is frequently found mutated in AML, is required for TRIB2 
mediated C/EBPα ubiquitination. It was determined by BMT that, despite 
functioning to degrade C/EBPα, C/EBPα is essential for TRIB2 induced AML. The 
data also show that in the presence of p42, TRIB2 and p30 cooperate to 
accelerate AML induction. Together these data reveal important insights into the 
degradative relationship between TRIB2 and C/EBPα and support a dichotomous 
role for C/EBPα in the pathogenesis of TRIB2 induced AML.  
Contrary to previously published data (Schwieger et al., 2004), p30 
overexpressing BM cells engrafted in a murine BMT and provided long-term 
reconstitution of the hematopoietic system in recipient mice. It is unclear why 
the p30 overexpressing cells in the study by Schwieger et al failed to engraft. 
The authors used an FMEV based retroviral vector and showed that BM cells were 
efficiently transduced by control and mut10 retrovirus (range 32%-69%). The 
discrepancy may relate to the expression vector itself, or differences in 
experimental conditions. Overexpression of p30 resulted in an increase in the 
number of mature CD11b+Gr1+ myeloid cells observed in the GFP+ compartment 
of p30 chimeric mice. There is evidence to support a role for p30 to promote 
myeloid differentiation as it shares with p42 a transactivation domain (TAD2) 
and thus there is overlap of transcriptional targets between p42 and p30. Indeed 
the observed ability for p30 to mediate the CMP to GMP transition in the absence 
of p42 as described in section 3.1.2.2 (Kirstetter et al., 2008) would also support 
the idea that p30 overexpression can induce myeloid differentiation. However, 
other studies show that increased p30 expression decreases expression of Gcsfr 
which would inhibit maturation of myeloid cells (Cleaves et al., 2004). Unlike 
p42, p30 was also unable to induce differentiation in the IL-3 dependent cell line 
32D (Keeshan et al., 2003). The fact that p30 induced myeloproliferation of 
CD11b+Gr1+ mature cells in the short-term which transformed into a mature 
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myeloid leukaemia in the long-term, albeit weakly penetrant, suggests that 
instead of inducing myeloid cell maturation p30 overexpression may induce cell 
proliferation.  
In a recent publication, genome-wide transcriptome analysis was performed on 
K562 cells carrying Tet-inducible p42 or p30 (Hughes et al., 2015). Expression of 
urothelial carcinoma associated 1 (UCA1), a long non-coding RNA, was 
significantly upregulated in p30 expressing cells, compared with control. In 
human AML patient samples, high UCA1 expression correlated with CN-AML 
carrying CEBPA mutations and it has been shown to promote tumour cell growth 
in solid tumours. The authors demonstrated that p30 bound to and activated 
UCA1 expression. Knockdown of UCA1 in K562 cells, a myeloid leukaemia cell 
line, induced a block at the G1-S phase transition of the cell cycle by increasing 
expression of the CDK inhibitor p27kip1. Thus it is possible that p30 
overexpression in the presence of physiological levels of p42 could cause 
aberrant proliferation of mature myeloid cells via activating transcription of 
UCA1, inhibiting expression of p27kip1 and promoting proliferation. 
When the primary p30 AML cells were transplanted into a secondary recipient 
they produced a B220+ disease. There is some evidence suggesting that p30 
overexpression may affect the B cell lineage.  In the aforementioned study from 
Kato et al (3.1.2.4), the authors generated retrovirus overexpressing a C/EBPα 
N-terminal mutant (C/EBPα-Nm) which only expressed p30. BM cells 
overexpressing C/EBPα-Nm were transplanted into lethally irradiated recipient 
mice with less than half developing disease, which correlates with the weak 
penetrance observed in the p30 driven AML (1 out of 3 mice). Most of the mice 
that did develop disease were phenotypically akin to B-ALL characterised by the 
accumulation of B220+CD19+cKitint/hi leukemic cells which infiltrated the spleen 
and liver.  
Ubiquitination analysis demonstrated that TRIB2 degrades p42 by K48 mediated 
proteasomal ubiquitination. This was supported by the observation that 
leukaemic U937 cells transduced with TRIB2 were more sensitive to proteasome 
inhibition than controls. Indeed enforced C/EBPα expression was shown to 
rescue cells from Bortezomib induced cellular toxicity. The specificity of 
proteasome inhibition on the Trib2-C/EBPα axis was demonstrated with the use 
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of C/EBPα null leukaemia cell lines (K562 and Kasumi 1), where overexpression 
of TRIB2 had no effect on sensitivity to Bortezomib. The ubiquitin proteasome 
system (UPS) is a highly regulated mechanism for protein degradation and 
turnover and targeting the UPS has recently emerged as a novel therapeutic 
route in cancer treatment. Activity of the UPS has been shown to be elevated in 
AML, ALL and MDS patient samples and combination therapy incorporating drugs 
targeting the UPS system represents a novel therapeutic development for 
hematological disorders (Salome et al., 2015). Bortezomib was the first 
proteasome inhibitor used successfully in a clinical trial. In multiple myeloma it 
was shown to reversibly inhibit the 26S proteasome preventing the breakdown of 
the NFκB inhibitor IκB thus stabilising NFκB stopping it from translocating to the 
nucleus inactivating key cell signalling pathways integral to myeloma cell 
function (Field-Smith et al., 2006). It has also proven effective in treating 
mantle cell lymphoma and is being used in a clinical trial in combination with 
other chemotherapeutics (daunorubicin and cytarabine) in AML (Attar et al., 
2013). As outlined in section 1.3.4.1.1, TRIB2 is elevated in a subset of human 
AML cases with WT CEBPA and targeting the TRIB2-C/EBPα axis by proteasome 
inhibition may represent a potential therapeutic avenue in these AML cases. 
The K313KK (K313dup) mutation is found in up to 10% of AML patients and leads 
to C/EBPα instability (Carnicer et al., 2008). As described in 3.1.2.3, the C-
terminal K313dup mutation was shown to cooperate with the N-terminal 
mutation (Bereshchenko et al., 2009). The data presented show that mutation of 
K313 to K313R abrogated TRIB2 mediated C/EBPα ubiquitination while retaining 
its DNA binding, transcriptional activation and downstream differentiation 
function, suggesting that K313 is a site of TRIB2 ubiquitination on C/EBPα. In the 
study of 285 AML patient samples organised into 16 clusters based on gene 
expression analysis discussed in section 1.3.4.1.1, elevated TRIB2 expression 
(cluster 4) was shown to correlate with CD7 expression and TCR rearrangement 
(Wouters et al., 2007). It has also been shown that patients with K313dup are 
positive for CD7 and have TCR rearrangements (Carnicer et al., 2008). In light of 
these findings it is possible that the K313dup mutation may increase the 
susceptibility of C/EBPα to be ubiquitinated by TRIB2 by providing an additional 
lysine residue for ubiquitin conjugation, resulting in increased C/EBPα 
degradation. However the K313 site is present in both p42 and p30, yet TRIB2 
  150 
 
was unable to ubiquitinate p30. It is unclear why TRIB2 selectively degrades p42 
and in the absence of a crystal structure for TRIB2, one can only hypothesise 
that the TRIB2-p42 and TRIB2-p30 protein complexes are structurally different. 
It is tempting to speculate that the conformation of the TRIB2-p30 complex 
inhibits the binding of COP1 to TRIB2 which has been shown to be essential for 
p42 degradation (Keeshan et al., 2010). 
The CebpaΔ/Δ  BM transduction and transplant data show definitively that the 
presence of C/EBPα is essential for TRIB2 mediated AML induction. This 
correlates with the aforementioned studies of HOXA9/MEIS1 (Collins et al., 2014) 
and MLL rearranged leukaemia (Ohlsson et al., 2014) which as described in 
section 1.2.2.2.1, also demonstrate the necessity for C/EBPα in leukaemia 
initiation. A recent publication has suggested that it is not C/EBPα, but rather 
granulocytic differentiation which is required for leukaemogenesis (Ye et al., 
2015). The authors demonstrated that in a Cebpa null background MLL-AF9 and 
MOZ-TIF2 were unable to initiate leukaemia, but pharmacological induction of 
granulopoiesis by GM-CSF administration returned the leukaemogenic potential 
of these oncogenes in the absence of Cebpa expression. Under normal 
physiological conditions the protein levels of p42 are greater than p30 protein 
levels, and when this balance changes toward higher p30 expression it is 
considered leukemic, as observed in leukaemia cell lines and AML patients 
(Leroy et al., 2005). The use of the Cebpafl/p30 model, which carries one WT 
allele and one p30 only allele, with TRIB2 overexpression, demonstrated that 
expression of the p42 isoform from one Cebpa allele was necessary and 
sufficient for TRIB2 to cooperate with p30 in AML. In the absence of p42, 
CebpaΔ/p30, the addition of TRIB2 did not further accelerate AML induced by p30 
itself, unlike the accelerated AML observed when p42 is present. It is possible 
that the cooperation observed in the presence of p42 is the result of TRIB2 
converting p42 to p30 but the mechanism by which TRIB2 increases p30 
expression remains to be elucidated. In light of the recent publication from Ye 
et al, it is also possible that the presence of p42 in the Cebpafl/p30 model 
influenced the latency of TRIB2 mediated AML through more efficient induction 
of granulocytic differentiation from the CMP to the GMP than p30 could provide 
alone.  
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Collectively these data show that TRIB2 mediated AML relies on the expression 
of C/EBPα. It degrades p42 through K48-specific ubiquitination at K313. While 
the mechanism by which TRIB2 overexpression upregulates p30 in AML induction 
is unknown, we show that unlike p42, TRIB2 is unable to ubiquitinate p30. 
Overexpression of p30 in the presence of physiological levels of p42 resulted in 
enhanced proliferation of mature myeloid cells with weak transformation ability. 
Using a conditional murine model TRIB2 was shown to cooperate with p30 in 
leukaemogenesis only in the presence of p42. These data highlight the molecular 
interplay between TRIB2 and C/EBPα in AML pathogenesis and present a novel 
therapeutic window for the use of proteasome inhibition in a subset of AML with 
high TRIB2 expression.  
Some of the data presented here have been published in O’Connor et al, 2016, 
details provided in section 0. 
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4 Results: Identifying the TRIB2 
leukaemia initiating cell 
Part of this chapter has been published in Liang et al, Cell Discovery, 2016, 
details provided in section 0. 
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4.1 Introduction 
As described in 1.1, the entire hematopoietic system is generated by a small 
pool of long-lived HSCs. Like all stem cells in the body, HSCs are characterised 
by both their ability to self-renew, and to give rise to more differentiated cells. 
While AML cells within a given disease often appear to be morphologically 
homogeneous, there is now a large body of evidence showing that leukemic cells 
comprise a heterogeneous population and these cells also contain a small 
number of leukaemia stem cells (LSCs) responsible for generating and 
maintaining the disease. 
4.1.1 Modelling tumour development  
There are 2 mutually exclusive models describing the way in which tumours 
develop - namely the stochastic model and the hierarchy or cancer stem cell 
(CSC) model (Figure 4. 1). 
4.1.1.1 The stochastic model 
The stochastic model of tumour development assumes that within a given 
tumour all cells have the potential to initiate tumours, but that each cells’ 
behaviour is affected randomly by intrinsic (e.g. levels of transcription factors) 
or extrinsic (e.g. microenvironment) influences. Central to this model is the idea 
that all tumour cells have the potential to be affected by these factors, and the 
effects are reversible. This has been expanded to include clonal evolution 
whereby new mutations accumulating within given cells will result in clonal 
diversity, further increasing the heterogeneity observed within tumours. Indeed 
some cancer types do appear to adhere to this model. It has been shown in 
melanoma that up to 50% of cells within a tumour are capable of forming 
secondary tumours in xenograft transplants (Quintana et al., 2010). The authors 
also tested 16 markers that were heterogeneously expressed on melanoma 
tumour cells including CD44 and cKit, as putative markers of tumour initiating 
cells, but expression or exclusion of any one marker failed to affect the tumour 
initiating activity of that cell. Furthermore the tumours that arose from each 
marker-defined fraction produced secondary tumours that were phenotypically 
similar to the parent tumour, regardless of the phenotype of the transplanted 
starting cells. These experiments show that melanoma tumours are not arranged 
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hierarchically, and contain a high number of tumorigenic cells that can initiate a 
disease in a secondary recipient which is phenotypically similar to the parent 
disease. 
 
Figure 4. 1– Schematic diagram of the stochastic and cancer stem cell models of tumour 
development 
4.1.1.2 The cancer stem cell model 
The cancer stem cell or hierarchy model proposes that CSCs exist which share 
characteristics of normal HSCs in their ability to self-renew and to differentiate 
into more mature progeny. The concept centres on a hierarchical tumour 
arrangement which mimics normal development, with only a biologically distinct 
subset of CSCs responsible for disease initiation and propagation. Therefore in 
order to therapeutically eradicate a disease, the CSCs must be targeted. The 
first CSCs were identified in AML, following the development of the xenograft 
transplant model. In 1995 the non-obese diabetic/severe combined immune-
deficient (NOD/SCID) mouse model was produced, by crossing the Nod mouse 
which has impaired NK and antigen-presenting cell function, with the Scid mouse 
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which lacks T and B cell function (Shultz et al., 1995). This permitted the 
transplantation of purified populations of cells from human AML samples into the 
immunocompromised mice, to determine if the cells were able to generate 
disease in vivo. In seminal work performed by John Dick and colleagues, human 
AML samples from a variety of FAB subtypes with different bulk populations of 
blast cells were fractionated based on their CD34 and CD38 expression. CD34 is a 
cell surface marker present on human stem and progenitor populations, while 
CD38 is expressed on more committed progenitor cells (Figure 4. 2). CD34+CD38- 
cells are therefore the most primitive type of leukemic cell. Only these cells, 
comprising a mere 0.2% of the bulk AML population, were able to generate 
disease when transplanted into NOD/SCID mice (Bonnet and Dick, 1997, Lapidot 
et al., 1994). As few as 5000 cells were able to initiate leukaemia in the 
recipient mice. However even with 100 times as many cells transplanted, neither 
CD34+CD38+ nor CD34- leukemic cells could generate leukaemia in vivo. 
Furthermore in addition to proliferating and differentiating in primary 
transplants, the CD34+CD38- leukemic cells were also able to re-establish AML in 
secondary transplants demonstrating self-renewal ability.  
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Figure 4. 2 – Schematic representation of CD34 and CD38 expression on human stem and 
progenitor cells 
 
Following these discoveries the NOD/SCID mouse model has been used to 
identify CSCs in solid tumour cancers. Using a modified NOD/SCID model where 
breast cancer tumours were generated in the recipients’ mammary fat pad, only 
Lin-CD44+CD24-/low breast tumour cells were able to generate tumours in vivo  
(Al-Hajj et al., 2003). CSCs have been identified based on their surface maker 
expression in a variety of other tumour models, including CD133+ CSCs in colon 
(O'Brien et al., 2007), brain (Singh et al., 2004) and lung cancer (Eramo et al., 
2008). These studies demonstrate that many forms of cancer, including AML, 
adopt the cancer stem cell model, with heterogeneous tumours containing a 
small population of CSCs that have the ability to induce and maintain tumour 
growth in vivo, as well as produce non CSCs, supporting a hierarchical 
arrangement of cells within the tumour. 
4.1.2 Leukaemia stem cell heterogeneity and plasticity 
The idea that LSCs are exclusively restricted to the CD34+CD38- compartment has 
been challenged with the development of new xenograft models. There are 
several limitations to using NOD/SCID mice to study the LSC in AML. NOD/SCID 
mice have a short lifespan and are prone to the spontaneous development of 
thymic lymphomas (Shultz et al., 1995). In addition there is a relatively low 
  157 
 
frequency of engraftment of primary human AML cells in NOD/SCID mice ranging 
from between 0.1% to 10% detection in BM of transplanted mice (Ailles et al., 
1999). To overcome these issues the NOD/SCID/IL2Rγnull (NSG) mouse was 
generated which has a deletion in the γ-common chain, eliminating residual NK 
cell activity (Shultz et al., 2005). These mice are not prone to spontaneous 
thymic lymphomas, they have a longer lifespan and they engraft human cells 
better than NOD/SCID mice.  
NSG mice have been used to extend our understanding of the AML LSC. In one 
study, CD34 expression in 19 AML samples from different subtypes with different 
karyotypes was shown to be highly variable among samples, with 32% lacking 
CD34 expression, yet all samples were able to engraft (range 10.4%-43.0%) in 
NSG recipient mice (Sarry et al., 2011). This suggested that the earlier 
characterisation of AML LSCs as CD34+CD38- in NOD/SCID transplants may have 
been too restrictive. The authors also assessed the ability for the Lin- and Lindim 
fractions of leukemic cells to initiate leukaemia in vivo, and surprisingly cells 
from both fractions could generate disease. Indeed most intriguing was the 
observation that the LSCs displayed a certain amount of plasticity. As expected, 
when primitive Lin-CD38- leukemic cells were transplanted they produced Lin-
CD38- and Lin-CD38+ cells in vivo as well as Lin+ cells. However when the more 
mature committed LindimCD38+ cells were transplanted, they too produced both 
LindimCD38+ and the immature Lin-CD38- cells. The authors also showed that LSCs 
were indeed enriched in the Lin-CD38- cell fraction (1 in 3.8x104), yet also 
present with the lowest frequency in the LindimCD38+ fraction (1 in 1.0x106).  
LSC heterogeneity and plasticity has been demonstrated many times with 
different models. Using the HOXA9/MEIS1 mouse model, leukemic cells were 
fractionated into 4 subpopulations – Lin-cKit+, Lym+cKit+ (where Lym represents a 
cocktail of lymphoid markers including B220, CD19, CD3ε, CD4, CD8a, and TCR-
β), Gr1+cKit+ and Gr1+cKitlo cells. Each population was assessed for their ability 
to initiate disease by limiting dilution transplant and the authors showed that all 
populations were able to initiate AML in vivo (Gibbs et al., 2012). However the 
frequency with which they initiated disease varied substantially. As few as 100 
Lin-cKit+ and Lym+cKit+ initiated a secondary disease, while 1000 Gr1+cKit+ and 
10,000 Gr1+cKitlo were required in order to generate AML in the secondary 
recipient. As with the aforementioned study, the secondary diseases represented 
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the parent disease fully regardless of the transplanted cell phenotype, meaning 
that even the more mature Gr1+cKitlo transplanted cells were able to produce 
cells of a less differentiated phenotype in vivo.  
Thus while LSCs are certainly far more commonly found in the most immature 
sub-fraction of leukemic cells, they can also be detected in mature subsets 
which are equally capable of recapitulating the heterogeneity of the parent 
disease. 
4.1.3 The leukaemia initiating cell 
The LSC is a cell which is capable of initiating and propagating leukaemia in 
vivo. As described in 4.1.2, cellular heterogeneity exists within the LSC fraction, 
and LSCs also exhibit plasticity. Thus characterising the LSC population does not 
identify the original cell that gave rise to the leukaemia. The cell of origin or LIC 
refers to the cell from which a specific leukaemia normally arises, and it is 
hypothesised that the LIC may influence the progression or phenotype of a 
disease, as well as its response to therapy. It is unclear whether the LIC is a HSC 
or a more committed progenitor cell, and it is likely dependent on the 
transforming event. In general terms the HSC is the most obvious candidate for 
the LIC of a given disease considering their shared self-renewal characteristics. 
Indeed gene expression analysis has revealed many shared pathways between 
HSCs and LSCs. In a 2011 study, 4 subpopulations were sorted from 16 human 
AML samples based on CD34 and CD38 expression, and each fraction was tested 
for LSC enrichment using a xenograft transplant assay (Eppert et al., 2011). As 
expected, LSCs were identified primarily in the CD34+CD38- fraction, but also in 
the CD34+CD38+ fraction. Global gene expression analysis was performed on each 
fraction and compared with HSC, progenitor cell and differentiated cell samples. 
The HSC gene signature was enriched in LSCs. The LSCs were also compared with 
previously generated data sets from stem, progenitor and mature cell 
populations, and here too LSC gene expression correlated positively with that of 
primitive cells, and negatively with mature populations.  However, considering 
the heterogeneity and plasticity of the LSC compartment committed progenitor 
cells may also represent the LIC.  
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Several studies have explored the LIC of specific oncogenes mostly using either a 
methylcellulose-based serial replating assay and/or a retroviral-mediated murine 
BMT, and these studies are outlined below and summarised in Table 4-1. The use 
of the serial replating assay for investigating oncogenicity became popular 
following a publication by Lavau et al in 1997. To determine if the fusion protein 
HRX-ENL would affect self-renewal and differentiation, Lin- BM cells transduced 
with the oncogene or control MSCV retrovirus and serially replated in 
methylcellulose medium supplemented with IL-3, IL-6, GM-CSF and SCF (Lavau et 
al., 1997). The authors observed that unlike the primary colonies which were 
similar for both control and HRX-ENL transduced BM and of a mature myeloid 
phenotype, the secondary colonies differed greatly. Control cells produced very 
small and diffuse colonies indicating limited self-renewal and proliferative 
capacity, whereas secondary colonies from HRX-ENL expressing cells were much 
larger and of 3 distinct phenotypes. Type I colonies contained immature myeloid 
precursor cells and were compact in size, Type II colonies contained more 
mature cells and had a compact centre surrounded by a diffuse halo of cells, 
while type III colonies were the most differentiated and comprised dispersed 
cells with no core. By the third replating control cells had exhausted their 
proliferative potential and were unable to generate colonies, whereas the HRX-
ENL expressing cells showed enhanced potential, with further increases observed 
at the fourth replating. This model is now frequently used to determine if an 
oncogene confers self-renewal and proliferative potential to BM stem and 
progenitor cells in vitro. 
4.1.3.1 MLL rearranged AML 
4.1.3.1.1 MLL-ENL 
As described in section 1.2.2.2.3, translocations resulting in MLL fusion proteins 
are commonly found in myeloid and lymphoid leukaemia. Over-expression of 
certain MLL fusion proteins, including MLL-ENL, induces AML in vitro (Lavau et 
al., 2000). The MLL-ENL translocation was assessed for its ability to transform 
different progenitor compartments (Cozzio et al., 2003). MLL-ENL transduced 
HSC, CMP and GMP cells produced identical compact colonies in an in vitro serial 
replating assay with a blast-like morphology, while the control transduced cells 
produced a range of colony types from undifferentiated to differentiated. MEPs 
transduced with MLL-ENL were not able to serially replate, or grow in culture. 
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HSC, CMP and GMP cells transduced with MLL-ENL retrovirus were transplanted 
into lethally irradiated recipients and all mice developed AML with the same 
latency (90-100 days). Titration of the injected number of MLL-ENL expressing 
cells revealed that HSCs were more efficient than CMPs, and CMPs more efficient 
than GMPs at inducing AML in vivo. 
4.1.3.1.2 MLL-GAS7 
In a similar study the fusion protein MLL-GAS7 was assessed. 5-FU treated BM 
transduced with control or MLL-GAS7 retrovirus serially replated in a CFU assay 
producing cells with a cKit+Sca1+ phenotype with low levels of B220 and CD11b 
expression but no other lineage markers, typical of an MPP (So et al., 2003). 
These cells generated 3 types of leukaemia upon transplantation: a 
cKit+CD11b+Gr1+B220-CD19- AML, a cKit+CD43+B220+BP-1+CD19+CD11b-Gr1- ALL and 
a cKit+CD11b+B220+CD19-Gr1- acute biphenotypic leukaemia (ABL). Purified HSCs, 
CLPs, CMPs, GMPs and MEPs were then transduced with MLL-GAS7 and serially 
replated in methylcellulose medium supplemented with myeloid or lymphoid 
cytokines. HSC, CMP and GMP transduced cells formed third round colonies 
under myeloid conditions producing primarily ckit+Gr1+CD11b+ cells, but unlike 
CMP and GMP transduced cells, the HSCs also had a small proportion of 
CD11b+B220+ bi-phenotypic cells. Only MLL-GAS7 transduced HSCs replated in 
lymphoid conditions producing 3 distinct subpopulations expressing either 
CD11b, B220 and CD19, or CD11b and B220. The HSC was the only subpopulation 
susceptible to multi-lineage transformation by MLL-GAS7 overexpression, giving 
rise to the MPP-like LSC. 
4.1.3.1.3 MLL-AF9 
In another study LSKs, HSCs and GMPs were transduced with the MLL fusion 
oncogene MLL-AF9 (Krivtsov et al., 2013). In a CFU assay single MigR1 transduced 
cells exhausted after 1-3 replatings, while MLL-AF9 transduced cells continuously 
formed colonies. However when transplanted, the transformed LSK induced AML 
with a shorter latency and much higher penetrance than the GMP. A limiting 
dilution experiment from MLL-AF9 transformed HSC and GMP single cell clones 
determined a much higher LIC frequency in the HSC (1 in 29388) compared to 
the GMP (1 in 168,427). Indeed the authors demonstrated that these 2 LICs also 
exhibit differences in gene expression. Leukemic GMPs isolated from an MLL-AF9 
leukaemia originating from the HSC (LGMPHSC) or GMP (LGMPGMP) were analysed 
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for expression of Evi1. It had been previously documented that MLL-AF9 
overexpression maintains Evi1 expression in the HSC, but does not activate Evi1 
expression in committed myeloid progenitor cells. The authors found that Evi1 
expression levels were 200-fold higher in the LGMPHSC than the LGMPGMP. Thus 
while both the LGMPHSC and LGMPGMP outwardly exhibit the characteristics of a 
GMP cell, there are significant differences in gene expression. Indeed the 
authors also showed that HSC-derived MLL-AF9 AML was less responsive to 
standard chemotherapeutics than GMP-derived AML. 
4.1.3.2 AML fusion proteins from other common chromosomal 
rearrangements 
4.1.3.2.1 MOZ-TIF2 and BCR-ABL 
MOZ-TIF2 is a fusion oncoprotein generated by inv(8) and is associated with M4/5 
AML by FAB classification, while BCR-ABL is a fusion gene caused by a t(9;22) and 
is found in most patients with CML, and some ALL and AML patients. In a 
comparative study of the ability of the MOZ-TIF2 and BCR-ABL oncogenes to 
transform stem and progenitor cells, MOZ-TIF2 was shown to be able to 
transform the HSC, CMP and GMP populations in vitro with the transduced cells 
exhibiting serial replating ability, whereas BCR-ABL could only transform the HSC 
(Huntly et al., 2004). Subsequently CMP, GMP or whole BM mononuclear cells 
(MNC) were transduced with either MOZ-TIF2 or BCR-ABL and transplanted into 
recipient mice. All mice receiving MOZ-TIF2 transduced cells developed AML 
with comparable latencies (113-240 days) and a virtually identical disease 
phenotype, while only the BCR-ABL transduced BM MNCs generated disease in 
vivo. The authors hypothesise that the differences observed may be in part due 
to the oncogenes themselves whereby BCR-ABL can provide the self-renewal 
signals to cells but fails to impair differentiation unlike MOZ-TIF2, which would 
lead to an expansion of mature myeloid cells, insufficient to generate leukaemia 
in mice.  
4.1.3.2.2 CALM/AF10 
The CALM/AF10 fusion protein is formed from a reciprocal translocation between 
chromosomes 10 and 11. The translocation is primarily associated with T-ALL but 
has also been observed in many myeloid leukaemias (Salmon-Nguyen et al., 
2000) and CALM/AF10 transduced stem and progenitor cells induce AML in mice 
(Deshpande et al., 2006). The phenotype of the disease showed that most cells 
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expressed CD11b and Gr1 but not B220 (B220-/MM+), but an additional 2 
populations of cells existed which were either CD11b+ or Gr1+ with B220 
expression (B220+/MM+) or were B220+ but lacked myeloid markers (B220+/MM-). 
All 3 populations displayed DJ rearrangements suggesting that the leukaemia 
originated from a DJ rearranged cell. Transcriptionally the B220+/CD11b- cells 
displayed significant upregulation of cell cycle, translation and DNA repair and 
replication genes, compared with B220-/CD11b+ where genes involved in cell 
death and communication were increased. A limiting dilution assay revealed, as 
expected, a very high frequency of leukaemia cell propagation from the 
B220+/CD11b- cells (1 in 36), compared with an extremely low frequency for the 
B220-/MM+ cells (1 in 19,717). Further characterisation of the CALM/AF10 LIC 
revealed a B220+CD43+AA4.1+CD24+CD11b-Gr1-Sca1- phenotype. Here, unlike with 
MLL-GAS7 which transforms a HSC and directs a multi-lineage leukaemia, the 
CALM/AF10 LIC is a progenitor cell with lymphoid characteristics which can 
generate a myeloid leukaemia in vivo.   
4.1.3.2.3 DEK/CAN 
In AML t(6;9) is characterised by the formation of the DEK/CAN fusion protein 
and is associated with early clinical onset and poor prognosis. DEK/CAN 
overexpression in Lin-Sca1+ BM cells had no effect on the replating efficiency of 
the cells when compared to controls with both unable to form colonies beyond 
the third replating (Oancea et al., 2010). However it did result in a higher 
number of colonies produced. To determine the effect of DEK/CAN on the 
potential of early progenitors/ST-HSCs the authors used a CFU-S12 assay where 
the DEK/CAN expressing cells from the first plating were injected into lethally 
irradiated recipient mice whose spleens were then analysed after 12 days for the 
number of splenic colonies present. DEK/CAN significantly increased the ability 
of the cells to generate splenic colonies in vivo. In a transplantation experiment 
the authors then demonstrate that DEK/CEN overexpressing long term (Lin-
Sca1+cKit+Flk2-) but not short term (Lin-Sca1+cKit+Flk2+) HSCs were able to 
generate leukaemia in vivo. This study demonstrates that the DEK/CAN LIC 
resides within the HSC compartment, but is restricted to the LT-HSC. 
4.1.3.2.4 PML-RARα 
As discussed in section 1.2.2.2.5, APL is characterised by a chromosomal 
translocation on chromosome 15 which results in the fusion of RARα and PML 
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genes. To study the APL LIC, human PMLRARA was expressed in transgenic mice. 
This induced a high level of mortality caused by the development of cutaneous 
tumours, thus leukaemic spleen cells were harvested and transplanted into 
sublethally irradiated recipient mice, to generate in vivo APL (Guibal et al., 
2009). From these mice LSKs, cKit-CD34+CD16/32+Gr1high, 
cKit+CD34+CD16/32+Gr1int cells were sorted and transplanted into sublethally 
irradiated tertiary recipients. Neither LSKs nor CD34-CD16/32+Gr1high leukaemic 
cells were able to initiate APL in vivo. However cKit+CD34+CD16/32+Gr1int 
transplanted mice all developed APL with a very short latency (median survival 
of 34.5 days). A limiting dilution transplant demonstrated that the 
cKit+CD34+CD16/32+Gr1int cells induced a dose-dependent leukaemia with as few 
as 30 cells being able to initiate disease, albeit it with a much longer latency 
(120 days). These data suggest that unlike the aforementioned models of AML, 
the APL LIC may reside in a more mature cell population. 
4.1.3.2.5 NUP98/HOXA9 
The NUP98/HOXA9 fusion protein forms as the result of a relatively rare t(7;11) 
translocation found most often in AML patients. NUP98-HOXA9 was able to 
confer serial replating ability in a CFU assay to transduced CMPs, GMPs and MEPs 
(Kvinlaug et al., 2011). NUP98-HOXA9 transformed CMP, GMP and MEPs were also 
able to generate AML in vivo when transplanted into recipient mice. The same 
study also evaluated AML1-ETO and FLT3-ITD (see section 1.2.2.2.6). 
Overexpression of FLT3-ITD was unable to induce replating ability in CMPs, GMPs 
or MEPs. AML1-ETO transduced CMPs and GMPs but not MEPs continuously 
replated, however, neither FLT3-ITD nor AML1-ETO transduced CMP, GMP or 
MEPs could initiate AML in vivo.  
4.1.3.2.6 MN1 
While MN1 is a frequent fusion partner with the transcription factor TEL in AML 
or MDS patients with t(12;22), alone its overexpression also induces AML in vivo. 
In an investigation of the MN1 LIC, single HSCs, CMPs, GMPs, MEPs and 
granulocytes were sorted and transduced with MN1. The authors showed that 
only the CMP was susceptible to transformation by MN1 with MN1 expressing CMP 
clones able to serially replate to P5 (Heuser et al., 2011). Transplanted MN1 
transduced CMP clones were also able to drive an aggressive leukaemia with an 
immature immunophenotype, which included some B220 expression. Gene 
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expression analysis revealed that healthy CMP cells when compared with bulk 
MN1 leukemic cells shared a large degree of overlap including Meis1 and Flt3 
expression. The authors theorised that it was the gene expression signature of 
the CMP which lent itself to MN1 transformation. This study demonstrates that 
CMPs are the MN1 LIC and their susceptibility to MN1 transformation is due in 
part to the gene expression profile of these cells. 
4.1.3.3 C/EBPα 
Conditional mouse models have been generated to mimic CEBPA mutations, as 
discussed in section 3.1.2. L/L mice are homozygous for the p30 allele and these 
mice develop AML with a 9-14 month latency (Kirstetter et al., 2008). The 
authors identified 3 age-dependent BM phenotypes in the L/L mice. Mice less 
than 2 months old had very few BM neutrophils, with normal cKit levels (L/L-1). 
This progressed to an intermediate stage with high levels of CD11b+Gr1+ mature 
granulocytes (L/L-2) which uniformly transitioned into granulocytic 
transformation with a block in differentiation and an accumulation of 
myeloblasts, as well as an increase in cKit+ cells by 6 months (L/L-3). C/EBPα is 
essential for the CMP to GMP transition in granulocytic transformation so the 
authors then showed that GMPs were still formed in L/L-1 mice indicating that 
p30 alone can mediate this transition. In a CFU assay comparing cells from L/L 
and L/+ mice, L/+ GMPs had a mild increase in replating capacity over +/+ GMPs, 
but L/L GMPs had a large increase in replating ability. The LSKs had comparable 
replating efficiencies until the fourth plating, but subsequently adopted the 
same plating efficiencies as the GMP cells. The MEPs did not serially replate 
from any of the genotypes. Indeed sorted CD11b+ BM cells from L/L-3 mice 
containing few if any LSK cells were able to initiate an aggressive AML in 
secondary recipients. These data support the idea that the self-renewal capacity 
of the cells occurs once the immature stem cells reach a committed myeloid 
progenitor stage.  
In a subsequent study, a knock-in allele was generated to introduce one of the 
most common C-terminal mutations – the K313dup (K allele) – into mice 
(Bereshchenko et al., 2009). Heterozygous K/+ mice were crossed with L/+ mice 
to produce KL mice. Cells from KL mice were able to generate AML in secondary 
recipients. To determine the KL LIC, three cell fractions were isolated from the 
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leukemic mice - a HSC-containing fraction I (Sca-1+), a myeloid progenitor 
fraction II (Sca-1-CD11blo/+cKit+) and a mature leukemic cell fraction III (Sca-1-
CD11bhicKitlo/-), and were transplanted into recipient mice. Only fraction II 
(containing myeloid progenitors) drove AML in the secondary recipients. CEBPA 
mutations frequently occur with FLT3-ITD mutations. Mutating a single Cebpa 
allele in cooperation with Flt3-ITD was shown to be insufficient to initiate 
leukaemia in vivo, however the combination of biallelic Cebpa mutations with 
Flt3-ITD (KLI) resulted in a significant shortening of the KL disease latency (33.8 
wks to 22.5 wks) (Reckzeh et al., 2012). KLI whole BM, GMPs and MPPs all 
induced AML in recipient mice, while KLI LT-HSCs did not generate disease in 
vivo. As expected only the KL whole BM and GMPs induced AML when 
transplanted. These findings support both the hierarchical ordering of leukemic 
cells, and similar studies which suggest that the LIC is a more committed 
progenitor cell which acquires self-renewal ability.  
Together these data demonstrate that the LIC can affect the disease latency, 
biology and thus therapeutic response of a given leukaemia. Indeed the LIC 
varies considerably depending on the nature of the transforming event and so it 
is necessary to examine oncogenes individually to determine their cell of origin.   
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Table 4-1 – List of LIC studies 
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4.2 Aims and Objectives 
It was hypothesized that TRIB2 functionally targets C/EBPα in normal and 
malignant hematopoiesis. TRIB2, expressed in 5FU enriched BM cells, was shown 
to induce AML in a murine transplant model dependent on C/EBPα degradation. 
The role of TRIB2 in normal hematopoiesis and specifically myelopoiesis is not 
known, nor has the TRIB2 LIC been identified. Cebpα is differentially expressed 
in stem and myeloid progenitor cells (Hasemann et al., 2014), being present at 
low levels in the HSC, and increasing expression during granulocytic maturation 
where its expression is highest at the GMP stage, and completely absent from 
the MEP. Thus it was hypothesised that the levels of C/EBPα protein available 
for degradation in stem and progenitor populations may affect the ability of 
TRIB2 to initiate AML, or may affect the latency or phenotype of the resultant 
disease. As such the specific aims of this chapter were:  
i. To identify the Trib2 LIC using  
a. an in vitro methylcellulose serial replating assay technique and 
b. an in vivo transplantation approach 
ii. To determine if loss of Trib2 affects steady state hematopoiesis by 
a. analysing the hematopoietic compartment of the Trib2-/- mouse 
and 
b. assessing the effect of Trib2 loss on in vitro myeloid differentiation 
  
  168 
 
4.3 Results 
4.3.1 Trib2 can transform all cell populations in vitro  
To investigate the ability of the oncogene Trib2 to transform HSCs, MPPs, CMPs, 
GMPs and MEPs, an in vitro approach was first utilised. FACS sorted stem and 
progenitor cells transduced with a lentiviral vector encoding Trib2, were seeded 
in methocult supplemented with cytokines that induce myeloid differentiation. 
Following P1, GFP+ cells were sorted and serially replated. If the cells still 
formed colonies by the third replating this implied acquisition of self-renewal 
ability and increased proliferation. The cells were serially replated to the P5, 
and colonies and cells were analysed from P3 to P5 (Figure 4. 3). All TRIB2 
transduced populations were still efficiently producing colonies at P3, and these 
cells still formed colonies by P5, however different efficiencies between groups 
were observed (Figure 4. 4A). By P5, CMP derived cells were producing very few 
colonies that were very small in size (Figure 4. 4B). TRIB2 transformed GMP 
derived cells also produced smaller sized colonies, while MPP derived cells 
produced the largest sized colonies. Colonies were also categorised based on 
their morphology as described by Lavau et al outlined in 4.1.3. Immature Type I 
colonies were well represented on transformed HSC, MPP, GMP and MEP plates, 
comprising 25-50% of colonies by P3 but much fewer on CMP plates (Figure 4. 5). 
The intermediate Type II colonies were rarely observed in TRIB2 transformed 
CMP or GMPs, being most prominent on transformed MPP plates, as well as HSC 
and MEP plates (Figure 4. 5). Interestingly, while type III mature colonies were 
present on all plates, they were predominantly on CMP and GMP plates with CMP 
plates being primarily composed of type III colonies. Cytospins of the cells 
demonstrated that TRIB2 transformed HSC, MPP, GMP and MEP derived colonies 
contained many undifferentiated cells with a high nucleus/cytoplasm ratio, 
while CMP derived colonies contained very few undifferentiated cells, with 
almost all cells showing evidence of granulocytic or monocytic differentiation 
(Figure 4. 6).  
It was next determined if the differences in colony size and shape, and cellular 
morphology correlated with cell surface marker changes. Flow cytometric 
analysis of P3 cells revealed that cells from HSC, MPP, GMP and MEP derived 
colonies had very similar expression levels of CD11b and Gr1 (Figure 4. 7A and 
  169 
 
B), while CMP derived cells demonstrated higher levels of Gr1 and virtually no 
CD11b expression. The cell surface expression of CD11b and Gr1 changed in 
some populations between P3 and P5. CD11b and Gr1 expression increased 
slightly in HSC and MPP derived cells (Figure 4. 7A and B). There was high cKit 
expression in almost all populations at each plating, although less than 50% of 
MPP derived cells expressed cKit by P5 (Figure 4. 8). Analysis of CD11b and Gr1 
expression was performed through the cKit+ and cKit- gates revealing no CD11b 
expression and low Gr1 expression on cKit+ cells, while as expected the cKit- 
cells expressed mature myeloid markers (Figure 4. 9). By P5, only the MPP 
derived cells retained a significant cKit- population (>50%), and these cells had 
high CD11b expression and some CD11b+Gr1+ cells (Figure 4. 10). Moreover by P5 
the CMP derived cells had acquired significant Gr1 expression with over 65% of 
cells cKit+Gr1+CD11b-. The high levels of cKit expression observed in HSC, CMP, 
GMP and MEP derived TRIB2 transduced cells correlates well with published data 
showing TRIB2-induced AML are cKit+ (Keeshan et al., 2006).  
Together these data show that Trib2 can transform stem and progenitor 
populations in vitro with different efficiencies, and the resultant transformed 
colony and cell type differs depending on the cell of origin. The data shows that 
Trib2 has conferred both self-renewal ability and a differentiation block to HSCs, 
GMPs and MEPs. While TRIB2 transduced MPPs also displayed self-renewal ability, 
by P5 there was a large population of cKit- cells still present which express the 
myeloid differentiation markers CD11b and Gr1. These data indicate that the 
Trib2 LIC resides in either the HSC or GMP or MEP as only these populations 
display pre-leukemic characteristics in vitro. 
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Figure 4. 3 - Schematic overview of CFU experiment used to identify the 
leukaemia initiating cell  
Murine BM cells were isolated and sorted for HSC (Lin-cKit+Sca1+CD150+CD48-), 
MPP (Lin-cKit+Sca1+CD150-CD48-), CMP (Lin-cKit+Sca1-CD34+CD16/32lo), GMP (Lin-
cKit+Sca1-CD34+CD16/32hi) and MEP (Lin-cKit+Sca1-CD34-CD16/32-) populations. 
Following transduction the TRIB2 expressing cells were plated in M3434 
methylcellulose media 24hrs later. After 7 days (P1) colonies had formed, cells 
were then removed and sorted for GFP expression before replating in M3434. 
GFP+ cells were serially replated to P5 and colonies and cells were analysed at 
P3, P4 and P5.  
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Figure 4. 4 – TRIB2 transforms stem and progenitor populations in vitro with 
different efficiencies 
(A) Average number of colonies at each replating normalised to GFP expression. 
Averages are of 2 independent experiments each with 3 technical replicates 
shown +/- SD. (B) Average number of cells produced at each replating. Averages 
are of pooled triplicate plates from 2 independent experiments +/- SD. 
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Figure 4. 5 - Colony size and type differs between TRIB2 transformed stem and 
progenitor groups 
(A) Representative images of colony types under 4x magnification. (B) 
Representative images of groups of colonies taken at P3 under 2x magnification 
(C) Distribution of colony types at P5. Bars represent the average of 2 
independent experiments each with 3 technical replicates +/- SD. 
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Figure 4. 6 – Cellular morphology of TRIB2 transformed stem and progenitor cells 
Cells from P3 colonies were spun onto glass slides using a cytocentrifuge and 
stained with the KwikDiff staining system. Representative images are shown, 
taken under 20X (top panel) and 40X (bottom panels) magnification.  
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Figure 4. 7 – Comparison of CD11b and Gr1 expression in transformed stem and 
progenitor cells from P3, 4 and P5 
Cells from each replating were stained for CD11b and Gr1 and analysed by flow 
cytometry. (A) Representative flow cytometric analysis of GFP+ TRIB2 
transformed stem and progenitor cells from P3 and P5. (B) Graphs represent the 
average percentage expression of CD11b (left) and Gr1 (right) of GFP+ TRIB2 
transformed stem and progenitor cells from P3, P4 and P5. Data represents the 
average of 2 independent experiments +/- SD. 
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Figure 4. 8 – Comparison of cKit expression in transformed stem and progenitor 
cells from P3, 4 and P5 
Cells from each replating were stained for cKit expression and analysed by flow 
cytometry. (A) Representative flow cytometric analysis of GFP+ TRIB2 
transformed stem and progenitor cells from P3 and P5. (B) Graphs represent the 
average percentage expression of cKit on GFP+ TRIB2 transformed stem and 
progenitor cells from P3, P4 and P5. Data represents the average of 2 
independent experiments +/- SD. 
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Figure 4. 9 - Differential expression of mature myeloid markers in cKit+ and cKit- 
populations of transformed stem and progenitor cells at P3 
Representative flow cytometric analysis of TRIB2 transformed P3 stem and 
progenitor populations showing cKit histograms (left) and CD11b and Gr1 
expression through the cKit+ (right) and cKit- gate (middle).  Data is 
representative of 2 independent experiments. 
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Figure 4. 10- Differential expression of mature myeloid markers in cKit+ and 
cKit- populations of transformed stem and progenitor cells at P5 
Representative flow cytometric analysis of TRIB2 transformed P5 stem and 
progenitor populations showing cKit histograms (left) and CD11b and Gr1 
expression through the cKit+ (right) and cKit- gate (middle).  Data is 
representative of 2 independent experiments. 
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4.3.2 Trib2 generates leukaemia in vivo with different latencies 
from the HSC and GMP, but not the MPP or CMP 
The results from the serial replating assay indicated that Trib2 conferred 
replating and self-renewal capacity to the HSC, MPP, CMP, GMP and MEP 
populations. Despite this, TRIB2 was unable to efficiently block differentiation in 
the MPP and to fully transform the CMP derived cells. In order to resolve these 
observations and to elucidate the leukaemia initiating potential of the stem and 
progenitor populations, a BMT was performed. It was hypothesised that 
transplanting pre-leukemic cells from the serial replating assay would shorten 
the disease latency in vivo (~6 months with unfractionated BM). By P3 of the 
serial replating assay all populations were exhibiting hallmarks of pre-leukemic 
cells i.e. efficiently producing colonies, high cKit expression and low expression 
of mature myeloid markers. Thus the CD45.2+ cells from P3 HSC, MPP, CMP and 
GMP derived colonies were selected to transplant into sublethally irradiated 
CD45.1+ C57BL/6 recipient mice and transplanted animals were monitored for 1 
year (Figure 4. 11). Attempts to culture MEPs ex vivo for viral transduction had 
failed, and thus MEPs are precluded from the analysis.   
Peripheral bleeds were taken at 7 weeks post-transplant and the levels of 
engraftment were determined by CD45.2 expression in the blood. Cells 
transplanted from HSC and GMP derived colonies displayed high levels of 
engraftment (Figure 4. 12A). Cells transplanted from MPP-derived colonies 
showed no engraftment in the recipient mice, while only 1 of 5 CMP transplanted 
mice displayed engraftment in the PB at 7 weeks post-transplant. The MPP and 
CMP transplanted mice who displayed no engraftment in the PB were culled at 
16 weeks post BMT (Figure 4. 12B) and all had normal white blood cell (WBC) 
counts, normal spleen weights, and normal percentages of circulating 
neutrophils, lymphocytes, monocytes, eosinophils and basophils (Figure 4. 13). 
Flow cytometric analysis revealed no engraftment of CD45.2+ cells in the BM, 
spleen or PB at 16 weeks post-transplant (Figure 4. 14). All mice transplanted 
with GMP derived cells succumbed to disease with a median latency of just 14 
weeks (Figure 4. 15). Of the cohort transplanted with HSC derived cells, only 1 
of 4 mice developed disease within 1 year, with a latency of 26 weeks. Further 
analysis of the mice that displayed peripheral engraftment but did not develop 
leukaemia within 1 year showed no disruption to hematopoiesis with normal 
  179 
 
spleen weights, WBC counts and normal percentages of circulating neutrophils, 
lymphocytes, monocytes, eosinophils and basophils (Figure 4. 16). 
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Figure 4. 11 – Schematic overview of transplantation model used to identify the 
TRIB2 leukaemia initiating cell 
BM cells were isolated from CD45.2+ mice and sorted for HSC (Lin-
cKit+Sca1+CD150+CD48-), MPP (Lin-cKit+Sca1+CD150-CD48-), CMP (Lin-cKit+Sca1-
CD34+CD16/32lo), and GMP (Lin-cKit+Sca1-CD34+CD16/32hi) populations. The cells 
were transduced with GFP tagged Trib2 lentivirus and plated in M3434 
methylcellulose media after 24hrs. After 7 days (P1) colonies had formed, cells 
were then removed and sorted for GFP expression before serial replating in 
M3434. P3 cells were transplanted into sub-lethally irradiated CD45.1+ recipient 
mice. 
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Figure 4. 12 – Varying engraftment levels in TRIB2 LIC transplanted mice 
Peripheral bleeds were taken at (A) 7 weeks and (B) 16 weeks post BMT and 
analysed by flow cytometry for CD45.2 expression. Each dot represents 
percentage CD45.2 expression in the PB of an individual mouse, HSC (n=4), MPP 
(n=2), CMP (n=5), GMP (n=4). 
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Figure 4. 13 – Normal hematopoiesis in mice that failed to engraft transplanted 
cells 
MPP and CMP transplanted mice that demonstrated no peripheral engraftment 
by 16 weeks were sacrificed and analysed. (A) WBC counts and (B) spleen 
weights of MPP and CMP transplanted non-engrafted mice. Each dot represents 
an individual mouse. (C) The white cell differential of the PB was analysed using 
a HemaVet 950 (Drew Scientific). Average percentage neutrophils (NE), 
lymphocytes (LY), monocytes (MO), eosinophils (EO) and basophils (BA) plotted 
+/- SD. Average of n=2 MPP, n=3 CMP. 
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Figure 4. 14 – No BM or splenic engraftment of donor cells at 16 weeks in mice 
failing to display peripheral engraftment at 7 weeks post BMT 
Representative flow cytometric analysis of cells from the BM, PB and spleen of 
mice at 16 weeks post BMT. MPP (n=2) and CMP (n=4) transplanted mice that did 
not display peripheral engraftment also lacked CD45.2 expression (middle panel) 
in the BM and spleen, and displayed normal myelopoiesis by CD11b and Gr1 
expression (right panel). 
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Figure 4. 15 – TRIB2 generates leukaemia from the HSC and GMP with different 
latencies, but not the MPP or CMP. 
Kaplan-Meier survival curve of mice reconstituted with cells derived from TRIB2 
transformed HSC, MPP, CMP and GMP colonies. The median survival of mice 
reconstituted with GMP derived cells was 14 weeks (n=4), 1 (of 4) HSC mouse 
developed disease within 1 year with a latency of 26 weeks, while none of the 
mice reconstituted with MPP (n=2) or CMP (n=5) derived cells developed 
leukaemia. *P=0.0171 by Log-rank test. 
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Figure 4. 16 – HSC and CMP transplanted mice that engrafted the donor cells, but 
did not succumb to disease displayed normal hematopoiesis after 1 year 
HSC and CMP transplanted mice that demonstrated high levels of peripheral 
engraftment, but did not develop disease, were sacrificed and analysed after 1 
year. (A) Spleen weights and (B) WBC counts of HSC and CMP transplanted mice. 
Each dot represents an individual mouse. (C) The white cell differential of the 
PB was analysed using a HemaVet 950 (Drew Scientific). Average percentage 
neutrophils (NE), lymphocytes (LY), monocytes (MO), eosinophils (EO) and 
basophils (BA) plotted +/- SD. Average of n=3 HSC, n=1 CMP. 
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4.3.3 TRIB2 propagates phenotypically different diseases from 
the HSC and GMP 
The leukaemias generated from TRIB2 transformed HSC and GMP derived cells 
were morphologically distinct. The HSC-transplanted mouse presented with a 
very high WBC count while the WBC count of GMP mice were within the normal 
range (Figure 4. 17A). There was massive infiltration of leukocytes in the spleen 
of the HSC mouse as evidenced by splenomegaly, whereas the spleen weights of 
the GMP mice were within the normal range (Figure 4. 17B). Flow cytometric 
analysis of the BM showed a much higher than normal percentage of CD11b+Gr1+ 
cells in the GMP derived disease coupled with a decrease in cells expressing B 
and T cell markers (Figure 4. 18). The HSC derived disease was wholly different 
from that of the GMP. BM cells of the HSC transplanted mouse had little to no 
Gr1 expression, with almost all cells expressing the B cell marker B220, but not 
CD19, and a fraction of cells expressing the T cell marker CD8 but not CD4. The 
patterns of expression for both the GMP and HSC diseases were also observed in 
the spleen (Figure 4. 19A) and PB (Figure 4. 19B). While the GMP transplanted 
mice did not display splenomegaly or elevated WBC, analysis of the absolute cell 
numbers in the BM and PB demonstrated that TRIB2 induced a 
myeloproliferative-like disease from the GMP (Figure 4. 20). The phenotype of 
neither the HSC nor GMP derived AML fully recapitulated TRIB2-induced AML 
from 5-FU treated BM with the bulk leukemic cells expressing cKit+CD11bintGr1int 
(Keeshan et al., 2006).   
Because the HSC transplanted mouse had a very unusual disease phenotype, a 
more extensive panel of cell surface markers were examined. As mentioned B220 
was expressed on all HSC derived leukemic cells, in contrast to a complete 
absence of B220 expression in GMP derived leukemic cells (Figure 4. 21A). There 
were comparably low levels of CD19 and IL7Rα expression in both groups, with 
slightly higher surface IgM expression in the HSC derived leukemic cells (Figure 
4. 21A). CD43 expression was high in both GMP and HSC derived leukemic cells 
(Figure 4. 21B), with almost all HSC derived leukemic cells staining double 
positive for B220 and CD43 expression. These 2 markers are co-expressed at the 
early stages of B cell development, suggesting a possible phenotypic B cell 
leukaemia had been generated from the TRIB2 transformed HSC. However, 
analysis of the T cell compartment revealed that approximately 24% of HSC 
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derived leukemic cells were also CD8+ (Figure 4. 22A), yet neither the CD8+ nor 
CD8- fraction expressed the T cell markers CD4, CD3 or TCRβ. Levels of CD8, 
CD4, CD3 and TCRβ expression were all very low in the GMP derived disease 
(Figure 4. 22B). Analysis of markers of mature myeloid cells revealed a slight 
increase in CD11c expression and a large increase in MHCII expression on HSC 
derived leukemic cells when compared with GMP derived cells (Figure 4. 23A), 
but much lower CD11b expression. CD8 was not co-expressed with either CD11b 
or MHCII (Figure 4. 23B). CD8 and CD11c, which in normal hematopoiesis are 
found co-expressed on regulatory T cells (Vinay and Kwon, 2010) were expressed 
together at low levels in HSC derived leukemic cells. Over 40% of HSC derived 
leukemic cells expressed MHCII, a surface molecule found primarily on dendritic 
cells, but also present on some B cells. Within the MHCII+ and MHCII- fraction of 
leukemic cells there was differential expression of CD11b and CD11c (Figure 4. 
23C). Thus in addition to approximately 24% B220+CD43+CD8+ cells, over 40% of 
the leukaemic population was comprised of B220+CD43+MHCII+CD8- cells, and 17% 
of these were also double positive for CD11c and CD11b expression, markers 
frequently co-expressed on dendritic cells. 
These data show that Trib2 cannot induce leukaemia from the MPP or CMP in 
vivo. It does induce leukaemia from the HSC and GMP in vivo, with different 
efficiencies, and has the ability to generate different types of leukaemia 
depending on the cell of origin. A uniformly myeloproliferative disease with 100% 
penetrance was generated from the TRIB2 transformed GMPs, while a weakly 
penetrant leukaemia with highly aberrant cell surface marker expression of 
mixed lineage was generated from the TRIB2 transformed HSC. 
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Figure 4. 17 – Physically distinct diseases arose from the TRIB2 transformed HSC 
and GMP 
(A) WBC count and (B) spleen weights of HSC (n=1) and GMP (n=4) transplanted 
leukemic mice. Each dot represents and individual mouse. 
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Figure 4. 18 – TRIB2 generates phenotypically different diseases from the HSC 
and GMP 
Representative flow cytometric analysis of mature myeloid (CD11b, Gr1), B 
(B220, CD19) and T (CD4, CD8) cell markers in the BM of a HSC transplanted 
mouse that did not develop leukaemia (top) and the BM of a HSC (middle)  and 
GMP (bottom) transplanted CD45.2+ leukemic mouse. Data is representative of 
n=1 HSC and n=4 GMP mice.  
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Figure 4. 19 – HSC and GMP derived leukemic cells infiltrate the spleen and 
peripheral blood 
Representative flow cytometric analysis of mature myeloid (CD11b, Gr1), B 
(B220, CD19) and T (CD4, CD8) cell markers in the (A) spleen and (B) PB of HSC 
and GMP transplanted CD45.2+ leukemic mice. Data is representative of n=1 HSC 
and n=4 GMP mice. 
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Figure 4. 20 – Absolute frequency of BM and PB CD11b+Gr1+ in leukemic mice 
Absolute numbers of CD11b+Gr1+ cells in the (A) peripheral blood and (B) bone 
marrow of HSC transplanted (n=1) and GMP transplanted (n=4) leukemic mice. 
Box and whiskers plot with whiskers denoting min to max, and line representing 
mean values. Dashed box denotes normal range in healthy mice as determined 
by HemaVet 950FS reference intervals (PB) and previously published data (BM) 
(Yang et al., 2013). 
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Figure 4. 21 – Distinct B cell surface marker expression patterns on HSC derived 
leukemic cells compared with GMP derived leukemic cells 
(A) Representative histogram overlay of expression of B cell surface markers on 
HSC and GMP derived CD45.2+ leukemic cells (B) Representative histogram 
overlays of expression of CD43 on HSC and GMP derived CD45.2+ leukemic cells 
(left) and representative contour plots of B220 and CD43 co-expression on HSC 
and GMP derived CD45.2+ leukemic cells. Data is representative of n=1 HSC and 
n=4 GMP mice.  
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Figure 4. 22 – Aberrant T cell surface marker expression patterns on HSC derived 
leukemic cells compared with GMP derived leukemic cells 
(A) Representative contour plots of T cell surface marker expression on HSC 
derived CD45.2+ leukemic cells. (B) Representative histogram overlays of 
expression of T cell surface markers on HSC and GMP derived CD45.2+ leukemic 
cells. Data is representative of n=1 HSC and n=4 GMP mice. 
  194 
 
 
Figure 4. 23 – Differential myeloid cell surface marker expression patterns on 
HSC and GMP derived leukemic cells 
(A) Representative histogram overlays of expression of myeloid cell surface 
markers on HSC and GMP derived CD45.2+ leukemic cells (B) Histogram overlays 
of myeloid cell surface marker expression on total or CD8 expressing HSC derived 
CD45.2+ leukemic cells (C) Representative flow cytometric analysis of CD11b and 
CD11c on MHCII+ (right) and MHCII- (middle) HSC derived CD45.2+ leukemic BM. 
Data is representative of n=1 HSC and n=4 GMP mice.  
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4.3.4 Loss of Trib2 does not perturb bone marrow hematopoiesis 
in vivo 
As outlined in 1.3.3.5, TRIB2 is differentially expressed in the hematopoietic 
system. Within the BM compartment its highest expression is in CD4+ T cells and 
in the myeloid lineage TRIB2 expression is highest in granulocytes and lowest in 
monocytes (Liang et al., 2013). Considering the fact that TRIB2 generated such 
different disease phenotypes from the HSC and GMP, it was hypothesized that it 
may play a role in steady state BM hematopoiesis. To investigate this, the Trib2 
knockout mouse was studied (described in section 2.3.3.1). First the PB was 
analysed by flow cytometry for circulating myeloid (CD11b+Gr1+), B 
(B220+CD19+), CD8+ T and CD4+ T cells. There was no difference between the 
percentages of myeloid, B and T cells in Trib2-/- PB when compared to WT 
controls (Figure 4. 24). Analysis of mature leukocytes in the spleen also revealed 
no differences in the expression of markers of mature myeloid, B and T cells 
(Figure 4. 25). The BM of WT and Trib2-/- mice was then analysed.  There was no 
difference between the distribution of differentiated leukocytes of WT and 
Trib2-/- BM (Figure 4. 26).  The immature erythroid cells in the BM were next 
analysed using the cell surface markers CD71 and Ter119. These 2 markers can 
be used to look at the 4 main stages of erythroid maturation in the BM 
identifying CD71hiTer119int pro-erythroblasts, CD71+Ter119+ basophilic 
erythroblasts, CD71intTer119+ polychromatic erythroblasts and  
CD71-Ter119+ orthochromatic erythroblasts. Loss of Trib2 did not have a 
significant effect on the percentages of any of the erythroid progenitors in the 
BM (Figure 4. 27).  
To ensure that loss of Trib2 did not affect the BM stem and progenitor 
populations, cells were stained using CD150 and CD48, members of the SLAM 
family of cell surface molecules (described in section1.1.2). There were no 
differences in the percentages of HSC, MPP, HPC-1 or HPC-2 cells (Figure 4. 28), 
nor of LSK cells. Committed myeloid progenitor cells were also identified by flow 
cytometry (also described in section1.1.2), and no differences were observed 
between the WT and Trib2-/- mice in CMP, GMP or MEP cells, nor in the LK 
compartment (Figure 4. 29). Overall no defect in homeostatic hematopoiesis was 
apparent by immuno-phenotypic analysis. However because TRIB2 has been 
shown to degrade C/EBPα, and C/EBPα is essential for terminal granulocytic 
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differentiation it was hypothesised that the absence of TRIB2 may result in 
increased levels of C/EBPα. C/EBPα facilitates and is essential for the CMP to 
GMP transition thus increased levels of C/EBPα could lead to accelerated 
differentiation. To explore this total BM isolated from WT or Trib2-/- mice was 
plated in methylcellulose. As described in section 2.2.3.2, M3434 
methylcellulose media is supplemented with SCF, IL-3, IL-6 and EPO supporting 
the formation of myeloid and erythroid colonies. The morphology of colony types 
produced (E, GEMM, GM, M and G) and the criteria for their classification are 
outlined in section 2.2.3.2 There was no difference in the number of colonies 
produced from Trib2-/- BM cells compared with WT control cells (Figure 4. 30A) 
and while Trib2-/- BM cells generated more erythroid colonies in vitro, this 
difference was not statistically significant (Figure 4. 30B). Flow cytometric 
analysis of myeloid cell surface marker expression also revealed no differences 
in the expression of CD11b, Gr1, F4/80 or CD11c on cells from Trib2-/- colonies 
compared with WT control colonies (Figure 4. 31).  
Taken together, these data indicate that TRIB2 may be dispensable for steady-
state BM hematopoiesis as there was no disruption to the distribution of stem, 
progenitor or differentiated cell populations in the Trib2-/- mouse. Indeed loss of 
TRIB2 also did not affect the ability of BM stem and progenitor cells to form 
colonies and differentiate in vitro. As discussed in section 1.3.2, the Tribbles 
family of pseudokinases share a large degree of structural homology and it is 
likely that they may share overlapping functions in the hematopoietic system. 
Therefore compensation from TRIB1 or TRIB3 may account for the normal 
phenotype of the Trib2-/- mouse.  
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Figure 4. 24 – Normal levels of circulating leukocytes in Trib2-/- mice 
(A) Representative contour plots of myeloid (CD11b, Gr1), B (B220, CD19) and T 
(CD4, CD8) cells in the PB of 6-14 week old WT and Trib2-/- mice. (B) Graph of 
average percentage expression of markers on WT (n=3) and Trib2-/- (n=10) PB 
cells +/- SD. 
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Figure 4. 25 – Normal distribution of splenic leukocytes in Trib2-/- mice 
(A) Representative contour plots of myeloid (CD11b, Gr1), B (B220, CD19) and T 
(CD4, CD8) cells in the spleen of 6-14 week old WT and Trib2-/- mice (B) Graph of 
average percentage expression of markers on WT (n=3) and Trib2-/- (n=6) spleen 
cells +/- SD. 
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Figure 4. 26 – Normal BM hematopoiesis in Trib2-/- mice 
(A) Representative contour plots of myeloid (CD11b, Gr1), B (B220, CD19) and T 
(CD4, CD8) cells in the BM of 6-14 week old WT and Trib2-/- mice. (B) Graph of 
average percentage expression of markers on WT (n=3) and Trib2-/- (n=9) BM 
cells +/- SD. 
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Figure 4. 27 - Normal BM erythropoiesis in Trib2-/- mice 
(A) Gating strategy for detection of committed erythroid progenitors (left) and BM cells 
from WT and Trib2-/- mice were stained for Ter119 and CD71 (right) to isolate 
subpopulations of erythroblasts. (B) Graph of average percentage of each erythroid 
subpopulation in 6-14 week old WT (n=2) and Trib2-/- BM (n=2)cells +/- SD where 
ProE denotes proerythroblasts, BasoE denotes basophilic erythroblasts, ChromoE 
denotes polychromatophilic erythroblasts and OrthoE denotes orthochromatophilic 
erythroblasts. 
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Figure 4. 28 – Normal distribution of stem and progenitor cells in Trib2-/- mouse 
(A) Representative flow cytometric analysis of BM stem and progenitor cells from 
6-14 week old WT and Trib2-/- mice. (B) Graph of average percentage of HSC 
(Lin-cKit+Sca1+CD150+CD48-), MPP (Lin-cKit+Sca1+CD150-CD48-), HPC-1 (Lin-
cKit+Sca1+CD150-CD48+), HPC-2 (Lin-cKit+Sca1+CD150+CD48+) and LSK (Lin-
cKit+Sca1+) cells present in WT (n=3) and Trib2-/-(n=3) BM.  
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Figure 4. 29 – Normal distribution of myeloid progenitor cells in Trib2-/- BM 
(A) Gating strategy and representative flow cytometric analysis of BM myeloid 
progenitor cells from 6-14 week old WT and Trib2-/- mice. (B) Graph of average 
percentage of LK (Lin-cKit+Sca1-), CMP (LK CD34+CD16/32lo), GMP (LK 
CD34+CD16/32hi) and MEP (LK CD34-CD16/32-) cells present in WT (n=3) and 
Trib2-/-(n=3) BM.
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Figure 4. 30 – Absence of Trib2 does not impair BM colony forming ability 
(A) BM was isolated from litter-matched 6-8 week old WT or Trib2-/- mice, RBCs 
were lysed and 20,000 cells were plated in triplicate in methylcellulose media 
(M3434). Colonies with >50 cells were counted and (B) scored based on 
morphology. All data points correspond to the mean and the standard deviation 
of 3 independent experiments. 
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Figure 4. 31 - No differences in the expression of mature myeloid markers on 
cells from P1 WT and Trib2-/- colonies 
(A) Representative flow cytometric analysis of myeloid cell marker CD11b, Gr1, 
F4/80 and CD11c expression on cells from P1 of methylcellulose assay. (B) Graph 
of average percentage expression of each marker. Bars represent averages of 3 
independent experiments +/-SD. 
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4.4 Discussion 
TRIB2 overexpression was able to confer self-renewal and proliferative capacity 
on stem and progenitor populations in vitro with all populations efficiently 
producing third round colonies in a serial replating assay. However the cell of 
origin affected the number, size and morphology of colonies produced, as well 
as the morphology and surface marker expression of cells within those colonies. 
Striking differences existed in the CMP derived colonies which had a 
predominantly mature myeloid phenotype and lost replating ability between P3 
and P5. While the MPP derived cells efficiently replated to P5, the cells were 
comprised of mostly cKit- cells expressing markers of myeloid maturation. These 
differences translated in vivo, where TRIB2 was only able to initiate leukaemia 
from the HSC and GMP, and not the CMP and MPP. The TRIB2 transformed HSC 
and GMP diseases differed greatly in disease latency, penetrance and phenotype. 
TRIB2 transformed GMPs efficiently produced a mature myeloproliferative 
disease while Trib2 transformed HSCs produced a weakly penetrant leukaemia 
with mixed myeloid and lymphoid characteristics. Despite the differential 
expression of TRIB2 in the hematopoietic system and the observed ability of 
TRIB2 to induce leukaemias with both lymphoid and myeloid characteristics, it 
was determined that TRIB2 was dispensable for in vivo steady state 
hematopoiesis, and in vitro myeloid differentiation. These data suggest that 
while TRIB2 can increase proliferation and self-renewal in all tested populations 
in vitro, the Trib2 LIC resides in the HSC and GMP. The differences in the 
resultant disease phenotype may be attributed to either the phenotype of the 
starting cell, or the mechanism of action of TRIB2 within that cell type. 
The data indicate that TRIB2 overexpression confers the ability to serially 
replate in vitro to HSCs, MPPs, CMPs, GMPs and MEPs. However while all 
populations efficiently produced colonies to P3, the CMP derived cells lost their 
replating and proliferative capacity by P5. Indeed CMP derived colonies were 
also different to all other populations in that they were primarily of a mature 
type III morphology and cytospins of cells from transformed CMP derived colonies 
revealed an almost completely monomorphic differentiated cell type. 
Furthermore when transplanted at P3 into sub-lethally irradiated recipients only 
1 in 5 mice engrafted the transplanted CMP derived cells. In a previous study 
looking at the effect of HRX-ENL transformation on BM cells, it was shown that 
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when type III colonies were individually selected from a plate they replated at a 
low frequency - with just 1 in 5 colonies successfully replating (Lavau et al., 
1997), correlating with the observed frequency of CMP colony engraftment. 
Despite efficiently producing many large colonies in the 5th replating, the cells 
from the MPP derived colonies also failed to engraft and generate disease in 
vivo. By P5, more than 50% of MPP derived cells expressed CD11b and Gr1 but no 
cKit. Indeed by P5 over 65% of CMP derived cells were expressing Gr1. These 
observations suggest that the reason the MPP and CMP derived cells did not 
generate AML in vivo was that, despite conferring self-renewal ability, TRIB2 
failed to block differentiation of the MPP and CMP derived cells, similar to 
observations made of BCR-ABL by Huntly et al outlined in 4.1.3.2.1.  
The ability of TRIB2 to immortalise the MEP in vitro is interesting. TRIB2 induces 
AML by degrading the essential myeloid transcription factor C/EBPα thereby 
blocking myeloid differentiation (Keeshan et al., 2006). However Cebpa is not 
expressed in MEPs (Miyamoto et al., 2002) indicating that the in vitro 
transformation of the MEP by TRIB2 must be through a different mechanism. In 
mammals the evolutionarily conserved FOX proteins comprise a family of 4 
transcription factors (FOXO1, FOXO3a, FOXO4 and FOXO6) which are involved in 
regulating genes that affect a variety of critical cell fate decisions. They are 
downstream effectors of the PI3K-Akt pathway (Burgering and Kops, 2002) and 
amongst other functions they regulate cell cycle progression and cell 
differentiation. They are well established as tumour suppressors and their 
dysregulation has been linked with numerous forms of cancer including prostate 
(Shukla et al., 2009), breast (Hu et al., 2004) and leukaemia (Parry et al., 1994). 
In a recent melanoma study, TRIB2 was shown to repress FOXO activity and 
support the growth of melanoma cells (Zanella et al., 2010). The authors used a 
293T cell line modified with a reporter construct capable of measuring FOXO 
transcriptional activity to study FOXO regulation. They performed a large-scale 
loss-of-function screen (>7500 human genes) to identify putative regulators of 
FOXO activity and showed that TRIB2 silencing resulted in FOXO transcription. In 
a luciferase reporter assay, silencing TRIB2 in the G-361 human melanoma cell 
line resulted in an increase in FOXO-driven luminescence. Loss of TRIB2 from the 
G-361 cells also greatly impaired their growth and expansion. FOXO1, FOXO3a 
and FOXO4 are all expressed in erythroid progenitor cells and during erythroid 
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differentiation (Mahmud et al., 2002). Indeed FOXO3a has been shown to induce 
erythroid differentiation through down-regulation of the Id1 gene (Birkenkamp 
et al., 2007). Therefore inhibition of Foxo activity in the MEP by TRIB2 
overexpression could account for the block in differentiation and acquired serial 
replating activity observed in vitro. However transplantation of TRIB2 expressing 
MEPs would be required to determine if the cells were fully transformed, and 
could generate disease in vivo.  
Only the TRIB2 overexpressing HSC and GMP derived cells were able to generate 
leukaemia in vivo, and they did so with different penetrance and latency. The 
median latency of the GMP derived disease was just 10 weeks while the latency 
of the HSC derived disease was significantly longer at 26 weeks. It was 
hypothesised that transplanting preleukemic cells from the third round of serial 
replating would decrease the latency of the disease in vivo (~25.5 weeks primary 
AMl and ~5 weeks secondary AML) (Keeshan et al., 2006). As such it is unclear as 
to whether the serial replating had any effect on TRIB2 mediated disease 
latency. A transplant of freshly transduced purified populations may result in 
similar disease latencies with the HSC representing the expected TRIB2 latency. 
It is possible that the GMP disease may have enriched for the TRIB2 LIC 
compared to the slower HSC derived disease. Support for this comes from 
previously described studies that the LIC can be enriched in the HSC (Bonnet and 
Dick, 1997, Sarry et al., 2011, Gibbs et al., 2012, Krivtsov et al., 2013, Cozzio et 
al., 2003) or a more mature myeloid progenitor population such as the GMP 
(Goardon et al., 2011, Bereshchenko et al., 2009, Heuser et al., 2011, Guibal et 
al., 2009, Reckzeh et al., 2012) and that the identity of the LIC can affect the 
disease latency. In addition to studies outlined in 4.1.3, a study of 100 primary 
AML samples showed that LSC activity was enriched in subsets which 
phenotypically resembled murine LMPPs and GMPs (Goardon et al., 2011). They 
observed that the leukemic LMPP-like (L-LMPP) cells gave rise to leukemic GMPs 
(L-GMP) which were the dominant cell type (~80%), but the inverse was not true, 
mimicking the normal hematopoietic hierarchy. When examined at the 
molecular level the L-LMPP and L-GMP cells resembled their normal counterparts 
suggesting that the LIC was a committed progenitor cell as opposed to a HSC 
with aberrant surface marker expression. However, the majority of these studies 
show that regardless of the LIC, the resultant diseases are virtually 
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indistinguishable from one another. Therefore, it is somewhat misleading to 
reconcile these observations with those of Trib2, because the Trib2 LIC resulted 
in striking differences in the phenotype, latency and penetrance of the disease, 
suggesting that distinct mechanisms of Trib2 leukaemogenesis from the HSC and 
the GMP exist.  
The differences in expression of myeloid and lymphoid markers in Trib2 HSC and 
GMP derived diseases are possibly attributable to the expression levels of lineage 
specific genes in the given LIC. A mature myeloproliferative disease was 
observed from the GMP. C/EBPα is essential for the CMP to GMP transition and 
its expression is highest in the GMP. A recent study by Ye at al has put forward 
an interesting hypothesis which reports that myeloid differentiation is required 
for the formation of LSCs and for AML initiation (Ye et al., 2015). They utilised 
the conditional Cebpa KO model in conjunction with overexpression of the MLL-
AF9 fusion gene. LSK and CMP cells were isolated from Poly I:C treated MxCre- 
Cebpaf/f (control) and MxCre+ Cebpaf/f (KO) mice and transduced with MLL-AF9 
virus , then transplanted into recipient mice. Transduced KO cells failed to 
initiate disease in vivo with control mice succumbing to disease within 4 months. 
The Cebpa GFP+ KO LSKs successfully generated B cells, CMPs and MEPs but were 
unable to produce GMP cells. Gene expression analysis revealed that in Cebpa 
GFP+ KO LSKs and CMPs, downstream targets of MLL-AF9 such as HoxA9 and 
Meis1 were expressed at equal or higher levels as in Cebpa GFP+ Control LSKs 
and CMPs. The authors then showed that MLL-AF9 leukaemia could be restored in 
Cebpa KO cells by treating cells with GM-CSF and IL-3 to overcome the block in 
differentiation caused by loss of C/EBPα, thus demonstrating that it was not loss 
of C/EBPα itself but rather impaired myelomonocytic differentiation which 
prevented leukaemia initiation. This may account for the transformation of the 
GMP and not the CMP or MPP by Trib2.  
A small proportion of acute leukaemias, known as bi-phenotypic, exhibit both 
myeloid and lymphoid characteristics. It has not been determined whether these 
diseases arise from the transformation of immature progenitors which have 
myeloid and lymphoid potential, or if the leukaemic cell phenotypes are due to 
aberrant expression of lineage related genes, and thereby lineage specific cell 
surface markers. While it has not been previously reported for Trib2, the 
transformation of the HSC by an oncogene resulting in a multi-lineage disease 
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phenotype is not a unique observation among LIC studies. As outlined in 
4.1.3.1.2, similar results were observed using the oncogene MLL-GAS7. MLL-GAS7 
overexpression induced a mixture of AML (80%), ALL (10%) and bi-lineage 
leukaemia (10%) in vivo (So et al., 2003). In a serial replating assay 
supplemented with myeloid cytokines, MLL-GAS7 transduced CMPs and GMPs 
serially produced colonies of cKit+Gr1+CD11b+ cells, while cells from HSC colonies 
also expressed B220. In a lymphoid permissive serial replating assay only the 
MLL-GAS7 transduced HSC was able to replate and produce colonies of cells with 
both myeloid and lymphoid characteristics. This demonstrates that, despite the 
observed plasticity of LSCs described in 4.1.2, only the HSC is prone to multi-
lineage transformation by MLL-GAS7, paralleling the observations made for 
TRIB2. Clearly the multi-lineage potential and transcriptional program of the 
HSC contributes to the myeloid, B and T cell features observed in the HSC 
derived TRIB2 leukaemia. What is unclear is the degree to which this phenotype 
can be attributed to the experimental model used. It is important to 
acknowledge that the methylcellulose media used favours myeloid cell growth 
and maturation and so lymphoid potential is hindered greatly. Despite this, cells 
with lymphoid characteristics were still observed in the TRIB2 transformed HSC 
derived disease. As described in section 1.3.3.5, TRIB2 expression is highest in T 
cells, it has been shown to be a downstream target of the T cell oncogenes 
NOTCH1, PITX1 and TAL1 and its expression is upregulated in a subset of B cell-
ALL with a t(1:19) translocation (Liang et al., 2013). Thus it is possible that 
under optimised experimental conditions, TRIB2 could generate a lymphoid 
leukaemia in vivo, perhaps from the HSC or CLP, instead of the observed mixed 
lineage leukaemia.  
Differences in the expression of lineage associated transcription factors may 
account for the differences in the HSC and GMP derived diseases. However, the 
ability of TRIB2, and other oncogenes, to generate leukaemia from functionally 
and phenotypically distinct stem and progenitor populations also suggests that 
there are overlapping gene expression signatures initiated by different 
oncogenes which facilitate leukemic transformation. This hypothesis has been 
addressed in some of the aforementioned studies. In the study outlined in 
4.1.3.2.5 the gene expression signature of MOZ-TIF2, NUP98-HOXA9, AML1-ETO 
or control transduced GMPs was examined (Kvinlaug et al., 2011). In order to 
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focus on genes related with self-renewal the authors first compared normal LSKs 
with normal GMPs, and identified a set of 167 genes which were differentially 
expressed including Foxo3a (self-renewal) and Meis1 (leukemic transformation). 
Comparing this “leukaemia initiation signature” with the transduced GMPs 
revealed a 76% overlap (127 of 167) in expression with 14 genes differentially 
expressed downstream of all 3 of the oncogenes tested, confirming the existence 
of common transcriptional programmes of leukaemogenesis initiated from 
different oncogenes. 
Based on the observation that TRIB2 overexpression could block myeloid 
development, and also induce a mixed lineage disease in vivo the hematopoietic 
compartment of the Trib2-/- mouse was examined. No significant differences in 
the percentage of mature myeloid cells, B and T cells were observed in the 
Trib2-/- mice when compared with WT controls. Indeed a normal distribution of 
stem and myeloid progenitor cells and erythroblasts was also observed in Trib2-/- 
BM. It was previously reported that TRIB2 is not essential for murine 
development (Takasato et al., 2008), and now it has been confirmed that steady 
state hematopoiesis also appears undisrupted in the absence of TRIB2. Indeed 
TRIB1 and TRIB3 have also been shown to be dispensable for development 
(Yamamoto et al., 2007, Okamoto et al., 2007). The 3 mammalian tribbles 
family members share more than 45% sequence homology, so one consideration 
in fully assessing a role for TRIB2 in hematopoiesis is the potential for 
overlapping function with other family members, in particular TRIB1. TRIB1 has 
been identified as a potent inducer of AML (Yokoyama et al., 2010) and this 
action is also driven by C/EBPα degradation, but TRIB3 does not possess this 
ability. Both TRIB1 and TRIB2 are capable of degrading CEBPβ (Naiki et al., 
2007), while Trib3 is able to block the activation of Cebpb (Bezy et al., 2007). 
The overlapping functions of TRIB1 and TRIB2 appear to be dependent on cell 
type, as TRIB3 has functional similarities with TRIB2 in adipocytes where they 
are both down regulated during adipocyte differentiation (Naiki et al., 2007). 
The understanding of how the Tribbles family contributes to hematopoiesis 
would be greatly enhanced by a study of a Trib1/2 double knockout mouse. 
Indeed a Trib1/2/3 triple knockout mouse could indicate whether or not these 
are an essential family of pseudokinases for development. However attempts to 
generate the double and triple knockout mice by researchers in the field have 
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thus far failed (Endre Kiss-Toth, Vishva Dixit; personal communication) 
suggesting potential lethality. The development of conditional models would 
greatly facilitate our understanding of the importance of the Tribbles family in 
hematopoiesis.  
In summary the data presented here show that TRIB2 overexpression leads to the 
immortalization of stem and progenitor populations in vitro regardless of their 
levels of Cebpa expression. However TRIB2 was only able to initiate disease in 
vivo from the HSC and GMP, driving a potent myeloproliferative AML from the 
GMP, while the HSC resulted in a weakly penetrant multi-lineage disease, 
suggesting that 2 distinct mechanisms of oncogenesis were involved. Together 
these data provide new insight into the TRIB2 LIC demonstrating that TRIB2 
produces very distinct diseases from the HSC and GMP. Further exploration of 
the ability of TRIB2 to induce lymphoid leukaemias in vivo could provide a new 
leukaemia model, a potentially valuable resource for therapeutic approaches 
considering the frequency of lymphoid leukaemias with high TRIB2 expression.  
Some of this work has been published in Ling Liang et al, 2016, details provided 
in section 0. 
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5 Results: NFIX expression critically 
modulates early B lymphopoiesis and 
myelopoiesis 
Part of this chapter has been published in O’Connor et al, 2015, provided in 
section 0. 
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5.1 Introduction 
5.1.1 Nuclear factor one (NFI)  
The nuclear factor one (NFI) transcription factor protein was first identified in 
1982 when it was isolated from the nuclear extracts of HeLa cells (Nagata et al., 
1982). The authors were studying the replication of adenovirus in vitro, during 
which a terminal protein of the virus forms a covalent bond with the 5’ end of 
the viral genome. This complex acts as a primer for replication, but it requires 3 
additional proteins from the host cell to complete replication. One of these 
proteins was identified as the 47kD NFI. It was shown to stimulate the formation 
of this complex by acting as a sequence-specific DNA binding protein that 
preferentially binds double stranded DNA (Nagata et al., 1983). NFI is often 
denoted as NFI/CTF because it was shown to be identical in polypeptide 
sequence to the CCAAT-binding transcription factor (CTF) (Jones et al., 1987). 
The CCAAT box is a conserved sequence of nucleotides (GGCCAATCT) which are 
found upstream of a transcription start site, in the -60/-100 region of eukaryotic 
gene promoters. It is one of the most common eukaryotic promoter elements, 
providing a binding site for a large group of transcription factors. NFI has been 
shown to stimulate DNA replication and transcription initiation in vitro, by 
activating RNA polymerase II transcription on a variety of promoters (Rossi et al., 
1988, Mink et al., 1992). 
5.1.2 Structure of NFI 
The general structure of the NFI gene comprises 11 coding exons, with a highly 
conserved 200-220 amino acid residue N-terminal domain which is responsible 
for DNA binding and dimerization (Mermod et al., 1989, Gounari et al., 1990). 
This region is also sufficient to stimulate the initiation of DNA replication in 
adenovirus. The transcriptionally active domain is located in the C-terminus and 
consists of a 100 amino acid, proline rich (~25%) sequence (Figure 5. 1). While 
the C-terminus is highly variable between NFI family members, the C-terminus of 
each member is highly conserved across species (Kruse and Sippel, 1994). NFI 
binds as either hetero- or homodimers to a palindromic DNA sequence 
TTGGC(N5)GCCAA (Gronostajski et al., 1985). NFI proteins can also bind to 
consensus half sites (TTGGC and GCCAA) but with lower affinity (Meisterernst et 
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al., 1988). In addition, in nearly every organ in the body, binding sites for NFI 
have been characterised, including the CNS, lung, liver, kidney, adipose tissue, 
blood, skeletal muscle and BM (Gronostajski, 2000). 
 
Figure 5. 1 – Generalised structure of NFI genes 
4 members of the NFI family have been identified in humans NFIA, NFIB, NFIC 
and NFIX, encoded by four separate but similar NFI genes (Rupp et al., 1990, 
Kruse et al., 1991), located on different chromosomes with NFIC and NFIX both 
localising on chromosome 9, position 13.3 (Qian et al., 1995), NFIA located on 
chromosome 1 position 31.2, and NFIB is located on chromosome 8 location 24.1 
(Figure 5. 1). The NFI transcripts each undergo differential splicing producing 
multiple NFI sub-family members. Some NFI splice variants are only detected in 
specific species (Kruse and Sippel, 1994, Grunder et al., 2003). Thus NFI proteins 
have distinct functions depending on the species, cell type, splice variant, target 
promoter, and dimerization partner. 
5.1.3 NFI proteins in hematopoiesis 
5.1.3.1 NFIA 
Several studies have implicated NFIA in hematopoiesis and lineage fate 
decisions. In 2005 Fazi and colleagues were the first to identify NFIA as a 
candidate target of the miR-223 gene – an important modulator of myeloid 
differentiation in humans (Fazi et al., 2005). They showed that there is overlap 
between the NFIA and C/EBPα binding sites on the miR-223 promoter. When APL 
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cells were treated with RA, which induces myeloid differentiation, NFIA was 
displaced and replaced with C/EBPα. Conversely when cells resistant to RA (and 
therefore unable to undergo differentiation) were treated, NFIA remained bound 
to the miR-223 promoter and no C/EBPα binding was detected, suggesting 
competition between these 2 proteins for regulation of the miR-223 promoter. A 
similar regulatory network was reported by Rosa et al. They demonstrated that 
PU.1 activates the transcription of miR-424, which in turn stimulates monocyte 
differentiation by repressing NFIA translation (Rosa et al., 2007). More recently 
it was shown that knocking down Nfia in murine BM CD11b+Gr1+ cells led to their 
efficient differentiation into macrophages and dendritic cells in vitro (McClure 
et al., 2014).  
NFIA has also been described in erythroid differentiation. When CD34+ 
hematopoietic progenitor cells were stimulated to enter either erythropoiesis 
(EPO, IL-3 and GM-CSF) or granulopoiesis (IL-3, GM-CSF and G-CSF), NFIA mRNA 
and protein expression were significantly upregulated in cells undergoing 
erythroid differentiation, and dramatically reduced in those undergoing 
granulocytic differentiation (Starnes et al., 2009). HPCs transduced with a 
lentiviral shRNA targeting NFIA were unable to differentiate into erythroid cells. 
Most of the cells had died by day 8, and any remaining cells by day 12 displayed 
a myeloid phenotype. Furthermore, a transcriptome-wide approach revealed 
that in both CD34+ and leukemic K562 cells, NFIA induces an erythroid 
transcriptional program (Starnes et al., 2010).  
5.1.3.2 NFIB 
Recently NFIB was identified as a novel regulator of megakaryocyte maturation. 
Loss of NFIB in CD34+ PB cells, dramatically reduced their ability to differentiate 
towards MKs, and conversely overexpression of NFIB in CD34+ cells increased cell 
maturation (Chen et al., 2014). It has also been implicated in polycythaemia 
vera (PV). PV is a rare hematopoietic malignancy involving uncontrolled 
proliferation of red blood cells in the BM, the molecular basis for which is 
unknown. Increased NFIB expression was detected in granulocytes and CD34+ 
cells of certain PV patients harbouring a 9qLOH mutation compared to those 
without this mutation (Kralovics et al., 2002). More recently single cell gene 
expression analysis showed an 8 fold increase of NFIB expression in the MPP 
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compared to the HSC (Notta et al., 2011), alluding to a role for NFIB in stem and 
progenitor cells of the BM. 
5.1.3.3 NFIC 
As with NFIB above, loss of NFIC was also found to disrupt megakaryocyte 
differentiation from CD34+ PB cells and, like NFIB, its overexpression promoted 
differentiation (Chen et al., 2014). In addition, in the BM compartment, NFIC is 
highly expressed in osteoblasts (Perez-Casellas et al., 2009). Nfic-/- mice display 
an osteoporosis-like phenotype and Nfic overexpression in Nfic-/- cells has been 
shown to reduce adipocyte differentiation via PPARγ signalling while increasing 
differentiation of osteoblasts (Lee et al., 2014). 
5.1.3.4 NFIX 
To date the only study of NFIX in the hematopoietic compartment was 
performed by the McKinney-Freeman group in 2013. Initially, Nfix was identified 
as a potential novel regulator of HSC repopulating ability in a transcriptome-
wide study of HSCs, purified from more than 2500 embryonic and adult mice 
(McKinney-Freeman et al., 2012). They subsequently reported that Nfix 
expression increases during embryonic development with high expression of Nfix 
in murine adult HSPCs (Holmfeldt et al., 2013). They showed that loss of Nfix in 
HSPCs resulted in a greatly reduced repopulating ability when transplanted into 
lethally irradiated mice, which was attributed to an increase in apoptotic cell 
death. They also reported down-regulation of key survival genes in HSPCs with 
loss of Nfix, demonstrating that Nfix plays a role in HSPC survival under stress 
conditions. 
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5.2 Aims and Objectives 
Nfix is differentially expressed in murine HSPCs during development with highest 
expression detected in the adult BM (Holmfeldt et al., 2013), and it is expressed 
at a much higher level than the other NFI genes. As outlined in 5.1.3.4, 
Holmfeldt and colleagues have demonstrated that Nfix regulates HSPC 
repopulating ability under stress conditions by modulating a number of key 
survival genes. However, its role in steady state hematopoiesis is unclear. In 
addition, there is an established role for the other NFI family members in the 
differentiation of hematopoietic stem and progenitor cells, but the role of Nfix 
in lineage determination is unknown.  In order to assess whether Nfix plays a 
role in differentiation in the hematopoietic system, the specific aims of this 
chapter were:  
i. To investigate the effect of Nfix on hematopoiesis 
a. Using a retroviral transduction and BMT approach to determine if 
ectopic expression of NFIX on stem and progenitor cells affects 
lineage distribution in vivo  
b. Examine the role of NFIX in lineage decisions using myeloid or B 
cell permissive culture conditions in vitro assays  
ii. To determine the effect of loss of Nfix on hematopoietic lineage 
specification 
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5.3 Results 
5.3.1 NFIX overexpression favours myelopoiesis over B cell 
lymphopoiesis in vivo 
In order to determine if NFIX plays a role in hematopoiesis, BM cells were 
isolated from 5-FU treated C57BL/6 donor mice and transduced with either 
control MigR1 or NFIX expressing retrovirus. The cells were transplanted into 
lethally irradiated recipient mice. At 6-10 weeks post BMT, PB was taken and 
assessed by flow cytometry for the reconstitution of the myeloid, B and T cell 
compartments. There was a significant reduction in the percentage of B220+ and 
CD19+ B cells in the GFP+ compartment of the PB of NFIX mice compared with 
the MigR1 mice (Figure 5. 2). No change in the percentage of circulating CD4+ 
and CD8+ cells was observed (Figure 5. 3). However, there was a significant 
increase in the percentage of circulating CD11b+Gr1+ myeloid cells in the GFP+ 
compartment of NFIX mice compared with MigR1 control mice (Figure 5. 4).  
These data indicate that NFIX overexpression disrupts B cell and myeloid 
differentiation in vivo. Subsequent analysis of the BM also revealed a 
pronounced loss of B cells, and significant increase in CD11b+Gr1+ myeloid cells 
(Figure 5. 5). Similarly, the splenic B cells were dramatically depleted in the 
GFP+ compartment of NFIX mice when compared with MigR1 controls. The 
concomitant increase in myeloid cells was also evident in the spleen (Figure 5. 
6).  
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Figure 5. 2 - NFIX overexpression results in decreased B220 and CD19 expression 
in the PB.  
C57BL/6 mice were reconstituted with BM cells transduced with MigR1 or NFIX 
retrovirus. (A) Representative flow cytometric analysis of PB cells showing 
engraftment of GFP (left panel), and B220+CD19+ B cells in the GFP- and GFP+ 
fractions. (B) Graph of percentage number of GFP+ B cells (B220+ left and 
CD19+right) in the PB at 6 weeks post BMT, MigR1 n=4, NFIX n=5. Results are 
representative of 2 independent experiments. For statistical analysis an 
unpaired, two-tailed, students t-test performed. 
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Figure 5. 3 – NFIX overexpression does not affect T cell maturation in vivo. 
Graph of percentage number of GFP+ CD4+ cells (left) and GFP+ CD8+ cells (right) 
in the PB of MigR1 and NFIX chimeric mice at 6 weeks post BMT, MigR1 n=4, NFIX 
n=5. Data is representative of 2 independent experiments. For statistical analysis 
an unpaired, two-tailed, students t-test performed. 
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Figure 5. 4 – NFIX overexpression results in a higher percentage of peripheral 
myeloid cells in vivo. 
(A) Representative flow cytometric analysis of PB cells showing engraftment of 
GFP (left panel) and CD11b+Gr1+ myeloid cells in the GFP- and GFP+ fractions. (B) 
Graph of percentage number of GFP+ myeloid cells (CD11b+Gr1+) in the PB at 6 
weeks post BMT, MigR1 n=4, NFIX n=5. Results are representative of 2 
independent experiments. For statistical analysis an unpaired, two-tailed, 
students t-test performed.  
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Figure 5. 5 - Disrupted hematopoiesis in the BM of NFIX mice. 
C57BL/6 mice were reconstituted with BM cells transduced with MigR1 or NFIX 
retrovirus. (A) Graphs of percentage GFP+ B cells (left, MigR1 n=5, NFIX n=6) and 
GFP+ myeloid cells (right, MigR1=5, NFIX =6) in the BM of chimeric mice 10 weeks 
post BMT. (B) Representative flow cytometric analysis in MigR1 and NFIX 
chimeric animals 10 weeks post BMT showing GFP engraftment (left panel). 
Results are representative of 2 independent experiments. For statistical analysis 
an unpaired, two-tailed, students t-test performed. 
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Figure 5. 6 - Disrupted hematopoiesis in the spleen of NFIX mice. 
C57BL/6 mice were reconstituted with BM cells transduced with MigR1 or NFIX 
retrovirus. (A) Graphs of percentage GFP+ B cells (left, MigR1=5, NFIX=6) and 
GFP+ myeloid cells (right, MigR1=5, NFIX=4) in the spleen of chimeric mice 10 
weeks post BMT. (B) Representative flow cytometric analysis in MigR1 and NFIX 
chimeric animals 10 weeks post BMT showing GFP engraftment (left panel). 
Results are representative of 2 independent experiments. For statistical analysis 
an unpaired, two-tailed, students t-test performed.  
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5.3.2 NFIX expression decreases during B cell development 
Due to the disruption of the B cell compartment in the NFIX chimeric mice, 
endogenous levels of Nfix during the different stages of B cell development 
(described in section 1.1.4) were determined. A publically available microarray 
dataset of mouse B cell lineage populations was analysed through the GEO 
database (Mansson et al., 2008). In this dataset the CLP (Lin-B220-CD19-
CD127+Flt3+Sca1lowKitlow) is subdivided into hCD25- and hCD25+. hCD25 is the 
interleukin-2 receptor (IL-2R) α-chain, a cell surface marker expressed on 
activated T cells, B cells and monocytes as well as progenitor populations 
(Kumar et al., 2008). It also included the pro-B (CD19+AA4.1+CD43low), pre-B 
(CD19+B220+CD43-IgM-) and mature spleen (IgM+CD19+) B cells. There was a 
dramatic decrease in Nfix expression between the CLP and the pro-B cell stage 
of differentiation, and Nfix expression continued to decrease as the cells 
matured into splenic B cells (Figure 5. 7A). Next qPCR was performed on sorted 
B cell progenitor cells from WT C57Bl/6 mice. Pre-pro-B (B220+CD43+CD19-), pro-
B (B220+CD43+CD19+), pre-B (B220+CD43-CD19+IgM-) and immature B (B220+CD43-
CD19+IgM+) cells were purified and Nfix expression determined. Consistent with 
the microarray data, Nfix expression decreased between the pre-pro-B and pro-B 
cell stages, and continued to decrease as the cells matured (Figure 5. 7B). Gene 
expression analysis of some lineage specific transcription factors (Cebpa, Notch1 
and Cd19) was performed as a control, on both the microarray dataset (Figure 5. 
7C top panel) and the sorted murine B cell progenitors (Figure 5. 7C bottom 
panel), and revealed consistent results. 
In order to evaluate this expression pattern in humans, a microarray dataset 
from human B cell compartments was accessed through the GEO database 
(Novershtern et al., 2011). NFIX expression was analysed in the HSC2 (Lin-CD38-
CD34+), early B-cell (CD34+CD10+CD19+) and pro-B cell (CD34-CD10+CD19+) 
compartments. Consistent with our murine data, there was a decrease in NFIX 
expression from the human HSC2 compartment to the pro-B cells (Figure 5. 8A). 
To examine the Nfix expression pattern of the myeloid BM progenitor 
populations, HSC (lin-cKit+Sca1+Flt3-), LMPP (Lin-cKit+Sca1+Flt3+), CMP (Lin-cKit-
CD34intCD16/32int), GMP (Lin-cKit-CD34+CD16/32+) and MEP (Lin-cKit-
CD34lowCD16/32low) populations were sorted and analysed by qPCR. No 
downregulation of Nfix was observed in the myeloid restricted progenitors 
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(Figure 5. 8B). Having observed the downregulation of Nfix during both human 
and murine B cell differentiation, a more detailed flow cytometric analysis of B 
cell development was performed in the NFIX chimeric mice. CD43 (leukosialin) 
was used in conjunction with CD19 and B220 to differentiate between the CLP, 
pro-B and pre-B stages of B cell differentiation (Figure 5. 9A). Compared with 
MigR1 controls the NFIX mice displayed a significant reduction in the percentage 
of pro-B cells (B220+CD43+) and the more mature populations (Figure 5. 9B and 
C). Consistent with the stage at which endogenous Nfix is downregulated, these 
data show, that overexpression of NFIX induces a differentiation block during the 
pre-pro-B to pro-B stage of early B cell development.  
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Figure 5. 7 – Gene expression in murine B cell progenitor populations.  
(A) Analysis of Nfix expression during murine B cell differentiation using the B-
cell lineage microarray dataset (GSE11110). (B) qRT-PCR analysis 
of Nfix expression in murine B cell populations fractionated by flow cytometry. 
Data in (A) and (B) are representative of three independent experiments, 
performed in duplicate and error bars denote +/-SD. (C top panel) Cebpa, 
Notch1, and Cd19 gene expression in the B-cell progenitor microarray data. Max 
gene expression data was calculated for each B-cell progenitor population from 
the B-cell progenitor microarray dataset (GSE11110). Microarray data was 
collapsed to max probe expression for each gene using the Collapse Dataset suite 
in GenePattern. Values for each progenitor cell type were then plotted using 
GraphPad. Error bars represent max and min values for each cell type. (C 
bottom panel) qPCR analysis of B cell and myeloid cell specific gene expression 
in sorted murine B cell populations fractionated by flow cytometry. Relative 
levels of Cebpa, Notch1, and Cd19 expression in pre-pro-B, pro-B, pre-B and 
immature B cell populations. 18S was used as an endogenous control. Each 
gene/18s ratio in pre-pro-B cell progenitors was normalized to 1. These analyses 
were performed by Maura Hannon.
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Figure 5. 8 - NFIX expression in stem and progenitor populations. 
(A) Analysis of NFIX expression in human B cell development from the human 
hematopoiesis microarray dataset (GSE24759). Plots represent raw values and 
error bars represent max and min values- HSC2 n=4, Early B-cell n=4, Pro-B cell 
n=5. This analysis was performed by Maura Hannon. (B) Analysis 
of Nfix expression by qPCR in murine stem and progenitor cells isolated from WT 
adult BM. Bars represent mean values +/- SD, n=3 for each sample.  
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Figure 5. 9 - NFIX overexpression results in a block at the pro-B cell stage of B 
cell differentiation. 
(A) Schematic depiction of the use of B220 and CD43 as markers of the stages of 
B cell differentiation. (B) Representative flow cytometric analysis, with gates 
and percentages showing B220loCD43+ populations (early B cells) in GFP- and 
GFP+ populations. (C) Graph of percentage expression of CD43+, B220+, and 
B220loCD43+ populations in BM cells from chimeras established with MigR1 
or NFIX progenitors 8–10 wks previously, n=3. Error bars denote +/- SD of 2 
independent experiments.   
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5.3.3 NFIX expression favours myelopoiesis over B cell 
lymphopoiesis 
Nfix expression was downregulated in the B cell lineage and its overexpression in 
vivo led to a block in B cell development before the pro-B cell stage of 
differentiation, with a concomitant increase in myeloid cell maturation. To 
further investigate these observed effects, an in vitro OP9 co-culture 
experiment was performed. As described in section 2.2.3.3, co-culture on OP9 
stromal cells in the presence of B cell permissive cytokines, IL-7 and FLT3, 
induces cells to differentiate into mature B220+CD19+ B cells. First, total FLCs 
were isolated from the FL of E14.5 C57Bl/6 embryos, transduced with MigR1 or 
NFIX retrovirus and co-cultured with OP9 cells supplemented with 5 ng/ml FLT3 
and 1 ng/ml IL-7. After 16 days in co-culture the control MigR1 expressing FLCs 
had fully differentiated into mature B cells, whereas the NFIX expressing FLCs 
were not able to differentiate showing little to no expression of B220 or CD19 
(Figure 5. 10). In fact NFIX expressing FLCs differentiated into CD11b+Gr1+ 
myeloid cells despite the presence of B cell supportive cytokines. To determine 
if NFIX could block B cell development from the HSPC population, FL HSPCs (Lin-
Sca1+cKit+Flt3-) were sorted and transduced with control MigR1 or NFIX 
retrovirus. The cells were co-cultured on OP9 cells supplemented with 5 ng/ml 
FLT3 and 1 ng/ml IL-7. Again the efficient differentiation of the MigR1 
expressing FL HSPCs into B220+CD19+ B cells was observed after 12 days in 
culture. However NFIX overexpression completely abrogated B cell development 
from the HSPC (Figure 5. 11). To determine what molecular changes were 
associated with NFIX overexpression gene expression analysis was performed on 
lineage specific targets in the BM. The upregulation of ID genes and E-protein 
inhibition, have been shown to be involved in promoting myeloid lineage 
commitment while suppressing lymphoid differentiation as cells leave the LMPP 
compartment (Cochrane et al., 2009). The BM analysis showed that NFIX 
expression leads to a small but significant decrease in E2a, and a concomitant 
increase in Id2 and Id3 (Figure 5. 12). Changes in the expression of these genes 
correlates with our in vivo and in vitro findings that NFIX disrupts B cell 
differentiation. 
In order to rule out a toxic effect of ectopic NFIX expression on B cells, and to 
show that the observed result was indeed a block in lymphoid commitment, NFIX 
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was overexpressed in the committed pro-B cell line BA/F3. The NFIX expressing 
cells were assessed for changes in proliferation and viability. NFIX expression 
was retained at a steady level in transduced BA/F3 cells over a 5 day period 
(Figure 5. 13A). These cells also proliferated at a normal rate by trypan blue cell 
counts (Figure 5. 13B) and using the CTV stain on sorted MigR1 or Nfix expressing 
cells (Figure 5. 13C). The effect of NFIX overexpression on BAF/3 cell viability 
was then determined by analysing DAPI and annexin-V expression in cells over a 
3 day period. There was no difference in cell viability between control MigR1 
and NFIX expressing cells (Figure 5. 14A and B). These data demonstrate that 
NFIX overexpression does not have a toxic effect on B cells and the changes seen 
in vivo and in vitro are due to its effects on cell fate decisions.  
The myeloid potential of NFIX expressing BM cells was then investigated by 
plating cells in methylcellulose media (M3434) which supports the growth of E, 
GM, G, M and GEMM colonies (see section 2.2.3.2). Total BM cells transduced 
with MigR1 or NFIX retrovirus were plated in M3434 and assessed after 9-11 days. 
NFIX expression in bulk BM cells had no effect on the number of colonies 
produced (Figure 5. 15A). However there was an increase in the number of 
mature colonies (GM, G, M) and decrease in the number of immature colonies (E, 
GEMM) observed, compared with MigR1 control plates (Figure 5. 15B). This 
correlated with flow cytometric data which showed higher CD11b and F4/80 
expression in the NFIX expressing cells (Figure 5. 15C). To determine if this 
effect was driven from an uncommitted HSC or a more committed progenitor 
population, HSCs, CMPs and GMPs were FACS sorted and transduced with MigR1 
and NFIX retrovirus, plated in M3434 media and assessed after 12-14 days. NFIX 
expression had no effect on the number of colonies produced from the HSC. 
However there was a significant decrease in the numbers of colonies produced 
from the CMP and GMP cells expressing NFIX, compared to control (Figure 5. 
16A). There was also an increase in the CD11b and F4/80 expression in cells from 
NFIX expressing CMP and GMP derived colonies compared with the control MigR1 
cells (Figure 5. 16B). These data indicate that NFIX expression drives myeloid 
maturation from committed myeloid progenitor cells. To further support this 
hypothesis NFIX was overexpressed in the 32D myeloblastic cell line and the 
effect on myeloid cell surface markers was assessed by flow cytometry. As 
outlined previously in section 2.2.3.1, 32D cells are IL-3 dependent and remain 
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in an undifferentiated state in its presence. When IL-3 is removed and replaced 
with G-CSF the cells will differentiate. In the presence of IL-3, a significant 
increase in the F4/80 expression of NFIX expressing 32D cells was observed, 
whereas the MigR1 expressing 32D cells remained in an undifferentiated state 
(Figure 5. 17). This increase was further enhanced when the cells were grown in 
the presence of G-CSF (Figure 5. 18). Gene expression analysis was then 
performed on 32D and BA/F3 cells which had been transduced with MigR1 and 
NFIX, and sorted for GFP expression. Matrix metalloprotinease 9 (Mmp9) and 
Gcsfr were significantly upregulated in 32D cells upon ectopic NFIX expression 
(Figure 5. 19A). MMP9 is involved in neutrophil functions like migration (Bradley 
et al., 2012), and is secreted by tumour-associated neutrophils to promote 
angiogenesis. As discussed in 1.1.3.1, G-CSFR is the cell surface receptor for G-
CSF which initiates granulocyte proliferation and differentiation, and is 
expressed in myeloid progenitors, immature and mature granulocytes. A 
significant increase in the expression of Cebpa, essential for granulopoiesis, was 
also observed in NFIX expressing BA/F3 cells (Figure 5. 19B). These data strongly 
indicate that NFIX overexpression in vitro and in vivo promotes myelopoiesis 
while suppressing B cell lymphopoiesis. 
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Figure 5. 10 – NFIX blocks B cell differentiation in vitro in favour of myelopoiesis. 
Total FLCs were transduced with MigR1 or NFIX retrovirus, plated on OP9 cells, 
and analysed by flow cytometry for 16 days. Representative flow cytometry plots 
of B cells (B220+CD19+, top panels) and myeloid cells (CD11b+Gr1+, lower panels). 
Data is representative of 3 replicates from 2 independent experiments.  Graphs 
show the mean GFP expression in B220+CD19+ cells (left) and CD11b+Gr1+ cells 
(right). Error bars denote +/- SD of 3 technical replicates.   
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Figure 5. 11 – NFIX blocks B cell differentiation from the HSPC. 
E14.5 FL HSPCs (Lin-Sca1+cKit+Flt3-) transduced with control MigR1 or NFIX 
retrovirus were plated on OP9 cells (day 0) and analysed by flow cytometry on 
day 12. Representative flow cytometry plots of day 0 and day 12 GFP expression 
(left histograms), and GFP- and GFP+ B220+CD19+ cells at day 12 (right contour 
plots) representative of 2 independent experiments.   
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Figure 5. 12 – Gene expression analysis of NFIX expressing BM relative to MigR1 
control. 
Total BM cells were sorted for MigR1 and NFIX expression 24 hr post transduction 
and qPCR was performed. Graph represents relative mRNA expression of Nfix, 
E2a, Id2 and Id3 genes presented relative to control MigR1 cells. Error bars 
denote +/- SD of 3 technical replicates. Data representative of 2 biological 
replicates. Analysis of gene expression data was performed by Joana Campos. 
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Figure 5. 13 - Ectopic NFIX expression does not affect BA/F3 cell growth. 
(A) Tracking GFP expression in MigR1 and NFIX expressing BA/F3 cells over 5 days 
in culture, showing mean of 3 technical replicates +/- SD. Graph is 
representative of 2 independent experiments. (B) Graph of 5 days of cell growth 
of GFP+ sorted BA/F3 cells transduced with either MigR1 or NFIX retrovirus. Each 
point represents the average number of cells from 2 independent experiments. 
Error bars denote +/- SD. (C) Tracking BA/F3 cell division after 5 days in culture 
as shown by dilution of CTV in GFP expressing cells. MigR1 and NFIX 
overexpressing cells are compared to unstained control and day 0 cells as 
positive and negative controls respectively. Graph is representative of 2 
independent experiments. 
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Figure 5. 14 - Ectopic NFIX expression does not affect BA/F3 cell viability. 
(A) Representative flow cytometry plot of the expression of apoptotic markers 
AnnexinV and DAPI in MigR1 or NFIX transduced, GFP sorted BA/F3 cells, 4 days 
after transduction. (B) Graph of the average percentage of GFP sorted BA/F3 
cells expressing DAPI, AnnexinV and live cells (double negative for DAPI and 
AnnexinV), from 2 independent experiments. Error bars denote +/- SD. 
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Figure 5. 15 - NFIX enhances myeloid differentiation in vitro. 
MigR1 and NFIX transduced total BM cells were plated in methylcellulose media 
(M3434) and colonies counted and scored according to morphological criteria 
after 9-11 days. Bar charts represent (A) the average number of colonies 
normalised to GFP expression +/- SD and (B) the mean percentage of erythroid 
(E), granulocyte/erythrocyte/monocyte/megakaryocyte (GEMM), 
granulocyte/monocyte (GM) macrophage (M) and granulocyte (G) colonies, from 
3 independent experiments +/- SEM. (C) Representative flow cytometric analysis 
of CD11b and F4/80 expression of cells from colony assay.  
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Figure 5. 16 – Differentiation of myeloid progenitor populations by NFIX in vitro. 
(A) Bars represent average number of colonies from HSCs, CMPs and GMPs 
transduced with control MigR1 or NFIX. Colonies were counted on day 12 and 
graph represents mean of triplicate plates normalized to GFP expression +/- SD. 
Data representative of 2 independent experiments. For statistical analysis an 
unpaired, two-tailed, students t-test performed. (B) Representative flow 
cytometric analysis of cells from colony assay in (A). 
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Figure 5. 17 – NFIX promotes differentiation of 32D cells in the presence of IL-3. 
32D cells were transduced with MigR1 or NFIX maintained in IL-3 for 5 days, and 
analysed for CD11b and F4/80 expression by flow cytometry. (A) Representative 
flow cytometric analysis at day 0 and day 5. (B) Graph of the mean percentages 
of F4/80 expression. Mean of 3 independent experiments are shown +/- SD. For 
statistical analysis an unpaired, two-tailed, students t-test performed.  
  
  240 
 
 
Figure 5. 18 – NFIX enhances 32D cell differentiation in the presence of G-CSF. 
32D cells were transduced with MigR1 or NFIX maintained in G-CSF for 5 days, 
and analysed for CD11b and F4/80 expression by flow cytometry. (A) 
Representative flow cytometric data at day 0 and day 5. (B) Graph of the mean 
percentages of F4/80 expression. Mean of 3 independent experiments are shown 
+/- SD. For statistical analysis an unpaired, two-tailed, students t-test 
performed. 
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Figure 5. 19 – Gene expression changes in NFIX expressing cells. 
(A) 32D cells and (B) Ba/F3 cells were transduced with MigR1 and NFIX, and qRT-
PCR was performed. Graphs represent relative mRNA expression of Nfix, Mmp9, 
Gcsfr and Cebpa genes presented relative to control MigR1 cells. Error bars 
denote +/- SD of 3 technical replicates. Data representative of 2 biological 
replicates. For statistical analysis an unpaired, two-tailed, students t-test 
performed.  
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5.3.4 Loss of Nfix expression promotes B lymphopoiesis while 
impairing myelopoiesis 
To investigate the physiological relevance of Nfix in hematopoiesis and lineage 
determination, the Nfix-/- mouse was studied. However, the loss of Nfix in mice 
leads to postnatal lethality at approximately 22 days after birth. The mice suffer 
from dramatic defects in the brain including brain hydrocephalus and complete 
or partial absence of the corpus callosum (Driller et al., 2007). As such Nfix-/- 
E14.5 FLCs were first analysed. Previous data suggested that Nfix expression is 
low in HSPCs isolated at the early embryonic stages (<E13.5) and is upregulated 
as HSPCs mature, with highest expression in the HSPCs of the adult BM 
(Holmfeldt et al., 2013). This data was corroborated using 2 publically available 
datasets downloaded from the Gene Expression Commons database (Seita et al., 
2012), which both included 2 adult populations. The first data set comprised 
E14.5 FL HSCs, and HSCs from young (3 month old) and old (25 month old) mice. 
Nfix expression was very low at the fetal stage, but was highly expressed in the 
adult HSCs (Figure 5. 20A). The second model contains samples of HSPCs isolated 
from the yolk sac at D9, the AGM at D11.5, the FL at E12.5, E13.5 and E14.5, as 
well as from young mice at 6-8 weeks of age. A similar pattern to that reported 
by Holmfeldt et al was observed, with low Nfix expression in HSPCs during the 
embryonic stage of development and high expression in the adult mouse (Figure 
5. 20B). Total FLCs were then isolated and analysed by flow cytometry for cells 
of the myeloid, B and T lineages. No significant differences between the 
expression of myeloid (CD11b, Gr1), B (B220, CD19) and T (CD4, CD8) cell 
surface markers were observed (Figure 5. 21). Cells isolated from WT and Nfix-/- 
FLCs were next plated in methylcellulose (M3434) to determine if loss of Nfix 
affected the ability of the FLCs to differentiate into myeloid cells in vitro. There 
was no difference in the number of colonies formed by the Nfix-/- cells compared 
to the WT (Figure 5. 22A). There was also no change in the type of colonies 
formed (Figure 5. 22B and C). Taken together these data suggest that loss of 
Nfix at this stage of embryonic development does not perturb lineage 
specification. 
BM was then isolated from P10 WT and Nfix-/- mice. Analysis of markers of 
myeloid (CD11b, Gr1), B (B220, CD19) and T (CD4, CD8) cells was performed, 
however there was no significant difference in the distribution of these 
  243 
 
differentiation markers in the Nfix-/- mice compared with WT controls (Figure 5. 
23). To evaluate whether loss of Nfix in the neonatal mouse would affect 
myeloid differentiation from progenitor cells, BM cells isolated from WT and 
Nfix-/- P10 mice were plated in a methylcellulose assay (M3434). Colonies were 
counted and scored after 11 days, and cells were analysed for surface marker 
expression. Unlike colonies derived from the Nfix-/- FLCs, Nfix deficient BM cells 
yielded significantly fewer colonies than their WT counterparts (Figure 5. 24A). 
There was no significant difference to the type of colony produced (Figure 5. 
24B). However cells derived from Nfix-/- BM expressed significantly lower 
percentages of mature myeloid markers Gr1 and F4/80 (Figure 5. 24C and D). 
The lymphoid potential of neonatal Nfix-/- BM was determined by co-culturing BM 
cells with OP9 cells in the presence of 5ng/ml FLT3 and 1ng/ml IL-7. An increase 
in B220+ cells was observed after 4 and 6 days in culture compared with WT 
littermate control cells (Figure 5. 25). qPCR was performed on BM cells isolated 
from WT and Nfix-/- P10 mice and gene expression analysis showed that Nfix 
deficient BM cells have a marked disruption to the expression of key 
transcription factors associated with lineage specification (Figure 5. 26). The 
Nfix-/- BM cells revealed a decrease in expression of the Id genes, and Mmp9, the 
inverse of our overexpression data, as well as an upregulation of Cd19 and Pu.1 
further supporting a role of Nfix in lymphoid cell fate. 
These loss of function experiments, show that loss of Nfix in the neonatal BM 
leads to altered hematopoiesis by enhancing B cell development while disrupting 
myeloid differentiation, and that this effect is mediated by changes in key 
transcription factors associated with lineage specification.  
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Figure 5. 20 – Nfix expression in fetal and adult HSC and HSPC. 
(A) Analysis of Nfix expression in FL (n=3), young (3 months) (n=4) and old (25 
months) (n=3) HSCs using a dataset (GSE ID:55525) (Seita et al., 2012) accessible 
from https://gexc.stanford.edu/models/920/genes. Error bars represent max 
and min Nfix expression values. (B)  Analysis of Nfix expression in HSPCs derived 
from the yolk sac (E9)(n=6), AGM (E11.5)(n=6), FLCs (E12.5, E13.5, E14.5) (n=6) 
and 6-8 week old mice (n=5) using a dataset (GSE ID:34723) (Seita et al, 2012) 
accessible from https://gexc.stanford.edu/models/920/genes. Error bars 
represent max and min Nfix expression values. Values in (A) and (B) represent 
absolute profiling of gene expression. The dynamic-range (-100 to 100) and 
threshold for high/low expression (represented by grey line) for each probeset 
were obtained by mapping sample data against the Common Reference, 
generated from 11939 Affymetrix mouse 430 2.0 microarray data and 25229 
Affymetrix human U133 Plus 2.0 microarray data, and Probeset Meta Profile. 
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Figure 5. 21 - Nfix-/- FLCs do not display abnormal hematopoieisis. 
FLCs were isolated from E14.5 WT and Nfix-/- embryos and analysed by flow 
cytometry. (A) Graph depicts mean percentage expression of cell surface 
markers +/- SD. Data is representative of n=6 WT samples, and n=6 KO samples 
from 3 independent litters. (B) Representative flow cytometry histograms of cell 
surface marker expression. 
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Figure 5. 22 – Loss of Nfix in the FLC does not affect myeloid differentiation in 
vitro. 
WT and Nfix-/- FLCs were plated in methylcellulose media (M3434) and colonies 
counted and scored after 8 days according to morphological criteria. Bar charts 
represent (A) the average number of colonies normalised to GFP expression +/- 
SD and (B) The mean percentage of erythroid (E), 
granulocyte/erythrocyte/monocyte/megakaryocyte (GEMM), 
granulocyte/monocyte (GM) macrophage (M) and granulocyte (G) colonies are 
shown from 2 independent experiments +/- SEM. Data is representative of n=3 
WT and n=4 KO samples. (C) Representative flow cytometric analysis of total 
cells from colony assay. This data is representative of n=2 WT and n=1 KO 
sample from 1 experiment. 
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Figure 5. 23 - Nfix-/- neonatal (P10) BM does not display abnormal 
hematopoieisis. 
BM cells were isolated from P10 WT and Nfix-/- mice and analysed by flow 
cytometry. (A) Graph depicts mean percentage expression of cell surface 
markers +/- SD. Data is representative of n=5 WT samples, and n=5 KO samples 
from 2 independent litters. (B) Representative flow cytometry histograms of cell 
surface marker expression.  
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Figure 5. 24 Loss of Nfix disrupts myeloid differentiation in vitro 
Total BM from WT or Nfix deficient mice was plated in methylcellulose (M3434). 
Colonies were counted and morphology assessed after 11 days. Bar chart 
represents (A) the mean number of colonies from 2 independent experiments +/- 
SD and (B) the mean percentage of erythroid (E), 
granulocyte/erythrocyte/monocyte/megakaryocyte (GEMM), 
granulocyte/monocyte (GM), macrophage (M) and granulocyte (G) colonies from 
2 independent experiments +/- SEM. (C) Representative flow cytometric analysis 
of cells from colony assay. (D) Bar chart shows the mean percentages of 
Gr1+ and F4/80+ cells from 2 independent experiments +/- SD.    
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Figure 5. 25– Loss of Nfix enhances B cell differentiation in neonatal BM in vitro 
Total BM from WT or Nfix deficient P10 mice was plated onto OP9 cells in the 
presence of 5ng/ml FLT3 and 1ng/ml IL-7, and analysed by flow cytometry on 
day 4 (A) and day 6 (B). Bar chart shows the mean percentages of B220+ cells 
from 3 independent experiments +/- SD. (C) Representative flow cytometric 
analysis of cells expressing B220 at day 6.  
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Figure 5. 26 - Gene expression analysis of WT and Nfix-/- BM. 
Total BM was isolated from P10 WT or Nfix deficient mice and qPCR performed. 
Graphical presentation of relative mRNA expression of indicated genes assessed 
using high-throughput qPCR on the 48.48 Dynamic Array IFC system (FluidigmTM). 
Bars represent the average of 3 biological Nfix-/- replicates normalized to WT 
control, and error bars denote +/- SD. 
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5.4 Discussion 
Nfix expression is downregulated as progenitor cells progress through B cell 
differentiation. NFIX overexpression prevents B cell differentiation in favour of 
myelopoiesis in vivo and in vitro causing a block at the pre-pro-B to pro-B cell 
stage of development, while loss of Nfix enhances B cell differentiation. These 
changes are coupled with alterations in the expression of key genes involved in 
lineage determination.  
The data show that ectopic expression of NFIX drastically impairs B cell 
development in the murine hematopoietic system. While some B220+CD19+ B 
cells persisted in the spleen, they were virtually absent from the BM 
compartment, and peripheral circulation. Gene expression analysis of both 
murine and human datasets revealed that Nfix mRNA expression was higher in 
the early B cell progenitor populations and its expression was downregulated as 
the cells commit and mature to the B cell lineage. In accordance with Nfix 
downregulation at this stage, an accumulation of B220loCD43+ early B cells was 
observed in the BM of NFIX chimeric mice. These data suggest that continued 
expression of NFIX impairs early-late B cell differentiation. Furthermore, in vitro 
experiments utilising the OP9 co-culture system, demonstrated that enforced 
NFIX expression in the HSPC compartment led to an almost complete absence of 
NFIX expressing cells at the end of the culture period. Those cells that did 
persist in culture expressed low levels of B220 and did not yet express CD19, 
consistent with the block at an early stage of development seen in vivo. When 
NFIX was overexpressed in total FLCs, containing a mixed pool of stem and 
progenitor populations, NFIX expressing cells were observed after 16 days in 
culture. However these cells were of myeloid origin. The culture system only 
contained cytokines for efficient B cell production and no cytokines to support 
myeloid differentiation. Together these data strongly suggest that NFIX has a 
functional role in lineage fate. To further ensure NFIX was blocking B cell 
development rather than having a toxic effect on B cells, it was overexpressed 
on a more mature lineage-committed B cell, the pro-B BA/F3 cell line. NFIX 
overexpression did not affect cell viability of cell growth after culture.  
These findings are contrary to the observations made by Holmfeldt et al (2013). 
In their study they performed 2 competitive BM transplants – one with Nfix 
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knocked down in HSPCs using 2 shRNAs against Nfix, and the other utilising 
conditional Nfixfl/fl cells. In both transplants the authors reported no statistically 
significant difference in the distribution of myeloid, B and T cells in cells lacking 
Nfix compared with their respective control groups. However, there is a clear 
trend towards a higher proportion of B cells in their experiments using the 
Nfixfl/fl cells, and with one of the two Nfix-shRNAs (Figure 4D and H, Holmfeldt 
et al, 2013). Furthermore, despite using 2 markers to identify mature myeloid 
(CD11b/Gr1) and T (CD4/CD8) cells, the authors only use B220 as a marker for 
cells of the B lineage. B220 has been shown to be expressed in activated CD4+ T 
cells (Renno et al., 1998), a subset of NK cells (Rolink et al., 1996) and a 
subpopulation of dendritic cells (Nikolic et al., 2002), therefore without the use 
of another co-expressed B cell marker, such as CD19, these results are 
inconclusive.  
The development of mature B cells from hematopoietic progenitors is regulated 
by the sequential expression of the transcription factors E2A, EBF, and PAX5 
(Cochrane et al., 2009). The earliest B cell progenitors express B220, together 
with CD43 (Mansson et al., 2007) and an accumulation of CD43+ B220lo cells was 
observed in our NFIX chimeric mice. It has been documented that the 
downregulation of both Id2 and Id3 is an essential event in B-lineage 
specification although the loss of either factor was not sufficient to promote B 
cell development (Benezra et al., 1990). Significant changes in Id2 and Id3 levels 
were observed in Nfix-deficient cells. This perturbation in the levels of Id gene 
expression would be consistent with promoting B cell differentiation. Our 
findings associate well with gene expression changes previously observed in LSKs 
lacking Nfix (Holmfeldt et al., 2013). LSKs isolated by FACS were transduced 
with control lentivirus or shRNA targeting Nfix and cultured for 7 days, then 
assessed for global transcriptional changes. Several B cell related genes were 
significantly upregulated in the LSKs with loss of Nfix. These included a 4 fold 
increase (p=.003) in Kruppel-like Factor 4 (Klf4), a transcription factor whose 
expression increases during B cell differentiation peaking in the mature B cell, 
and has also been shown to play an important role in B cell activation and 
proliferation (Klaewsongkram et al., 2007). A 3 fold increase (p=.003) was found 
in the expression of IL-7 receptor (Il7r).  Il7r expression is required for the early 
stages of B cell development in mice (Namen et al., 1988). It is expressed 
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through B cell differentiation, and down-regulated in the mature B cell (Wei et 
al., 2000). Stat1 showed a 2-fold (p=.02) upregulation with loss of Nfix in the 
LSK, and is known play an essential role in B cell survival and proliferation (Lee 
et al., 2000). These transcriptional changes in B cell specific genes with loss of 
Nfix expression, supports the hypothesis that it plays a role in hematopoietic 
lineage determination. 
In addition to a block in B cell development, NFIX overexpression caused an 
increase in the percentage of CD11b+Gr1+ cells in the BM, spleen and PB of NFIX 
chimeric mice. Enforced NFIX expression on whole BM promoted myeloid 
differentiation in an in vitro colony forming assay, with an increase in expression 
of mature myeloid cell surface markers seen on cells from NFIX expressing 
colonies. From the HSC, NFIX expression did not drive myelopoiesis in vitro. 
However from CMP and GMP committed myeloid progenitors, NFIX 
overexpression enhanced myeloid differentiation. NFIX overexpression also 
induced myeloid differentiation in the 32D myeloblast cell line in the presence 
of IL-3, and significantly enhanced differentiation in the presence of G-CSF. As 
previously discussed in section 1.1.3.3.1, C/EBPα is a myeloid transcription 
factor essential for granulopoiesis (Zhang et al., 1997), highly expressed in GMPs 
where it is switched off and another family member, C/EBPε is turned on to 
drive these committed progenitors to fully differentiate (Lekstrom-Himes, 2001). 
It has previously been shown that C/EBPα loss-of-function mutations decrease 
myeloid priming of HSCs while impairing myeloid-lineage commitment (Kueh et 
al., 2013). The down regulation of Cebpa that was observed in the BM of the 
Nfix deficient mice and the increase of Cebpa with NFIX overexpression in BAF/3 
cells is consistent with dysregulation of myelopoiesis. It was also shown that 
ectopic expression of C/EBPα and ID1 can restore neutrophil development in 
myelodysplasia (Geest et al., 2009). The fact that Nfix deficient BM has both of 
these transcriptional regulators downregulated, underpins a functional role for 
NFIX in hematopoiesis.  
In 32D cells overexpressing NFIX, a significant increase in Gcsfr expression was 
observed. The previously mentioned knockdown experiments performed by 
Holmfeldt et al on LSK cells, also revealed down-regulation of this myeloid 
specific gene with loss of Nfix (Holmfeldt et al., 2013). There was a 2-fold 
decrease (p=.02) in Csf3r expression in LSKs lacking Nfix. The Csf3r gene 
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encodes the cell surface receptor for G-CSF, which initiates proliferation and 
maturation of BM granulocytes (Thomas et al., 2002). Furthermore, increased 
expression of Pu1 was observed in the BM of Nfix deficient mice. PU.1 is a 
transcription factor with a well-documented role controlling myeloid and early B 
cell development, and PU.1 expression levels are important in the determination 
of lineage fate with high PU.1 levels in the MPP/LMPP favouring myelopoiesis 
and low levels favouring B cell lymphopoiesis (DeKoter and Singh, 2000). PU.1 
expression increases with B cell maturation and its expression becomes 
dispensable once the progenitors are committed to the lymphoid lineage 
(Iwasaki et al., 2005). The modulation of Pu1 seen in Nfix-deficient cells is 
consistent with the role of PU.1 in myeloid versus B lineage cell fate. 
Collectively these findings demonstrate that in stem and progenitor cells, NFIX 
expression can influence the cell fate decisions between myeloid and lymphoid 
lineages, possibly by direct modulation of downstream transcriptional targets. 
While there is little in the literature describing the role of NFIX in hematopoietic 
differentiation, there are studies which support a role for NFIX in stem and 
progenitor cell differentiation in other tissues. NFIX is highly expressed in 
embryonic muscle progenitor cells (myoblasts), where it has been shown to 
activate a transcriptional program responsible for the embryonic to fetal 
myoblast transition. NFIX is then dramatically down-regulated in fetal myoblast 
cells. In this context NFIX behaves as a transcriptional activator by activating 
expression of the fetal-specific gene Mck, but also as a repressor by suppressing 
NFATc4 – a transcriptional activator of embryonic proteins (Calabria et al., 
2009). Furthermore, in the human brain, the expression of the NFIX3 splice 
variant is dramatically upregulated during the differentiation of neural 
progenitors to astrocytes, and it has been shown to activate the GFAP promoter 
which induces glial differentiation from astrocytes (Singh et al., 2011). NFIX is 
also involved in neural progenitor cell differentiation by repressing the stem cell 
maintenance gene Sox9 during the development of the hippocampus (Heng et 
al., 2014). Thus there is evidence from over tissues supporting the modulation of 
genes involved in stem and progenitor cell fate by NFIX. 
Unlike the P10 BM, in the E14.5 fetal Nfix-/- liver, there was no apparent lineage 
effect from loss of Nfix. This may be due in part to the differential expression of 
Nfix in the HSPCs of the developing embryo and adult mouse, suggesting that the 
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role of Nfix in lineage determination may occur when it is more highly expressed 
in the adult mouse during steady state hematopoiesis. Other NFI family members 
may also be compensating for the loss of Nfix. The NFIX gene is not redundant in 
the CNS i.e. Nfix KO alone leads to lethality from brain malformations (Campbell 
et al., 2008). However its’ necessity may be tissue specific. Nfib null mice die 
from severe respiratory dysfunction (Grunder et al., 2002) whereas the Nfia, 
Nfic or Nfix null mice display no obvious lung defects despite being expressed 
during lung development. Thus, in the embryonic hematopoietic system, Nfix 
may be dispensable and other NFI family members may compensate for Nfix loss. 
The most likely candidate for a compensatory role would be Nfic. Its expression 
in the E14.5 FLC HSPC is higher than Nfia or Nfib (Holmfeldt et al, 2013). Nfic 
and Nfix are frequently co-expressed at similar levels compared with other 
members in a tissue-specific manner. Endogenous Nfic and Nfix expression is 
high in the skeletal muscle, intermediate in the brain, heart, kidney, liver and 
lung, and low in the spleen and testis (Chaudhry et al., 1997), while Nfia and 
Nfib expression are different from Nfic and Nfix, and different from each other. 
It was also shown that in the developing embryo, detectable levels of both Nfic 
and Nfix appear at 11.5 days post coitus, whereas Nfia and Nfib occur at 10.5 
days post coitus. There is already evidence to indicate that they may have 
overlapping functions. Expression of NFIC or NFIX in HeLa cells abrogates the 
induction of MMTV expression through glucocorticoid repression, whereas NFIA 
and NFIB do not (Chaudhry et al., 1997). Analysis of the expression of the other 
NFI family members in Nfix-/- FLCs may provide insight into our observations. 
A recent study identified 36 factors that could reprogram a committed B cell 
into a myeloid cell and Nfix was one of these factors (Riddell et al., 2014). The 
data presented here demonstrate that NFIX can alter the fate of stem and 
progenitor cells. It can drive myelopoiesis from a committed progenitor cell and 
blocks B cell lymphopoiesis between the pre-pro and pro B cell stage. There is 
growing evidence to suggest that, despite being considered the earliest B cell 
precursor, pre-pro B cells retain some degree of multilineage potential with 
studies demonstrating this fraction can give rise to T, NK and dendritic cells 
(Nagasawa, 2006). As shown, NFIX overexpression in the committed pro-B cell 
line BAF/3, resulted in a 15 fold increase in Cebpa expression (Figure 5.19). 
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Enforced Cebpa expression has been shown to rapidly reprogram committed 
CD19+ B cells into functional macrophages in vitro (Xie et al., 2004).  
Collectively the data presented suggest that NFIX may act as a molecular switch 
at the myeloid/lymphoid branch point, potentially at the level of the MPP or 
LMPP, mediating changes in the expression of key lineage genes to restrict 
lineage potential in favour of myeloid differentiation.  
This work has been published in O’Connor et al, 2015, provided in section 0. 
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6 General discussion  
The data presented in this thesis represent findings which impact on 3 key areas 
-lineage determination in hematopoiesis, the pathophysiology of AML, and future 
therapeutic approaches in cancer treatment. 
The process of hematopoiesis is an intricately regulated organisational system 
producing vast numbers of functionally and morphologically distinct blood cell 
types from a rare pool of long-lived HSCs. Understanding the regulation of this 
process will underpin our understanding of how its dysregulation results in 
leukaemia. The data in this thesis contribute to our understanding of lineage 
determination by identifying NFIX as a novel regulator of lineage fate decisions 
and by providing evidence that TRIB2 may influence the lymphoid lineage. The 
Nfix gene locus was identified as a retroviral insertion site in TRIB2-mediated 
myeloid leukaemia and in NOTCH1-mediated lymphoid leukaemia. TRIB2 
overexpression results in the development of AML, its expression is highest in T 
cells and it is a NOTCH1 target gene, while NOTCH1 is a critical transcription 
factor in early T cell development and it is dysregulated in over 50% of T-ALL. It 
remains to be discerned what the exact relationship between NFIX, TRIB2 and 
NOTCH1 is, but it appears as though, together with CEBPA these genes may form 
a regulatory network involved in the bifurcation of the myeloid and lymphoid 
lineages. The data presented in chapter 5 show that NFIX overexpression drives 
myelopoiesis at the expense of B cell lymphopoiesis and that overexpression of 
NFIX in a committed B cell line results in a 15 fold increase in Cebpa expression. 
In addition, NFIX supports myeloid differentiation from the CMP and GMP but not 
the HSC. It is possible that at the level of the MPP/LMPP, NFIX may act as a 
molecular switch by activating CEBPA expression at the myeloid-lymphoid 
branch-point to promote myelopoiesis and thus inhibit lymphopoiesis. TRIB2 and 
NOTCH1 insertion into the NFIX locus may inhibit NFIX expression and its 
downstream effector C/EBPα, thus contributing to the resultant disease 
phenotypes. Overexpression of TRIB2 from the GMP induced a mature myeloid 
AML, but from the HSC induced a mixed lineage leukaemia even in a myeloid 
biased assay. As discussed in chapter 4, loss of TRIB2 from the hematopoietic 
compartment did not result in perturbation of lineage distribution. However, 
expression of TRIB2 is highest in the T cell compartment and it should be noted 
that our group have recently identified TRIB2 as a novel regulator of thymocyte 
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proliferation (Ling Liang et al, 2016 – details provided in section 0). As discussed 
in section 1.3.3.5 TRIB2 is also implicated in megakaryocyte and erythroid 
lineages where it is hypothesised to be activated by FOG1 in MkE precursor cells 
in order to degrade C/EBPα to permit MkE differentiation. The data presented 
suggest that TRIB2 mediated degradation of C/EBPα may also influence 
lymphopoiesis in a cell context dependent manner. 
Collectively the data presented in chapter 3 show that TRIB2 degrades p42 
through K48 mediated proteasomal ubiquitination but is unable to degrade p30, 
instead increasing oncogenic p30 expression in AML. Despite this, not only is 
C/EBPα expression essential for TRIB2 mediated AML, but it is the degradation of 
p42 which is the key driver of this oncogenic pathway. As previously discussed, 
the requirement of C/EBPα expression for TRIB2 leukaemia induction correlates 
with published studies (Collins et al., 2014, Ohlsson et al., 2014). A recent 
publication has provided a fresh perspective on the role of C/EBPα in 
leukaemogenesis. The authors demonstrated that loss of C/EBPα stunts AML 
induction by MLL-AF9 and MOZ-TIF2 (Ye et al, 2015). However upon treatment 
with GM-CSF and IL-3, Cebpa null cells differentiated and restoration of 
differentiation was sufficient to restore the ability of MLL-AF9 and MOZ-TIF2 to 
induce AML in these cells. Thus the authors hypothesise that it is not the 
presence of C/EBPα itself but rather the differentiation state of the cell which 
provides a transformation permissive environment. Our data fully supports this 
hypothesis as TRIB2 overexpression in the committed GMP produced a potent 
myeloid leukaemia whereas it was unable to initiate AML from the CMP or MPP. 
Indeed the hypothesis that the self-renewal capacity of putative LICs occurs 
once the immature stem cells reach a committed myeloid progenitor stage is 
also supported by the observation that only in the presence of p42 which 
promotes myeloid differentiation, did TRIB2 and p30 cooperate to decrease the 
latency of the AML. Together the data presented in chapter 3 and 4 support the 
emerging hypothesis that C/EBPα plays a dichotomous role in the 
pathophysiology of AML. On the one hand, its expression is required to promote 
myeloid differentiation until the cells reach a stage of maturation (GMP) 
permissive for oncogenic transformation. On the other hand, loss of C/EBPα at 
this stage contributes to leukaemogenesis by causing a block in differentiation as 
well as loss of cell cycle control through disrupted inhibition of E2F1.  
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The current standard approach to AML treatment, in place for over 40 years, is 
wholly inadequate. The complexity and heterogeneity of acute leukaemia is 
central to the difficulty in its successful treatment. Representing this 
heterogeneity in preclinical mouse models presents a fundamental obstacle in 
the development of targeted therapies for AML. The availability of human 
samples for preclinical research is also a limiting factor in drug development. 
Indeed clinical trials are also fraught with drawbacks, in particular in AML where 
in order to provide efficient treatment, multiple targets may need to be treated 
concurrently, and clinical trials generally deal with one drug.  
Despite these factors there have been several exciting developments in the field 
recently. Next-generation sequencing has revolutionised our understanding of 
AML genetics and we are now seeing the emergence of several new types of 
treatment including small molecule drugs targeted against mutations in genes 
such as IDH1/2 and Flt3. One especially promising agent is the IDH2 inhibitor AG-
221 which, in a phase 1 clinical trial, has been shown to achieve complete 
remission in 33% of AML patients bearing an IDH2 mutation (Rowe, 2015). The 
characterisation of unique cell surface markers present on leukaemic cells is 
opening the door for the development of antibody drug conjugates (ADC) in AML 
treatment. While there have been no successfully trialled ADCs to date – 
gemtuzumab ozagomicin which targets CD33 was withdrawn from the market – 
there are promising data now emerging. CD47, expressed at very low levels on 
healthy BM, is highly expressed on leukaemic cells (Majeti et al., 2009) and the 
humanised anti-CD47 antibody HuF9-G4 is currently in clinical trials with AML 
patients (Liu et al., 2015). Another promising avenue of AML therapy utilises 
chimeric antigen receptor (CAR)-expressing T cells to target cell surface markers 
on leukaemic cells. CD19 directed CAR-T cell therapy has yielded very promising 
results in the treatment of ALL and this technology is being adapted for the 
tailored treatment of AML (Ritchie et al., 2013). The data presented here 
support the further exploration of proteasome inhibition in the treatment of 
AML. Indeed TRIB2 mediated degradation of CEBPA has also been implicated in 
the progression of liver (Wang et al., 2013) and lung (Grandinetti et al., 2011) 
cancer, thus the development of clinically effective proteasome inhibitors could 
also impact on therapeutic strategies for treatment of these cancer types.  
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